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ABSTRACT 
This thesis has made use of real-life clinical practice to provide guidance for secondary 
prevention of cervical cancer. We combined epidemiological, virological and 
biostatistical investigations using HPV DNA and HPV E6/E7 mRNA tests in women 
who were identified with abnormal findings through the organised cervical cancer-
screening programme. The majority of cytological abnormalities detected through the 
Swedish cervical cancer-screening programme are minor, i.e. atypical squamous cells 
of undetermined significance (ASC-US, 3.6 %) or low-grade intraepithelial lesions 
(LSIL, 2.1 %). Since only a minority of women with minor abnormal cytology harbour 
underlying cervical disease, or rarely invasive cervical carcinoma (ICC), management 
of ASC-US/LSIL remains a major challenge to system efficiency. The realisation that 
infection with high-risk human papillomavirus (HR-HPV) causes cervical cancer and 
its precursor lesions has led to development of new molecular tests for detection of HR-
HPV.  
Study 1 compared the effectiveness of HR-HPV DNA testing, using Hybrid Capture 2 
(HC2), with repeat cytology using Pap smear for detection of underlying high-grade 
cervical intraepithelial neoplasia (CIN2-3) in an evaluation of 177 women with minor 
cytological abnormalities, identified through the population-based cervical cancer 
screening programme. The HPV DNA test was positive in 66% of the women. 
Sensitivity for detection of CIN2-3 was 82% (95% CI; 80-97) using HR-HPV DNA 
testing and 61% (95% CI; 45-74) using Pap smear. These results indicated that HR-
HPV DNA testing found more underlying disease than follow-up with repeat Pap 
smear and suggest that HR-HPV DNA-positive women should be referred for further 
examination including colposcopy and directed biopsies.  
This study was published in 2005 and since then a large number of other studies have 
addressed this issue. There is now consistent evidence indicating that HPV triage with 
HC2 is more accurate than repeat cytology to triage women with equivocal (ASC-US) 
cytology. HR-HPV DNA testing has also been considered useful as a follow-up test in 
women treated for high-grade CIN to predict success or failure of treatment. HPV 
testing identifies residual disease more rapidly, with higher sensitivity and with similar 
specificity compared with follow-up cytology or histological assessment of section 
margins. Since expression of the HR-HPV E6/E7 oncogenes, resulting from 
deregulation of p53 and retinoblastoma protein, is necessary for malignant 
transformation and persistence in cervical tissue, a diagnostic test that identifies E6/E7 
mRNA in 14 HR-HPV types was developed (APTIMA HPV Assay).  
In study 2 we compared the performance of APTIMA with HR-HPV DNA testing and 
cytology in 143 women treated for CIN with conisation. These women were followed 
over a median time of 3.2 years and high-grade residual/recurrent disease was 
identified in 7 (4.9%) of them. Presence of HR-HPV DNA at the first follow-up visit 
predicted all (100%; 95% CI; 64.6-100) high-grade disease during follow-up, while the 
APTIMA failed to identify 3 women with high-grade disease (sensitivity 57.1% 95% 
CI 25.0-84.2). We concluded that APTIMA sensitivity was too low to be used for 
follow-up surveillance after conisation. 
HPV DNA triage of ASC-US cytology is an established technique, but less effective in 
women with LSIL due to high prevalence of HPV. HPV DNA testing has high 
sensitivity, but is also positive in many women without disease (low specificity). Thus, 
a molecular marker, such as HPV mRNA, which allows more specific identification of 
a transforming infection, holds promise.  
In study 3 we compared the triage effectiveness of APTIMA testing with for HPV16 
DNA testing, HPV16/18 DNA testing and repeat cytology, in a cohort of 205 HR HPV-
positive women with minor cytological abnormalities. Nine of 25 (36%) women with 
ASC-US and 64 of 180 (36%) with LSIL developed CIN2+ over a 4-year follow-up 
period. APTIMA had the highest sensitivity to predict CIN2+ and CIN3+ among 
patients with ASC-US (77.8% and 100%) and LSIL (78.1 and 75.8%), although 
specificity was insufficient (<50%). HPV16 DNA testing, HPV16/18 DNA testing and 
repeat cytology were all less sensitive, but more specific than APTIMA. Our results 
support the use of APTIMA in triage of women with ASC-US, but not with LSIL. All 
evaluated tests showed accuracy estimates that indicated poor LSIL triage capability 
and risk of disease remained even when triage tests were negative. Additional 
biomarkers need to be evaluated to stratify women with LSIL. 
Finally, in study 4 we addressed long-term risk of developing cervical pre-cancer 
among 314 women with ASC-US or LSIL in relation to age, HPV status and HPV 
DNA genotype. Median follow-up was 3.8 years. Data for these women were linked to 
the Swedish National Quality Register for Cervical Cancer Prevention (NKCx) to 
identify cases of histologically confirmed CIN2+. We showed that HPV status was the 
most important factor in determining risk for developing pre-cancer. Risk was low 
among HPV-negative women during the first 4.5 years, suggesting that they could 
safely return to the regular screening programme. The highest risk of pre-cancer was 
observed among women positive for HPV16/18, suggesting a need for more aggressive 
follow-up. 
The purpose of our findings is to facilitate risk stratification in women with minor 
cytological abnormalities and in women treated for CIN, as well as to provide guidance 
for clinical management. In Sweden the second major peak in incidence of cervical 
cancer is among women aged 60-85. Older women are clearly a vulnerable risk group 
for cervical cancer. One approach to reduce CC incidence in Sweden is to extend the 
screening programme up to at least the WHO-recommended age of 65 years and to 
complement or replace cytology screening with HPV testing in older women and in 
those who never participate in screening programmes. Women’s health would greatly 
benefit from more clinically effective and cost-effective screening strategies to identify 
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1 INTRODUCTION 
 
Since HPV infection is the requisite common denominator underlying cervical cancer, 
new approaches aimed at prevention have evolved in recent years through improved 
screening methods and HPV vaccination. In fact, it has become the leading preventable 
cancer and although research continues to make significant strides, several challenges 
remain before fully effective cancer control can be achieved. Pap smear screening has 
successfully reduced morbidity and mortality from cervical cancer over the past 50 
years. Unfortunately, the incidence of squamous cervical cancer (SCC) is no longer 
decreasing, while the incidence of adenocarcinoma (AC) is now increasing. Pap smear 
testing has been found to be inefficient due to high rates of false negative findings and 
the need for repeat testing. The introduction of liquid based cytology (LBC) improved 
laboratory efficiency in processing cytology slides, but the problems of low sensitivity, 
subjective interpretations and sampling error still remain. Adjunctive HPV DNA testing 
has opened up new opportunities. Studies have consistently demonstrated advantages 
such as greater sensitivity—albeit lower specificity—than cytology, higher 
reproducibility, less need for staff training, automation with high-volume testing and 
the opportunity to use self-collected cervical samples. However, many questions still 
remain before successful implementation can become feasible. HPV is the most 
common sexually transmitted infection (STI) worldwide and is so prevalent that it is 
almost unavoidable. However, the majority of infections are transient and cervical 
cancer is the rare end stage of persistent infection with certain high-risk types. Despite 
our tremendous knowledge about HPV and interactions with host cells, tissues and 
immune systems, we still cannot predict whether a specific infection will regress or 
persist. A range of promising new biomarkers has emerged from the research pipeline, 
one of which is mRNA from the HPV E6 and E7 oncogenes, which provides high 
specificity to distinguish between benign productive infection and those where 
neoplastic progression has been initiated or already resulted in cancer. 
This thesis aims to evaluate testing for the presence of HR HPV DNA, specific viral 
genotypes and HR HPV mRNA in women with minor cytological abnormalities and 
women treated for dysplasia, for the ultimate goal of improving the effectiveness of 
secondary cervical cancer prevention and thereby perhaps contribute a small piece of 
knowledge to this vast puzzle. 
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2 BACKGROUND 
2.1 CERVIX 
The cervix is the inferior part of the uterus and is divided into two portions. The lower 
portion (portio) extends into the vagina and can be visualized through speculum 
examination. The upper or supravaginal portion extends from the vaginal attachment to 
the lower uterine segment. The cervix is about 3 cm long and 2 cm in diameter. The 
cervical canal is approximately 3 cm long and extends from the external os to the 
internal cervical os. The ectocervix is covered by stratified squamous epithelium, while 
a single layer of columnar cells lines the endocervical canal. The area where these two 
cell types meet is known as the squamocolumnar junction (SCJ). In this area, a gradual 
transformation process takes place where columnar cells transform into squamous cells 
in a process known as metaplasia. The new squamous epithelium may obstruct mucus 
secretion, thereby causing formation of Nabothian cysts. Underneath the epithelium is a 
layer of connective tissue and beneath that is smooth muscle. Factors that induce 
metaplasia are still poorly understood, but may include environmental conditions, 
mechanical irritation, chronic inflammation, pH changes or changes in sex hormone 
balance. 
The original squamocolumnar junction (SCJ) between squamous and columnar 
epithelium, called the congenital junction, remains unchanged until puberty. Post 
puberty, in addition to the congenital junction, the adult or functional junction forms 
and is termed the new SCJ. The TZ occupies the area between the original and the new 
SCJ and becomes larger with age as it expands towards the cervical opening. There are 
three types of TZ. In the type 1 TZ, the SCJ is fully visible on the ectocervix, in type 2 
TZ, the SCJ is only fully visible if the cervical os is open and the endocervix can be 
inspected, while in type 3 TZ, the SCJ is not visible. The TZ plays a crucial role in the 
pathogenesis of cervical cancer (1) (2). 
 
Fig 1. Anatomy of the cervix 
2.2 HPV INFECTIONS AND RELATED DISEASES 
The worldwide prevalence of HPV infection in women with normal cytology is around 
11–12%, with the highest rates in sub-Saharan Africa (24%), Eastern Europe (21%) 
and Latin America (16%). There are large regional variations with particularly high 
prevalence in Eastern Africa and the Caribbean, where rates exceed 30%. Maximum 
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HPV prevalence is observed in women under age 25 and declines in older age groups 
(>45 years), though in many populations an unexplained secondary peak occurs in 
perimenopausal women. Globally, the five most prevalent types are HPV16 (3.2%), 
HPV18 (1.4%), HPV52 (0.9%), HPV31 (0.8%) and HPV58 (0.7%). The prevalence of 
all other HPV types is 0.6% or less. The overall prevalence of high-risk HPV (HR 
HPV) among women with normal cytology has been estimated at around 0.4%-2.6%. 
In a Swedish study of 44 146 adolescents, who were offered free Chlamydia 
trachomatis testing, samples were subjected to HPV genotyping (2008) in order to 
evaluate HPV prevalence before implementation of the HPV vaccination programme. 
The results showed that HPV positivity peaked at 54.4% among 21-year-old women 
and at 15.0% among 23-year-old men, although urine samples uniformly show lower 
HPV prevalence than genital swab samples. In general, HPV positivity was 37.8% in 
women and 11.2% in men. The most prevalent types among men and women were 
HPV16 (10.0%), and HPV51 (6.0%), HPV31, HPV18, HPV66 and HPV52, in 
descending order (3). HPV type distribution although, varies among different 
populations and among different sample assays (4). 
 
Prevalence increases in direct proportion to the severity of lesions in women with 
cervical dysplasia by cytology, with 12.6% prevalence seen in normal cytology, and 
about 90% in women with cervical intraepithelial neoplasia grade 3 (CIN3) and 
invasive cervical cancer (ICC). Retrospective investigations have shown that nearly 
100% of all cervical cancer patients are HPV positive. The proportion of HPV-positive 
women in whom HPV16 is detected also increases with lesion severity. The three most 
commonly found HPV types in women with invasive cancer are HPV16, 18 and 45, 
which were found in 20%, 8% and 5%, respectively, of HPV-positive women with 
normal cytology and in 63%, 16% and 5%, respectively, of women with cancer (5-7). 
A major novelty found in a recent review by Bzhalava et al. was the broad range of 
non-HR HPV types commonly detected in both low-grade and high-grade cervical 
abnormalities, and the extraordinarily high prevalence of multiple infections associated 
with these lesions. The proportional protective impact of HPV16/18 vaccination on 
cervical lesions can be predicted to rise from 17% in ASC-US, through 49% in HSIL 
and up to 70% in ICC, given that all HPV16/18 infections are causally related to the 
lesions in which they are found, even when other HPV types are present (Table 1). 
 
HPV prevalence data from other body sites are less readily available. Detection of 
genital HPV infections in men depends on sampling techniques. HPV is most 
commonly detected in the shaft, glans, and scrotum; less often in the urethra. 
Prevalence of genital HPV in men generally correlates with prevalence of genital HPV 
infections in women within the same population, but does not vary by age as it does in 
women. HPV is also frequently detected in the perianal region and anal canal in both 
sexes. The highest prevalence of anal HPV is found among individuals positive for 
human immunodeficiency virus (HIV) and in men who have sex with men (MSM). 
Incidence of anal cancer among HIV-positive MSM in the US is similar to the rate of 
cervical cancer among women in sub-Saharan Africa(8). 
Detection of oral HPV infection also varies substantially depending on sampling 
technique. In a meta-analysis the pooled prevalence of oral HPV infection was 4.5% 
among 4581 cancer-free individuals, with equal prevalence in men and women (9). 
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HPV prevalence in the anogenital tract and in the oral cavity is associated with anal and 
oral intercourse (8).  
 
Table 1. Results from a meta-analysis showing women tested for HPV and HPV16, 
percent positive by cervical disease grade (5). 
Grade	  of	  cervical	  
disease	  
%	  HPV	  positive	   %	  HPV	  16+/	  HPV+	  
Normal	  cytology	   12	   20	  
ASC-­‐US	   52	   23	  
LSIL	   76	   25	  
HSIL	   85	   48	  
CIN1	   73	   28	  
CIN2	   86	   40	  
CIN3	   93	   58	  
ICC	   89	   63	  
 
Around 2 million (16%) new cancer cases that occurred in 2008 were attributable to 
infections(10). Infection with HR HPV is a major cause of infection-related cancer. 
Strong evidence for HPV causality has been cited by the International Agency for 
Research on Cancer (IARC) for cancers of the cervix, penis, vulva, vagina, anus and 
oropharynx (including base of tongue and tonsils). In 2008, 610 000 new cases of 
cancer attributable to HPV were diagnosed, representing 4.8% of the worldwide burden 
of cancer. Cervical cancer is the third most common female cancer, with an estimated 
530,000 new cases in 2008. Approximately 86%, occurred in underdeveloped regions. 
The other five HPV-related types of cancer accounted for the remaining 80 000 cases. 
There is a strong association between cervical cancer incidence and level of 
development. Incidence and mortality rates tend to be at least four times higher in less 
developed countries, as indicated by the much lower 5-year survival rate (20%, 
compared with 65% in developed countries) (6). Unlike other important cancer-causing 
infections (Helicobacter pylori and hepatitis B and C virus), HPV is almost exclusively 
sexually transmitted and is not sensitive to general improvements in medical care or 
standard of living. Consequently, only vaccination and organised cervical cancer 
screening programmes can prevent or combat HPV epidemics and their cancer sequelae 
in any given population. 
The 12 most common HPV types associated with cervical cancer worldwide, by 
decreasing prevalence, are HPV16 (57%), 18 (16%), 58, 33, 45, 31, 52, and 35, with 
small regional variations. HPV16 is by far the most likely to persist and cause CIN3 
and cervical cancer. 
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Figure 2 Cervical cancer, global map showing estimated age-standardised (world 
standard) incidence per 100,000 in 2008 (all ages). Based on GLOBOCAN 2008(6). 
 
2.3 CERVICAL CANCER SCREENING IN SWEDEN 
In 1968 Wilson and Jungner established a list of general criteria for screening that have 
stood the test of time; cervical cancer screening satisfies these criteria well (11). 
The criteria are as follows: 
1. The condition should be an important health problem.   
2. There should be accepted treatment for patients with recognised disease.   
3. Facilities for diagnosis and treatment should be available.   
4. There should be a recognisable latent or early symptomatic stage. 
5. There should be a suitable test or examination.   
6. The test should be acceptable to the population. 
7. The natural history of the condition, including development from latent to 
declared disease, should be adequately understood.    
8. There should be an agreed policy on what patients to treat. 
9. The cost of case-finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation to possible 
expenditure on medical care as a whole.   
10. Case-finding should be a continuous process and not a “once and for all” 
project. 
 
The aim of cervical screening is to reduce the incidence of invasive cervical cancer 
(ICC) through detection and treatment of cancer precursors, as well as through early 
detection of invasive disease to thereby improve prognosis and reduce mortality (12). 
Swedish population-based screening with Pap smear has been used to detect 
precancerous lesions since the early 1960s (1964) and by 1977 all counties participated. 
Current screening guidelines from the National Board of Health and Welfare (1998) 
recommend a Pap smear every three years for women aged 23-50 and every five years 
for women aged 51-60. Most counties (70%) call women for screening based on 
elapsed time since last recorded cytology, including opportunistic tests (tests on 
demand), and most counties re-call non-responders the following year or earlier. 
The screening programme has had a major impact on both morbidity and mortality 
from squamous cervical cancer (SCC), reducing the incidence of SCC and mortality by 
35-70% (13-16). From 2007 to 2011, approximately 446 new cases of cervical cancer 
were detected annually (1.9% of all cancer cases in Sweden), among which 139 deaths 
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occurred. The age- standardized rate was 7.0/100 000 person years. (17) and relative 5- 
year survival was 73% (relative 1-year survival 89%). Nearly 700 000 Pap smears are 
performed annually in Sweden, of which 8% show some form of cellular atypia; 3.6 % 
were ASC-US, <1% koilocytosis, 2.1 % LSIL (CIN1), 0.1% ASC-H,  0.8% HSIL 
(CIN2) and 0.4% HSIL (CIN3)(18). Despite an increase in the number of cases of 
adenocarcinoma in situ (AIS) found by screening, the incidence of adenocarcinoma 
(AC), has increased (15), calling the protective effect of the screening programme (Pap 
smear) against AC into question (19). 
Bray et al. recently presented an overview of cervical cancer and other HPV-related 
diseases in Central and Eastern Europe, where the incidence of cervical cancer is high 
in many countries due to lack of effective screening. They found a clear birth cohort 
effect in which risk of cervical cancer is increasing in successive generations of women 
born after 1940-1950, a general phenomenon reflecting changes in sexual behaviour 
with increased risk of persistent HPV infection (20). 
In 2012, participation in the Swedish screening programme among women aged 23-50 
was 78% and among women aged 51-60, 84%. Variation between counties was large, 
ranging from 66% in Uppsala county to 93% in Dalarna. In 2012, 681 411 cervical 
cytology samples were taken in Sweden, 71% of which were through the screening 
programme (18). The National Register for Cervical Cancer Prevention (NKCx) 
includes a copy of the same file used to report the diagnoses from all cytological and 
histopathological laboratories in Sweden, for which reason the data are 100% complete. 
The NKCx presents annual reports of these data. “Cytburken”, an information system 
on gynaecological cytology and histopathology results, provides information on patient 
history directly to healthcare providers. 
Andre et al. used this nationwide population register to identify all cases of invasive 
cervical cancer (ICC) diagnosed in Sweden between 1999 and 2001. They verified the 
histopathological diagnoses and checked the Pap smear screening histories. They 
demonstrated that non-adherence to screening was the major reason for cervical cancer 
morbidity. Approximately 64% of all cervical cancers and 83% of advanced cases 
(FIGO stage II or higher) were diagnosed in women who were not screened. Two-
thirds of the cancer cases were younger than 66 years at diagnosis, implying that they 
have had the opportunity to participate in screening. The results from the audit support 
benefit from screening of women younger than 30 but as only one case of ICC occurred 
below the lower screening age 23, this, supports the view that screening of women 
younger than 23 years is unnecessary. Women found to have abnormal Pap smears 
when screened within the recommended interval comprised 11.5% of all cases of ICC, 
implying that risk of ICC could partly be reduced through improved management of 
abnormal Pap smears. Women with abnormal Pap smears who did not have a follow-up 
biopsy were at even greater risk; 7% of cancer cases were diagnosed in women with an 
abnormal Pap smear who were not followed up with histopathology (12). However, 
about 92% of women with cervical cancer discovered through screening were cured, 
including those who underwent screening for the first time. Early diagnosis 
significantly improves the chance of successful treatment, which is a powerful 
argument for having a Pap smear when called for cervical screening.  
A nationwide population based cohort study of all cervical cancer cases diagnosed 
during 1999-2001 (n=1230) and prospectively followed for 8.5 years found that, in 
addition to preventing cervical cancer, screening detected ICC also had a better 
prognosis than cancers detected on the basis of symptoms. Andre et al. also showed 
  7 
that the improved cure rate was largely attributable to detection at an earlier clinical 
FIGO stage. Symptomatic cancers are generally associated with a later stage (21). This 
effect was not attributable to lead time bias. Lead-time bias is “when detection at an 
early stage adds time to follow-up but does not alter the course of the disease”. Lead-
time is the length of time between detection of disease by screening and the detection 
resulting from the usual clinical presentation and stage at diagnosis.  
Analysis of where the greatest medical benefits of quality improvement can be realised 
has identified four important areas: 1. Increased participation; 2. Increased protection 
for women over age 60; 3. Improved prevention through better management of AIS; 4. 
More sensitive screening tests (HPV test)(18).  
 
2.3.1 Screening by conventional cytology (Pap smear) 
The method was first described by Dr Papanicolaou in 1941 and ever since this test has 
been referred to as the Pap smear. Since precursor lesions of cervical cancer usually 
arise in the transformation zone (TZ), it is important that cell material is adequately 
sampled from this zone. The presence of metaplastic squamous cells and endocervical 
cells indicates that the TZ has been properly sampled (22). European guidelines 
recommend three sampling methods (22): 1. the combination of a wooden spatula 
(Ayre or Aylesbury) and an endocervical brush (e.g. Cytobrush), 2. a cervical broom 
(Cervex-Brush, Rovers) or 3. an extended tip spatula alone (Aylesbury). The best 
sampling device is the combination of Cytobrush with spatula, particularly with 
extended tip (23). The cells are smeared on a glass slide and immediately fixed to 
prevent air-drying, which distorts cellular detail. Ethyl alcohol 95% is used as fixative. 
The slides are stained according to the Papanicolaou staining method, which includes 
five separate dyes applied in a three-step process. 
Cytology testing has limited sensitivity for histologically confirmed CIN2+ (70-80%), 
with a high degree of variation among cytopathologists due to low-moderate 
reproducibility (24) (25) (26) (27) (28). Specificity for pronounced cytological 
abnormalities is high (92%-96%) and positive predictive value (PPV) is about 42%. 
Cervical cancer screening has been successful despite the low sensitivity of a single 
Pap smear because the repeated testing of screening programmes improves sensitivity. 
 
2.3.2 Liquid-based cytology (LBC) 
Liquid-based cytology (LBC) was developed to improve the quality of conventional 
Pap smears. It is a new technique for transferring cellular material and improving 
sample preparations on microscope slides. The cells are collected just as in 
conventional cytology, but only plastic sampling devices may be used. The cells are 
then immersed and rinsed in a vial containing 20 ml of collection fluid (PreservCyt 
Solution) and samples are processed according to the methodology used. Two major 
types of LBC are commercially available, ThinPrep (Cytec Corp. Marlborough, MA, 
USA) and SurePath (BD, Franklin Lakes, NJ, USA). The ThinPrep 2000 is a semi-
automatic processor that prepares one slide at a time. In the laboratory the vial is placed 
into the ThinPrep 2000 Processor, where cells are separated using a dispersion 
technique that breaks up blood, mucus, non-diagnostic debris and mixes the cell 
sample. The cells are then collected on a ThinPrep Pap Test Filter specifically designed 
to collect diagnostic cells in a thin layer, after which they are transferred to a glass slide 
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in a 20 mm-diameter circle and deposited into a fixative solution (29). The slides are 
then stained as in a conventional smear. The ThinPrep method was US FDA-approved 
(Food and Drug Administration) in 1996. The advantages of the method include greater 
likelihood of representative smears, fewer obscuring factors such as blood, mucus and 
inflammatory cells, and cellular material deposited in a thin layer that facilitates 
microscopic interpretation, thereby increasing laboratory efficacy and importantly, also 
facilitating supplementary analysis (e.g. HPV reflex testing). 
Previous studies have demonstrated that LBC increases the proportion of abnormal 
cytology findings. A Swedish study by Zhu et al. (30) comparing sensitivity for 
detection of high-grade lesions showed that the ThinPrep method was somewhat more 
accurate (66%) than conventional cytology (CC) (47%). Another Swedish randomised 
controlled trial (RCT) comparing the performance of LBC with CC in a population-
based screening setting showed a 40% increase in sensitivity for detection of high-
grade lesions with LBC (31), but the question is still controversial since subsequent 
studies failed to support improved diagnostic accuracy. A meta-analysis by Arbyn et al. 
from 2008 (32) found LBC is neither more sensitive nor more specific for detection of 
high-grade CIN compared with conventional Pap testing. A large 2009 RCT from the 
Netherlands (33) involving 89 784 women concluded that neither sensitivity nor 
positive predictive value (PPV) for detection of cervical cancer precursors improved 
with LBC compared with conventional Pap testing. Another large RCT from Italy, 
Ronco et al., involving 45 000 women, came to the same conclusion, but also showed a 
large reduction in unsatisfactory smears. In a Swedish study by Fröberg et al. 2013, no 
significant differences in screening performance between LBC+HPV triage and 
conventional cytology were observed. Both methods showed similar detection rates for 
high-grade CIN and PPVs for detection of these lesions, indicating similar sensitivity 
and specificity for both cytological methods (34). Despite its higher cost, LBC has 
largely replaced CC in several countries and the Swedish Society for Obstetrics and 
Gynaecology now recommends LBC (35).  
However, cytological interpretation is subjective and requires quality control and 
assurance to achieve and maintain accurate clinical performance. Since it is also labour-
intensive, automated high-throughput screening has been difficult to achieve. Despite 
its low cost, cytology may not be the most cost-effective screening option for the 
reasons mentioned above (25). Although LBC has its advantages, it is more expensive 
and neither more sensitive nor more specific than conventional cytology, for which 
reason newer methods need to be evaluated. A 2013 Danish study (36) showed that 
implementation of image-assisted reading of LBC samples, regardless of the brand 
used, increased the proportion of abnormal findings by about 30% in all age groups 
(range from 19% to 41%). A laboratory equipped with conventional technology 
showed no trend towards an increase in abnormal findings during the study period.  
 
2.3.3 Cytology and Histology Classification systems 
Different classification systems have been used to evaluate cytological smears. 
Uniform grading of cellular abnormalities is essential for registration and comparisons 
over time and between different settings and countries. The Bethesda System (TBS) 
was developed to serve as a uniform system of terminology that would provide clear 
guidance for clinical management (37). This system was most revised in 2001. 
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European guidelines state that laboratories should use a nationally agreed terminology 
for cytology that is translatable into TBS (38). (Table 1) 
The Swedish Society of Pathology and Clinical Cytology has formulated a uniform 
classification system that is essentially based on the CIN (Richart) System (39, 40) and 
which can easily be translated into TBS. This classification system is termed “Sverige-
remissen”. According to the Swedish Society for Clinical Cytology, koilocytosis 
without nuclear atypia should be reported as non-pathological and not as LSIL; 
however, this would be a rare finding. Furthermore, AIS and adenocarcinoma are 
classified together and not subdivided as in TBS, because both are unusual diagnoses. 
 
Table 2. Conversion table for different cytological classification systems (41). 
 
WHO	   CIN	   TBS	  2001	  
Normal	   	   Negative	  for	  epithelial	  
abnormality	  
Atypia	   	   ASC-­‐US,	  ASC-­‐H	  
Atypical	  glandular	  cells	   	   Atypical	  glandular	  cells	  
Mild	  dysplasia	   Condyloma	  
CINI	  
LSIL	  
Moderate	  dysplasia	   CIN	  II	   HSIL	  
Severe	  dysplasia	   CINIII	   	  
CIS	   	   	  
AIS	   CGIN	   AIS	  
Invasive	  carcinoma	   	   	  
 
European guidelines for cervical histopathology strongly recommend CIN 
classification for histological diagnosis (42). CIN grading reflects the biology of the 
underlying lesion. CIN1/koilocytosis (correlating to LSIL) is likely to be reversible, 
associated with productive HPV infection and has low potential to progress to cancer 
(43). Cytological, virological and molecular profiles of CIN1 appear to be similar to 
those of epithelium without CIN (44). CIN2 and CIN3/carcinoma in situ (CIS) 
(correlating to HSIL) are more likely to persist or progress if left untreated and are also 
more likely to be associated with HPV integrated into the host genome (43), indicating 
a considerable risk of developing cancer. There is consensus on recommending 
treatment for CIN2 and CIN3 (45), which is why they are often included under the term 
high-grade CIN. However, it is clinically relevant to distinguish CIN2 from CIN3 (46). 
CIN2 is an intermediate condition, which contains over-called CIN1 and under-called 
CIN3, while CIN3 is a more robust and reproducible diagnosis than CIN2 and is 
therefore more useful as a gold standard for outcome (46). Any distinction between 
individual grades of CIN is poorly reproducible, but improves with increasing grade. 
Intraepithelial squamous lesions are characterised by abnormal cellular proliferation 
and maturation, together with nuclear atypia.  
Intraepithelial lesions are classified into three categories following Richart´s description 
of cervical intraepithelial neoplasia (CIN) terminology (47). In CIN1 (flat condyloma, 
koilocytosis, mild dysplasia), atypical cells are present in the lower third of the 
epithelium. These lesions frequently show marked HPV cytopathic effects including 
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perinuclear halos, multinucleation with nuclear membrane irregularities, and 
hyperchromasia (e.g. “koilocytosis”). In CIN2 (moderate dysplasia), neoplastic 
basaloid cells and mitotic figures occupy the lower two thirds of the epithelium. In 
CIN3 (severe dysplasia; carcinoma in situ) the full thickness of the epithelium is 
engaged where the cells have high nuclear/cytoplasmic ratios with scant cytoplasm and 
dense, hyperchromatic nuclei with coarse clumped chromatin and irregular nuclear 
outlines (48). CIN terminology is used for reporting both histological and cytological 
diagnoses. 
When attempting to distinguish reactive squamous proliferations from HPV-induced 
lesions pathologists frequently make errors. The most common error in the category of 
mild dysplasia is “overcall” of non-specific inflammatory or reactive lesions as 
productive HPV infections. In the ASCUS-LSIL Triage Study (ALTS), 45% of 
biopsies initially classified as CIN1 were downgraded to non-CIN when reviewed by a 
panel of expert gynaecological pathologists (49). Distinction between CIN2 and both 
CIN1 and CIN3 in biopsy specimens is complicated by the fact that the thickness of the 
epithelial changes often varies greatly within any given cervical biopsy specimen, while 
the angle at which the epithelium has been cut during histological sectioning may also 
have an effect. Immature metaplasia, atrophy, and reparative processes are lesions 
unassociated with any risk for progression to carcinoma and may be misinterpreted as 
CIN2 and CIN3. In such cases p16 staining and repeat cytology after oestrogen 
administration, as well as additional HPV testing may be helpful. 
 
  
Fig 3. CIN1-3 From Tavassoli & Devilee (2003)  
However, in regard to reproducibility, LSIL is one of the most robust cytological 
interpretations. Conditions that mimic HPV-associated koilocytosis include 
intracytoplasmic glycogen, especially in women taking oral contraceptives or hormone-
replacement therapy, and “pseudo koilocytosis”, which may be identified in some older 
women with atrophic findings. HPV-negative LSIL women in the ALTS study who 
demographically resembled a lower risk population were more likely to be older and 
report fewer sex partners than women with HPV-positive LSIL, supporting the view 
that some HPV-negative LSIL represents false-positive cytology. Newer staining 
methods and biological markers will help to distinguish between these diagnoses. 
 
2.4 COLPOSCOPY 
The purpose of colposcopic examination is to identify diseased tissue by localising and 
diagnosing suspicious areas of the ectocervix and vaginal fornices (sites where 
dysplasia may occur) to allow targeted sampling (biopsies) from these areas for 
histopathological confirmation. The procedure provides illuminated magnification (6-
40x) of the cervix and the vagina. Various solutions (normal saline, 3%-5% acetic acid 
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and Lugol’s iodine) are then applied in a given order to the cervical epithelium, which 
turns precancerous lesions “acetowhite”. A green filter can also be used to examine the 
sub-epithelial vascular pattern (Sellors & Sankaranarayanan, 2003). Abnormalities 
preferentially develop within the TZ and are graded according to morphological 
features such as acetowhiteness, margins, blood vessels and iodine uptake. 
Microinvasive and invasive squamous cancers are densely acetowhite with markedly 
atypical blood vessels. The surface configuration gradually changes from small 
protuberances to raised edges, irregular surface contours and bleeding blood vessels. 
Dr. Hans Hinselmann from Germany first described this method in 1925. 
The International Federation of Cervical Pathology and Colposocpy (IFCP) 
recommended new terminology for colposcopy in 2011. The new nomenclature covers 
terminology related to the cervix and the vagina. Various types of cervical excision 
methods and specimen dimensions are also included. The terms “satisfactory 
colposcopy and unsatisfactory colposcopy” have been replaced. The colposcopic 
examination should be assessed for three variables: Adequate or inadequate, including 
reason why, squamocolumnar junction visibility and transformation zone type (Table3). 
 
2.4.1 Terminology and the Transformation Zone (TZ) 
The TZ is the area between the original squamous epithelium and columnar epithelium 
within which varying degrees of maturity may be identified. Three types of TZs have 
been described and are classified according to these findings: 
¥ Size of the ectocervical component 
¥ Position of upper limit 
¥ Visibility of the upper limit 
 
¥ Transformation zone Type 1 Completely ectocervical and fully visible  
¥ Type 2 Fully visible with an endocervical component 
¥ Type 3 Endocervical component present, but not fully visible (50). 
Fig 4, TZ types 
 
The following points may provide clinical guidance:  
¥ ¥Describe features  
¥ ¥ Surface contour and edges 
¥ ¥ Speed of uptake of acetic acid/whiteness 
¥ ¥ Features of acetic acid/whiteness 
¥ ¥ Iodine staining 
¥ ¥Transformation zone type  
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¥ ¥Extent of lesion 
¥ ¥Colposcopic opinion 
¥ ¥Management plan 
 
2.4.2 Colposcopic findings and biases in assessment 
Studies have shown poor correlation between colposcopic impressions and histological 
diagnosis and therefore scoring systems have been developed to improve clinical 
prediction. The Reid Colposcopic Index (RCI) is the most well known (51). Strander et 
al. (52) developed a new scoring system, which in addition to the parameters evaluated 
in the RCI also includes lesion size. Studies have shown that the sensitivity of 
colposcopic biopsies is dependent on lesion size (53). KŠrrberg et al. also used the 
Swedish scoring system to evaluate pregnant women and concluded that it seems to be 
a useful tool that may reduce the need for diagnostic biopsies (54). 
Colposcopically directed punch biopsy from abnormal cervical areas is of great 
importance because a small piece of cervical tissue, often <5 mm in diameter, may be 
taken to confirm the clinical impression, since colposcopy alone misses approximately 
one-third of high-grade CIN. Biopsies may sometimes be randomly taken from the TZ 
when no lesion is observed (55). Such biopsies are often combined with histological 
sampling from the endocervical canal, especially if the ÒnewÓ squamocolumnar 
junction cannot be examined (inadequate colposcopic examination) or when an 
endocervical lesion is suspected. Colposcopy can also be used to assess the vagina, 
vulva and perianal skin. 
ÒAssessed sensitivity and specificity in colposcopy and directed biopsies are 
susceptible to biasÓ. According to IARC handbook on cervical cancer screening, the 
colposcopic impression confounds the reference standard of diagnosis (histology) since 
it dictates where the histological specimen is obtained (48, 56). Verification bias exists 
when diagnostic tests influence whether or not directed biopsies (the gold standard) are 
used to verify test results. In clinical practice this is more likely to occur when 
colposcopy is negative and no biopsies are taken. In this scenario, sensitivity estimates 
may be too high and specificity too low. Underwood et al. looked at possible reasons 
for missed high-grade CIN. Such reasons may include limitation of colposcopy to 
identify the specific abnormality, skill level of colposcopist, or failure to sample an 
identified abnormal area. Improved image quality is associated with improved detection 
of CIN2+, but seemingly normal cervical tissue, even with enhanced imaging, has been 
shown to contain CIN2+ disease in 25% of women referred for colposcopy. The 
conclusion therefore was that colposcopy itself, rather than punch biopsy, is the 
limiting factor for detecting CIN2+ (57). Newer technologies, such as electrical 
impedance spectroscopy and computer-assisted diagnosis, have been shown to improve 
colposcopic performance (58, 59). 
 
2.4.3 Accuracy of colposcopy 
Underwood et. al stated that there is increasing concern over the accuracy of 
colposcopically directed punch biopsies to diagnose high-grade CIN since recent 
reports have indicated lower sensitivity than previous reports. A Norwegian study 
reported that 24% of women with negative colposcopy-directed biopsies were found to 
have CIN2+ when follow-up biopsy was performed (57, 60). For example, the meta-
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analysis of colposcopic accuracy by Mitchell (61) found that sensitivity to predict 
CIN2+ was 96% and specificity 48%. Pretorius et al. (2004) demonstrated a 57% 
sensitivity to detect CIN2+ and that sensitivity increased to 95% by adding random 
biopsies at the squamocolumnar junction. Adding endocervical curettage also increased 
sensitivity by 5.5% in women with adequate colposcopy. Pretorius concluded that 
random biopsies should be considered if cytology was high-grade. (55, 62).  
The ALTS trial demonstrated that sensitivity depends more on number of biopsies 
taken than on training of the colposcopist, and that taking random biopsies increases 
detection of CIN2+, but data are limited since only women with ASC-US or LSIL were 
included (53, 63, 64). Pretorius also stated that regardless of skill, performing more 
biopsies increases the sensitivity of colposcopy (65).  
A meta-analysis by Underwood, which included 32 papers published between 1969 and 
2011, demonstrated that pooled sensitivity for a single punch biopsy was 90% and 
when one or more punch biopsies were performed, the sensitivity increased to 93%. 
When multiple biopsies are routinely taken, sensitivity approaches 100%. Specificity to 
diagnose CIN2+ was 24.6%.  
The TOMBOLA trial identified a proportion of false-negatives associated with punch 
biopsy, but concluded that the impact on clinical outcome was insignificant because the 
next screening round would pick up missed cases (66). Missed disease may simply 
represent an over-diagnosis of small regressive foci of CIN2/3.  
Another valuable outcome from the TOMBOLA trial was the establishment of a policy 
of targeted punch biopsies with subsequent treatment for CIN 2+, as well as a policy of 
cytological surveillance for CIN 1 or less to provide the best balance between benefit 
and harms for management of women with low-grade abnormal cytology who were 
referred for colposcopy. Immediate large loop excision results in over-treatment and 
should not be recommended (67). Since management decisions on whether to treat or 
monitor abnormal cervical cytology are often determined by the findings on punch 
biopsy, it is important for colposcopists to be aware of the limitations of the method.  
Underwood concluded that the observed high sensitivity and low specificity for high-
grade CIN in colposcopy-directed biopsy might result from verification bias. 
Sensitivity appears to be high, but is probably a “spurious” finding because most 
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Table 3. Provided by the International Federation of Cervical Pathology and 
Colposcopy, 2011. 
 
2.5 REFRAMING CERVICAL CANCER PREVENTION 
Cervical cancer is a rare complication of persistent infection with high-risk types of 
HPV. There is no consensus regarding the definition of “persistence” other than 
presence of HPV DNA on repeated testing of cervical specimens. The lifetime 
probability of encountering HPV at some point is as high as 80%-90%. However, most 
infections clear spontaneously without clinical signs or symptoms. In all, 4%-10% of 
middle-aged women are estimated to be persistent carriers and thus represent a true 
high-risk group for cervical cancer and probably also for other HPV-related cancers. 
The underlying mechanisms that determine whether infections resolve or become 
persistent are still unclear. Because lag time between age at peak incidence of HPV 
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infection and age at peak incidence of cancer is two to four decades, the initiating 
infection and its precursor lesions become a perfect target for screening and early 
detection.  
The majority of vaginal cancer and their precursor lesions are associated with high-risk 
HPV types, with a reported range of 51.4%-81% (68-71). Fuste et al. concluded that 
HPV-positive tumors of the vagina tend to affect women with history of cervical 
neoplasia (72) and Alonso et al. demonstrated that HPV-positive early stage (FIGO I 
and II) vaginal squamous cell carcinoma had a better prognosis than early HPV-
negative tumors (69). An estimated 40%-50% of cancers of the vulva have also been 
associated with HPV. In men, HPV DNA is found in cancer of the penis (40%-50%) 
and in both sexes, HPV DNA is detected in anal cancers (88%-94%). In head and neck 
cancers, the prevalence of HPV varies, but has been found in 35%-50% of 
oropharyngeal cancers. HPV16 is the most common type in all non-cervical cancers. 
According to a meta-analysis by De Vuyst et a., HPV 16 was found more frequently 
(>75%) and HPV18 less frequently (<10%) in HPV-positive vulvar, vaginal and anal 
carcinomas than in cervical carcinoma. HPV6 and HPV11 are common among genital 
warts and respiratory papillomatosis (RRP) but De Vuyst also reported that HPV6 and 
HPV11 were common in VIN1 and AIN1, but not in VAIN1 (vulvar, anal and vaginal 
intraepithelial neoplasia)(73). Current vaccines have been shown to protect against 
type-specific precancerous lesions and against genital warts in both females and males. 
HPV vaccination of men has also shown high efficacy against HPV-related anal 
precancerous lesions and anal cancer. 
The tremendous amount of new knowledge has “prompted a paradigm change” of 
cervical cancer prevention to include prevention of HPV infections and related diseases 
(74).  
 
2.6 NATURAL HISTORY  
Of all HPV infections, cervical infections are the best understood, but we still lack 
insight into the final steps of carcinogenesis. At all ages, new infections are benign 
unless they persist.  Persistence of an infection is the known necessary event for 
development of cervical pre-cancer and cancer. There is conflicting evidence as to 
whether any single type of HR HPV (especially HPV16) persists longer than others in 
the absence of development of CIN3+. 
Studies have demonstrated that up to half of infections clear within 6 months and the 
great majority (90%) clear within a few years after acquisition.  
 
 
Fig 5. From: Updating the natural history of human papillomavirus and anogenital 
cancers(75) 
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According to Moscicki, the major steps in cervical carcinogenesis are: 
1. Infection of the metaplastic epithelium of the cervical transformation zone (TZ) 
with one or more high-risk HPV types 
1. Viral persistence 
2. Clonal progression of the persistently infected epithelium to cervical pre-cancer 
3. Invasion 
4. The time between infection and clonal development of CIN3 cannot be precisely 
determined, because it depends on the intensity of surveillance and diagnostic limits 
of colposcopic biopsies, but the time required for detectable CIN3+ is likely 7-10 
years. 
5. The time from initial development of a small CIN3 lesion to invasive cancer may 
be up to 10 years(75). 
 
2.6.1 Risk of CIN3+ following a positive HPV test. 
Large cohort studies have estimated the absolute risks associated with different HPV 
genotypes. A Swedish study by Sundström et al. demonstrated that the presence of 
HPV16/18 in the first smear was associated with an 8.5-fold increased risk of CIS and 
an 18.6-fold increased risk of SCC, compared with women who are HPV-negative. 
Infection with other HR HPV types in the first smear was also associated with 
significantly increased risk. Persistence of HPV16 infection conferred a relative risk of 
18.5 for CIS and 19.5 for SCC (76), which as expected represents a substantial increase 
in risk due to repeated HPV positivity. 
Another Swedish study by Dahlström et al. investigating the risk of adenocarcinoma in 
situ (AIS) and invasive adenocarcinoma (AC) found that HPV 16-positivity in a normal 
smear was associated with an increased risk of both future AIS (OR: 12, 95% CI: 3-47) 
and AC (OR: 16, 95% CI: 4-67), when comparing with women who were HPV16-
negative. Moreover, HPV 18-positive smears were associated with even higher risks for 
AIS (OR: 26, 95% CI: 3-192) and AC (OR: 28, 95% CI: 4-206)(19). A Danish cohort 
study by Kjaer et al. (77) showed that HPV16 had the greatest tendency to persist and 
was associated with the highest probability for progression when persistent, followed 
by infection with HPV18, HPV31, and HPV33, while HPV-negative women remained 
at very low risk. Women who tested positive for HR HPV at baseline and 2 years later 
were found at 12 years to have a 19.3% absolute risk of CIN3+. For a persistent HPV16 
infection, the risk of CIN3+ within 12 years was 47.4%. However, rates of HPV16 
persistence after an incident infection are similar to other high-risk HPV types (75, 77).  
 
2.6.2 Risk of CIN3+ following a negative HPV test 
Several large cohort studies have confirmed that risk of CIN3+ is very low in the years 
following one or two negative HPV tests, regardless of age. Dillner et al. studied long-
term cumulative incidence of CIN3+ in six European countries and observed that after 
six years cumulative incidence rate was considerably lower among women who were 
HPV-negative at baseline (0.27%) than among women who only had negative cytology 
at baseline (0.97%) (78). The longest follow-up time was 16 years, where cumulative 
risk of cervical cancer among HPV-negative women was 0.26%(79). 
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Since HPV-negative women include both women who have cleared their infections and 
women who have never been positive (the two sub-groups cannot be distinguished) and 
because a negative HPV test is associated with a very low risk of ICC, the conclusion 
that can be drawn is that once cleared, infections neither reappear nor cause large 
numbers of CIN3+ cases (75). Young women are vulnerable to reinfection with a 
different or the same HPV types after documented clearance (80). Median time to the 
first negative test after incident infection (following a previously negative HPV test) 
was 9.4 months. In all, 90.6% of infections became undetectable within 2 years and of 
those, 19.4% were redetected within 1 year. The bulk of cancers in a population can be 
attributable to infections that were acquired at a young age and do not clear (81). 
 
2.6.3 Non-viral co-factors  
The most well-established co-factors (risk factors) for ICC among HPV-infected 
women are smoking, long-term hormonal contraceptive use, multiparity and human 
immunodeficiency virus (HIV) infection. It is unknown whether the mechanism of 
action for these co-factors is to increase risk of viral persistence or risk for progression, 
given persistent infection, with the exception of HIV, where results indicate that 
infection increases risk of persistence regardless of age. However, these known 
behavioural co-factors are less etiologically important than HPV genotype.  
One study by Hwang L.Y. et al. found that smoking and oral contraceptives enhances 
squamous metaplasia, which is believed to support viral persistence (82). Studies have 
also found that age at first intercourse is a risk factor for cancer development. The 
prevalence of HPV peaks at a young age, when the process of metaplasia is also active. 
Risk of ICC was 2.4-fold higher among women reporting their first intercourse or first 
pregnancy before age 16, compared with those over 21 (83). Early first intercourse may 
also be a marker of high-risk behaviour, through which more HPV infections are 
acquired. 
Lifetime number of sexual partners also correlates with higher exposure to HPV 
infections and a history of more than five partners doubles the risk(84). Risk of ICC 
also increases with the number of full-term pregnancies. More than seven full-term 
pregnancies have been shown to quadruple risk, while two full-term pregnancies 
double risk. Data from a recent Danish cohort study also support the notion that 
childbirth increases risk of subsequent CIN3+ in addition to the already increased risk 
for CIN3+ among women with persistent HPV infections. No associations were found 
with number of pregnancies, use of intrauterine devices, or sexual behaviour (85). 
Mechanisms that have been proposed to explain the increased risk of pre-cancer or ICC 
among multiparous women include elevated hormone levels and impaired immune 
responses. The TZ also remains on the ectocervix for a longer time, which may make 
these women more vulnerable to exposure to HPV and other cofactors. However, the 
Danish study could also be interpreted to mean that increased risk is related to delivery 
rather than to pregnancy per se, perhaps because of local tissue damage or cellular 
oxidative stress with DNA damage(85). 
Sex hormones appear to be involved in cervical carcinogenesis. It has been suggested 
that oestrogen stimulates HPV gene expression, influences cervical immune response 
and stimulates cell proliferation in the TZ (85). Oral contraceptive (OC) use involves 
low-intensity hormone stimulation, but is often more long-term than pregnancy and 
childbirth. Data are conflicting regarding risk of pre-cancer and ICC, where some 
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prospective studies have shown no association (86, 87) while others indicate increased 
risk associated with long-term use of OCs (88). 
However, the strongest risk factor resulting in persistent infection is likely to be lack of 
an adequate immune response, as reflected by high risk of HPV-related diseases among 
HIV-infected individuals, as well as among patients receiving immunosuppressive 
treatment. 
The role of Chlamydia trachomatis as a co-factor is also controversial. A study by 
Safaeian et al. (89) suggested that the association between Chlamydia and HPV may 
partly be due to an increased susceptibility to HPV, since they found no association or 
risk of pre-cancer in this regard, as was found in earlier studies. However, a recent large 
European study with 9 years of follow-up also indicated that Chlamydia and Herpes 
Virus 2 may possibly contribute to cervical carcinogenesis. It further identified HPV16 
E6 seropositivity as the strongest marker to predict ICC well before disease 
development (90). In addition, a recent Finnish study concluded that concomitant 
infection with HPV18/45 and C. trachomatis was associated with very high risk of 
CIN3 (91). 
A European cohort study (92) also found that smoking is a major risk factor for 
developing cervical pre-cancer and ICC, which is consistent with previous findings. 
Smoking status, duration and intensity relate to disease and are associated with an up to 
a two-fold increased risk of CIN3/CIS and ICC, while length of time since quitting 
reduced risk by up to a factor of two. The strong beneficial effect of quitting smoking is 
an important finding that can support public health policies for smoking cessation. 
In a large pooled analysis by Castellsagué, the only differences in cofactors observed 
relate to adenocarcinoma, where smoking and Chlamydia infection were unrelated, in 
contrast to SCC (93). 
 
2.6.4 Re-infection, re-activation or clearance 
This is a complex issue, but there is evidence that transient infections are cleared by 
innate immune responses and are less likely to result in a memory immune response, 
thereby leaving women vulnerable to re-infection. Moscicki et al. found that sexual 
behaviours were highly associated with redetection of infections, suggesting they may 
be due to re-exposure. The ambiguity may arise because antibodies are not the likely 
mechanism of protection against natural infections and cell-mediated immunity is more 
difficult to measure. Redetection may also be due to autoinoculation from other 
mucosal sites (75). 
 
CIN2 is thought to be an intermediate stage between CIN1 (HPV infection) and CIN3 
(direct cancer precursor), but this has recently been questioned, since many studies 
have shown that reproducibility of the CIN2 diagnosis is quite poor (94). Two review 
pathologists agreed with 84% and 81% of initial diagnoses of CIN3, compared with 
only 13% and 31% of the CIN2 diagnosis. However, several studies, especially in 
young women, have found rather poor reproducibility of the CIN3 diagnosis as well 
(95). Regression rates of CIN2 among young women under age 25 are high, up to 75% 
(96). In older women, regression rates are lower at around 30-50% over a 2-year period 
(97). For all ages, the regression rate for CIN2 appears to be lower than for CIN1, 
which is about 90%, but higher than for CIN3, which is about 20%-30%. The 
discrepancy in making diagnoses may also be due to misclassification of lesions. An 
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interesting study examined the protein expression from supernatants from fresh 
biopsies and found that several proteins could be used to differentiate CIN2 from CIN3 
lesions, where Cytokeratin 2 was found to be the best discriminator with 90% correct 
classification (98). A frequently cited review from Östör reported that the likelihood of 
regression of CIN1 is 60%, persistence 30%, progression to CIN3 10%, and 
progression to invasive disease 1%. The corresponding numbers for CIN 2 are 40%, 
40%, 20%, and 5%, respectively. The likelihood of CIN 3 regression is 33% and 
progression to invasive disease, greater than 12%. McCredie et al. reported results from 
an unethical clinical study where treatment for CIN3 was withheld from 1229 women 
in Auckland, New Zealand (1965 to1974). In women managed only by punch or wedge 
biopsy, cumulative incidence of invasive cancer of the cervix or vaginal vault was 30% 
(95% CI 23–42) at 30 years, and 50% (95% CI 37–65) in the subset of 92 women who 
had persistent disease within 24 months. The risk of cancer at 30 years was only 0.7% 
among women who were initially treated with conventional therapy (99).  
 
2.6.5 Heterosexual transmission and autoinoculation 
Transmission can be calculated in many different ways, like transmission probability 
per partnership, viral quantity, and nature of sexual encounters or per coital act. 
Transmission between heterosexual couples is very common, although rates vary 
widely among studies. The cumulative transmission probability over a 6-month period 
(i.e. the probability that an infected partner transmits HPV to a susceptible partner) 
ranged from 5%-28% for male-to-female and 19%-81% for female-to-male. Most 
studies have observed a higher rate of female-to-male versus male-to-female 
transmission. Specimens from women collected soon after vaginal intercourse (up to 
48h) may result in false HPV positivity due to contamination from the sex partner and 
not to a true infection. The highest transmission rate was observed when one partner 
had a persistent infection (extended exposure) and probably a higher viral load (100). 
Sexual transmission to the oral tract via oral sex and open-mouthed kissing is 
associated with cancers of the oropharynx, tonsil and base of tongue (75, 101). Studies 
indicate that the anus may serve as a reservoir for HPV infection of the cervix but also 
the opposite. Moscicki reports a higher relative risk (RR) of acquiring an anal infection 
after a cervical infection with the same HPV genotype (20.5) than vice versa (8.8). It is 
more likely that the cervical infection serves as the source as vaginal discharge is 
frequently found on the perineum and can easily be transmitted to the anus (toilet 
paper). Anal sex can also be underreported in studies. HPV of the same genotype on the 
fingers as on the genitals most likely represents deposition of HPV DNA rather than a 
true infection but nonsexual routes of transmission (inoculation through fingers) cannot 
be ruled out (75). 
Studies have shown that anal infections in women and in men who have sex with men 
are quite common but clearance is also common, unless the individual is infected with 
HIV. HIV strongly influences development of anal intraepithelial neoplasia (AIN). 
Women with other HPV-associated lesions, including CIN3+ and vulvar cancer, have 
higher rates of anal cancer (8). 
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2.7 HPV BIOLOGY AND LIFE CYCLE  
2.7.1 HPV Classification 
Human papillomaviruses (HPV) have evolved over millions of years and survived in a 
wide range of animal species and humans. HPVs comprise a large and diverse group of 
viruses with 174 fully characterised types and new HPV types are continually being 
found (102). There are five major HPV genera, based on DNA sequencing, each with 
different epithelial tropism and disease associations: Alpha papillomavirus, Beta 
papillomavirus, Gamma papillomavirus, Mu papillomavirus and Nu papillomavirus. 
HPVs infect epithelial cells of genital mucosa (alpha papilloma viruses only), oral 
mucosa and skin (all five genera). HPV types belonging to different genera have less 
than 60% similarity, based on the nucleotide sequence of the capsid protein L1. 
Different viral species within a genus share 60%-70% similarity. A novel HPV type has 
less than 90% similarity to any other HPV type; i.e., a new genotype differs by more 
than 10% in the DNA sequence of the L1 open reading frame (ORF) from the closest 
known HPV type. When DNA only differs by 2%-10%, the two viruses are considered 
subtypes of the same HPV type. Variants by definition differ from one another by a 
maximum of 2% in the L1 gene (103). A novel HPV type is assigned a number after 
the whole genome has been cloned and deposited at the International HPV Reference 
Center, which was established in Heidelberg in 1985 and subsequently transferred to 
Karolinska Institutet in 2012 (www.hpvcenter.se)(7). 
HPV causes a wide range of diseases from benign lesions to invasive tumours. The 
various diseases appear to be associated with different strategies of transmission and 
propagation within the epithelium, as well as different interactions with the immune 
system. Various HPV types have adapted to specific epithelial niches with different 
types having different disease associations (102).  
Alpha papilloma viruses are divided into cutaneous and mucosal types. Mucosal Alpha 
types are the most studied and clinically important and can be subdivided into high-risk 
and low-risk groups. High-risk Alpha types have been clearly linked with development 
of SCC and AC of the cervix. Approximately 40 different HPV types are known to 
infect the genital mucosal epithelium and a subset of 10–15 HPV types are associated 
with lesions that can progress to cancer. In 2009, an IARC working group 
(International Agency for Research on Cancer) classified 12 mucosal HPV types 
(HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56 58 and 59) as carcinogenic to humans 
(Group 1) (104). They are referred to as high-risk (HR) HPV types. These 12 types 
cluster together in the same evolutionary branch or “high-risk clade”. Eleven additional 
types in the high-risk clade were classified as possibly carcinogenic (Group 2B) based 
on their phylogenetic relatedness to Group 1 types, with the exception of HPV68, 
which was upgraded to probably carcinogenic (Group 2A). Types that are closely 
related evolutionarily (e.g., HPV16 and 31) may exhibit different degrees of cancer 
risk, thought to be related to different protein functions and patterns of gene expression. 
Low-risk HPV types share many similarities with HR types, but are not found in ICC. 
HPV6 and 11, also belonging to the Alpha papillomavirus genus, cause benign genital 
condylomas. HPV3 and 10 are cutaneous Alpha types that cause flat warts (105). High-
risk HPVs do not cause cancer in the vast majority of individuals they infect. 
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Fig 6. Alpha Papillomavirus Disease Association and Genome Organisation of HPV16 
(102) 
 
2.7.2 Genome organisation 
HPVs are small, circular double-stranded DNA viruses containing almost 8000 base 
pairs. The viral icosahedral capsid is composed of two structural proteins, the major 
capsid protein L1 and the minor L2. The viral genome is functionally divided into three 
domains based on location – the long control region (LCR) and eight genes termed 
either “early” or “late”. They encode for a large number of viral proteins that are 
necessary for different stages of the viral life cycle, where E and L signify early and 
late events in the viral life cycle. The LCR is non-coding and shows the highest degree 
of variation in the viral genome. It contains binding sites for transcription factors and 
for viral E1 and E2 proteins, which control viral replication and gene expression. 
HPV16 has two promoter elements known as PE (early promoter) and PL (late 
promoter) that regulate the expression of differentially spliced mRNAs during epithelial 
differentiation (102). The early region consists of six open reading frames (ORF): E1, 
E2, E4, E5, E6 and E7. An ORF is a sequence of bases coding for a protein. These 
early genes are involved in regulation of replication and transcription, cell growth, 
maturation and virus release and malignant transformation. The late genes code for the 
structural proteins L1 and L2. 
 
2.7.3 Start of infection 
HPVs are intracellular parasites, dependent on the cell machinery of basal cells in 
stratified epithelium to replicate. Through a micro wound in the epithelium, HPV binds 
via its L1 major capsid protein to heparan sulfate proteoglycans (HSPG) on the 
basement membrane (BM) and undergoes a conformational change that exposes the N-
terminus of the L2 minor capsid protein. This leads to furin cleavage and proteolysis of 
the L2 protein exposes a previously occluded surface of L1 that then binds to a surface 
receptor on the keratinocytes. This second receptor binding leads to virus 
internalization and uncoating of the virus in endosomes. The endosomal escape 
mechanism is L2-dependent and the L2-genome complex is transported to specific 
subnuclear domains, ND10 bodies where viral gene transcription is initiated. The L1 
protein is retained in the endosome and undergoes lysosomal degradation. The 
infectious process is slow and takes 12-24 hours before transcription begins. The 
effectiveness of neutralizing antibodies after vaccination might partly be due to the 
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extended exposure of antibody neutralizing determinants on the BM and the cell 
surface (106). 
 
2.7.4 Function of LR and HR HPV proteins 
It is thought that infection is followed by an initial phase of genome amplification and 
then maintenance of the viral episome at a low copy number in the basal cell layers 
(200 copies/cell). The viral replication proteins E1 and E2 are thought to be essential 
for the initial amplification phase, but their exact role is not yet clear. E2 regulates viral 
transcription, binds to the LCR and can recruit viral E1 protein. The role of E6/E7 
proteins in infections with LR HPV types is uncertain, but the functional differences 
between the low-risk and high-risk E6/E7 proteins contribute to their different 
pathogenesis and to their different patterns of gene expression. 
The proliferation of basal and parabasal cells by HR HPV leads to lesion growth and is 
mediated by the E6 and E7 proteins. A key function of the E6/E7 proteins is to 
stimulate cell cycle re-entry in mid-epithelial layers to promote genome amplification. 
Deregulation of E6/E7 expression is critical in determining neoplastic grade, even in 
the absence of viral integration. Functional differences between HR and LR E7 proteins 
relate to their different affinities for binding to the retinoblastoma (Rb) protein family. 
HR E7 binds and degrades p105 and p107, which control cell cycle entry in the basal 
layers, as well as p130, which is involved in cell cycle re-entry in the upper layers. HR 
E7 also stimulates host gene instability through deregulation of the centrosome cycle in 
the basal cells. A key difference between LR E6 and HR E6 is that the latter has a PDZ-
domain motif at the C terminus and is able to interact with PDZ targets, which are 
involved in regulation of cell polarity, proliferation and signalling. Other important and 
unique differences from LR E6 include the capacity of the HR E6 protein to: 1. 
upregulate telomerase activity to maintain telomere integrity during repeated cell 
divisions and 2. to mediate intracellular p53 degradation. As mentioned above, a key 
function of HR E6 and E7 expression is to allow infected cells in the upper epithelial 
layers to re-enter S-phase in order to increase viral copy numbers. Viral proteins E1 and 
E2 are also upregulated and increase in quantity. The proliferating epithelial cells 
express both markers of differentiation (keratins 1, 10, 4 and 13) and markers of cell 
cycle entry (MCM, Ki-67, PCNA, Cyclin E and Cyclin A). Cellular DNA replication 
occurs first, followed by replication of the viral genome. 
E4 and E5 proteins modify the cellular environment and E5 is involved in koilocyte 
formation (102). 
 
2.7.5 HR HPV life-cycle, regulation and deregulation 
As mentioned above, a micro wound in the epithelium is required to allow virions to 
gain access to the basal lamina. Infection of the columnar cells may be facilitated by 
their proximity to the epithelial surface and the TZ. The proliferating cells of the 
metaplastic epithelium in the TZ are accessible and particularly susceptible to infection.  
As these cells divide, they produce daughter cells that are pushed outwards towards the 
epithelial surface, which triggers various events in the virus life cycle.  
In lesions caused by high-risk HPV types, cells in the lower layers express E6 and E7, 
which stimulate cell division. Genome amplification occurs when the proteins 
necessary for this event become elevated in the mid layers of the epithelium. The cells 
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will then express viral E4 protein and enter cell cycle phase S or G2. The S phase is 
when DNA replication occurs and the G2 phase is a gap between DNA synthesis and 
mitosis, during which a process is underway to ensure that everything is ready for 
mitosis to begin. When the cell cycle is finished in the upper epithelial layers, a subset 
of E4-positive cells starts to produce viral L1 and L2 proteins. These proteins form the 
shell of the virus and packaging of the viral genomes can now occur. An interesting 
hypothesis is that lesion formation begins with infection of basal stem cells and the 
longevity of the stem cells is the key factor in the formation of a persistent lesion (102). 
 
 
Fig 7. Regulation of Cell Cycle Entry and Proliferation in HR HPV Infected 
Epithelium. Locations of cells driven into cell cycle are marked by red nuclei in the 
epithelium. A yellow nucleus represents the appearance of L1 (102).  
 
In HR HPV infections, the E7 protein indirectly inactivates the retinoblastoma tumour 
suppressor protein without the need for phosphorylation, as in uninfected epithelium, 
by displacing E2F from pRb (p105) and from p130 (pRb family member) thereby 
allowing transactivation of the genes necessary for S-phase progression. The absence of 
effective inhibition of cell cycle progression by p16ink4a leads to its accumulation in 
the cell and also to elevation of MCM, Ki-67 and PCNA levels in the infected epithelial 
layers. p16ink4a normally forms a negative feedback loop that suppresses growth 
factors (cyclinD/cdk) that control cell cycle entry and cell division activity, the 
overexpression of itself and other E2F-activated genes (MCM, Ki-67, PCNA). This 
leads to elevated p14arf levels which compromise the normal p53 degrading function 
of MDM. Consequently there is an increase in p53. P53 mediates cell cycle arrest, but 
this function is now countered by high levels of HR E6 proteins in the proliferating 
cells, which associate with E6AP. The result is ubiquination and proteasomal 
degradation of p53 (102). Detection of HPV in tissue biopsy or in exfoliated cervical 
cells may indicate productive infection (CIN1), abortive infection (CIN3), and presence 
of recently deposited virus particles that have not caused infection or latent infection. 
To distinguish between these possibilities, markers of viral gene expression may be 
useful to confirm active disease.  
Methylation of the viral genome can sometimes suppress gene expression and lead to 
silent infection in which viral genomes are retained in the basal cell layer without 
apparent disease.  
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Fig 8. The image on the left is a histology section showing uninfected epithelium, CIN1, 
CIN2 and CIN3. The image on the right shows the same piece of tissue stained with two 
biomarkers (MCM and HPV16 E4). The cellular marker MCM (red) is expressed at 
low levels in the basal and parabasal layers in uninfected tissue. As a surrogate marker 
of E7 expression, MCM protein is elevated to different extents in neoplasia. In HPV-
induced lesions viral E4 protein (green) becomes abundant as MCM levels decline 
during differentiation. Detection of E4 using type-specific antibodies confirms HPV16 
as the causative HPV type in this lesion (102). 
 
Expression levels of E6/E7 increase from CIN1 to CIN3, contributing to the 
accumulation of cellular genetic changes and ultimately leading to invasive disease. 
Viral deregulation is thought to facilitate integration of the viral episome into the host 
cell chromosome, where it encodes for viral oncogenes. Deregulation of early gene 
expression may follow from hormonal changes or epigenetic modifications, such as 
viral DNA methylation. The HPV16 LCR contains hormone response elements that can 
be stimulated by oestrogens, and there is abundant evidence that oestrogens and HPV 
co-operate in the development of cervical cancer. Different methylation patterns are 
linked to different degrees of disease severity and relate to changes in viral gene 
expression. Integration of the viral genome into the host cell genome occurs in many 
high-grade lesions, although cancer may arise from cells exclusively containing 
episomes. Host genetic susceptibility plays an important role. The host cell genome 
contains a number of fragile sites where viral integration is more likely to occur, 
although integration is generally a random event that may sometimes result in 
disruption of viral genes that regulate transcription from the LCR. E2 is of particular 
importance because it normally regulates E6/E7 expression. The majority of cervical 
cancers contain one or more copies of HPV randomly integrated into the host cell 
chromosome. Viral integration sites frequently lie within the regulatory E1 or E2 gene 
regions. Loss of E6/E7 regulation may facilitate persistent high-level expression of 
these genes. It is believed that once this occurs expression may increase even further. 
About 70% of HPV16-associated cervical cancers contain integrated HPV16 sequences 
in the host genome, while about 30% arise from cells containing only episomes. In the 
case of HPV18, the viral genome is almost always integrated (102). 
 
2.7.6 Immune response 
Cell-mediated immune response clears most infections, but HPV16 persists longer than 
other high-risk types, which may contribute to its higher risk for cancer. Models have 
provided evidence that cell-mediated immune responses and lesion regression are 
modulated by antigen-specific CD4+ T-cell dependent mechanisms. However, the 
hallmark of HPV infection is the effective evasion of innate immune recognition. The 
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viral productive life cycle is totally intraepithelial, which means there are no viraemia, 
no viral-induced cytolysis and no associated inflammation.  
HPV down-regulates the innate immune signalling pathways and also inhibits 
Langerhans cell activation and recruitment of dendritic cells. In high-risk HPV types 
the mechanisms of immune evasion have essentially been established. Immune 
regression results from cross presentation of HPV antigens by Langerhans cells, 
followed by T-cell infiltration and shut-off of viral gene expression. However, 
apparently normal cells can still contain silent viral episomes and may not be 
effectively cleared from the basal cell layers. It has been suggested that the virus may 
be reactivated following immune suppression, hormonal changes, or as a result of 
aging. Immune response failure and inability to recognise viral antigens has been 
reported among cervical cancer patients (102).  
 
2.8 TESTS FOR THE DETECTION OF HPV 
HPVs cannot be cultured in conventional cell cultures, and classical virological 
diagnostic techniques (electron microscopy, immunohistochemistry) are suitable for 
routine detection due to lack of sensitivity and specificity. Serological assays for 
detection of anti-HPV antibodies have limited analytical accuracy and, so far, no 
clinical utility. All HPV tests currently in use are based on detection of HPV nucleic 
acids in clinical specimens. A recent review by Poljak et al. identified at least 125 
commercially available HPV tests and, additionally, at least 84 variants of the original 
tests (107). They predicted that the number of commercial HPV tests will continue to 
increase in the future due to wide clinical applications which offer promising marketing 
opportunities for manufacturers. The design of new HPV tests will be guided by the 
categorisation of different HPV types into different risk categories. Since this varies 
over time and certain HPV types have been moved from one risk category to another, 
test design will need to accommodate such changes. 
The key issue for HR HPV DNA testing is to detect HR HPV infections associated 
with high-grade cervical disease and to differentiate them from transient HR HPV 
infections. There needs to be a balance between clinical sensitivity and specificity for 
detection of CIN2+. Compared with cytology testing, HPV testing has been shown to 
have higher sensitivity and therefore higher negative predictive value (NPV). A 
negative HPV test is therefore reassuring that no clinically significant lesion is present. 
Other advantages of HPV testing include high reproducibility, no inter-observer 
variation, dichotomous results (positive or negative), high throughput and automation. 
HPV tests to evaluate HPV vaccine development require different analytical parameters 
(higher sensitivity) than clinical tests. Validated cut-off thresholds adapted for clinical 
use are therefore important. The Hybrid Capture 2 (HC2) HPV DNA Test (QIAGEN 
Inc., Gaithersburg, MD; USA (previously Digene Corp.)) was the first test to gain 
approval from the United States (US) Food and Drug Administration (FDA), which 
occurred in 1999. Currently five tests are approved by the FDA for clinical use. Four of 
them are DNA-based: HC2, Cervista HPV HR (Hologic, WI, USA), Cervista HPV 
16/18 (Hologic Inc., Bedford, MA, USA) and Cobas 4800 (Roche Molecular 
Diagnostics, Pleasanton, CA, USA). One test is an RNA-based assay (APTIMA HPV 
assay (formerly GenProbe Inc., San Diego, CA, USA)(FDA-approved in 2011)(108). 
Cervista HPV16/18 is a test that screens for a panel of HR HPV types, and for 
HPV16/18 if the panel is positive (109). In April 2011 the FDA also approved the 
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Cobas 4800 HPV test, which allows detection of HPV16/18 while concurrently testing 
for 12 other high-risk HPV types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). 
The Cobas 4800 was evaluated in the ATHENA (Addressing THE Need for Advanced 
HPV Diagnostics) study and is currently used by the Virology Department at 
Karolinska University Hospital in Stockholm (110). Below I will focus on the HPV 
tests that we used for our studies, namely the HC2 HPV DNA Test (HC2), the Linear 
Array® HPV Genotyping Test (LA) (Roche Molecular Systems Inc., Alameda, CA, 
USA) and the APTIMA HPV Test. 
 
2.8.1 Hybrid Capture 2 Assay (HC2) 
The Hybrid Capture® 2 HPV DNA test was originally developed by Digene 
Corporation (Gaithersburg, MD), but is currently marketed by Qiagen (MD, USA) and 
is the most commonly used HPV test worldwide. The B-probe of HC2 targets 12 HR 
HPV types (IARC-2009) plus HPV68. The US FDA approved HC2 in 2003 for triage 
in cases of atypical squamous cells of undetermined significance (ASC-US) and as an 
add-on test to cytology screening for women age 30 and older. HC2 has been evaluated 
in many RCTs and cohort studies, which have demonstrated the clinical value of HPV 
testing in general. It has therefore been recommended that new HPV tests do not need 
to be evaluated in extensive longitudinal clinical trials, but should demonstrate that they 
possess clinical characteristics equivalent (non-inferior) to HC2, before they can be 
used for screening purposes (107). The HC2 sampler kit includes a special cervical 
brush and a vial containing specimen transport medium (STM). Exfoliated cells are 
first treated with an alkali-denaturing reagent to release host and any existing HPV 
DNA molecules into the solution. The processed samples are hybridized with two 
mixtures of unlabelled single-stranded full-genomic-length RNA probes. One is 
complementary to the DNA sequence of 13 high-risk HPV types (high-risk probe 
cocktail B) and the other to five low-risk HPV (LR HPV) types: HPV-6, HPV-11, 
HPV-42, HPV-43 and HPV-44 (low-risk probe cocktail A). 
Positive specimens are detected by binding the hybridization complexes onto the 
surface of a microplate coated with monoclonal antibodies specific to RNA–DNA 
hybrids. Immobilized hybrids are detected (or captured, hence the name “hybrid 
capture”), by the addition of a second alkaline phosphatase-conjugated antibody to the 
RNA–DNA hybrids and subsequently followed by addition of a chemiluminescent 
substrate. Light emission is measured semi-quantitatively as relative light units (RLU) 
in a luminometer. The emitted light from the specimen is compared to the average 
value of intensity of emitted light from three positive controls containing 1.0 pg of 
HPV16 DNA per ml (about 5000 copies of the HPV genome). RLU greater than or 
equal to 1.0 are considered positive. For high throughput HC2 testing, the Rapid 
Capture System (Qiagen) with semi-automated pipetting and microplate handling has 
been available for the last few years. One technologist can use the Rapid Capture 
System to process up to 352 patient specimens in 8 hours with 3.5 hours of hands-free 
operation (111). HC2 testing cannot determine specific HPV types since viral detection 
is performed using a combined probe mix. The main problems are cross-reactivity with 
low-risk HPV types, especially HPV11, 53, 54, 55 and 66 and the fact that HC2 does 
not contain an internal cellular control, to help adjudicate false negatives. HC2 also has 
an additional 5% false-positive rate in samples that contain no HPV DNA according to 
highly sensitive polymerase chain reaction (PCR) tests (108).  
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One study comparing clinical sensitivity and specificity for detection of high-grade 
CIN in a population of women referred for colposcopy because of abnormal cytology, 
showed that HC2 had a sensitivity of 99.6%, a specificity of 28.4% and a positive 
predictive value (PPV) of 36.1% (112). They studied the effect of different cut-off 
thresholds on clinical accuracy and found that clinical specificity of HC2 increased 
with increasing cut-off threshold. The authors suggested that HC2 might benefit from 
adjusting the positivity cut-off value to 2.0 RLU/CO, to improve clinical specificity and 
PPV, while still retaining similar clinical sensitivity. Based on these results, the 
manufacturer changed the positivity interpretation criteria, but only for samples 
collected in Thin Prep PreservCyt solution (Hologic, Madison, WI, USA) and not for 
samples collected in Digene STM (111). 
 
2.8.2 Polymerase chain reaction (PCR) 
PCR is a technology to selectively amplify a target sequence of DNA. Key components 
include primers (short DNA fragments) containing sequences complementary to target 
regions and heat stable DNA polymerase (for which the method is named). As the PCR 
progresses, the DNA itself is used as a template for replication, setting in motion a 
chain reaction in which the DNA template is exponentially amplified. The method 
makes use of thermal cycling, consisting of repeated cycles of heating and cooling of 
the reaction for the purpose of DNA melting (involving physical separation of the two 
strands of the DNA double helix) and enzymatic replication of the DNA. PCR has 
extremely high molecular sensitivity, permitting detection of less than 10 copies of 
HPV DNA in a mixture. The primers are able to amplify sequences from several 
different HPV types because they target conserved DNA regions within the HPV 
genome and the amplicons can be genotyped by sequencing or hybridization with type-
specific probes using Dot blot, Southern blot or line strip hybridization. Three 
consensus primer systems are now well established: PGMY09/11, GP5+/6+ and 
SPF10LiPA. They target segments of considerably different sizes: 450 base pairs (bp), 
140 bp and 65 bp respectively. Shorter fragments tend to yield better sensitivity when 
testing severely degraded specimens, such as paraffin-embedded, archival tumour 
tissue (48). 
 
2.8.3 Linear Array HPV genotyping test (LA) 
HPV DNA genotyping tests allow individual determination of several HPV types. 
However, the clinical value of HPV DNA-based genotyping assays has not yet been 
fully established, but these tests are indispensable research tools for the study of natural 
history, transmission, pathogenesis and prevention of HPV infections. DNA sequencing 
is still considered to be the ‘gold standard’ for HPV genotyping, even though it is 
costly, time-consuming and difficult to apply in routine diagnostic settings.  
These tests are based on the principle of reverse hybridization, where a fragment of the 
HPV genome is first PCR-amplified, and the resulting amplicons are denatured and 
subjected to detection using HPV type-specific probes immobilized on a strip, filter or 
microtiter well.  
The Linear Array HPV Genotyping Test (LA) is one of the most commonly used HPV 
genotyping assays for the identification of (37 HPV types in toto) 36 alpha-HPV types: 
HPV6, HPV11, HPV16, HPV18, HPV26, HPV31, HPV33, HPV35, HPV39, HPV40, 
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HPV42, HPV44, HPV45, HPV51-54, HPV56, HPV58, HPV59, HPV61, HPV62, 
HPV64, HPV66-73, HPV81-84 and HPV89, and one subtype (subHPV82 or IS39). LA 
is based on the co-amplification of a 450 base pair (bp) region of the HPV L1 gene and 
on a 268 bp region of the human β-globin gene, using biotinylated primer sets 
PGM09/PGMY11 and PC04/GH20, respectively. The resulting amplicons are then 
denatured and hybridized with HPV-specific oligonucleotide probes immobilized as 
parallel lines on nylon or a nitrocellulose membrane strip. After hybridization, 
streptavidin-conjugated alkaline phosphatase or horseradish peroxidase is added, which 
binds to any previously formed biotinylated hybrid. Incubation with chromogenic 
substrates yields a coloured precipitate at the probe positions where hybridization 
occurs. The genotyping strip is then read and interpreted visually by comparing the 
pattern of HPV-positive probes with the test reference guide for each of the targeted 
HPV types. At the same time, a region within the human beta-globin gene is amplified 
as a control for cell adequacy, nucleic acid extraction, and PCR efficiency. In a study 
by Szarewski et al. which compared the clinical sensitivity and specificity of six 
different HPV assays for detection of high-grade CIN in a population of 953 women 
referred for colposcopy because of abnormal cytology, LA had a sensitivity of 98.2%, a 
specificity of 32.8% and a PPV of 37.7% for detection of CIN2+ lesions (112). 
 
2.8.4 HPV mRNA as biomarker and test (APTIMA HPV Assay) 
As cervical lesions progress to cervical cancer the viral HPV DNA frequently integrates 
into the host-cell genome and the viral genes E6 and E7 are continuously expressed. 
Transcripts from the E6 open reading frame are either unspliced (full length (FL) E6 
transcripts) or spliced. FL E6 proteins bind most powerful to p53, which results in 
degradation of the p53. Full length E6 therefore has the strongest association to 
carcinogenesis and FL transcripts are always present in cervical cancer. The E6 and E7 
proteins have been difficult to analyze due their unstable nature in solution but their 
transcripts can be analyzed. Tests that detect these transcripts have are more likely to 
detect clinically significant disease (113). 
Several studies have shown that testing for HPV mRNA instead of HPV DNA can be 
useful, due to higher clinical specificity and similar sensitivity. Transcripts encoding for 
viral oncoproteins E6 and E7 are of greatest interest. Viral mRNA can be detected by 
reverse transcriptase PCR or by nucleic acid sequence-based amplification (NASBA). 
The APTIMA HPV Assay (Gen-Probe Inc., San Diego, CA) was approved by the US 
FDA in 2011 and is at present the only FDA-approved mRNA-based HPV test. The 
indications are a) triage of women 21 years and older with ASC-US to determine 
whether referral for colposcopy is needed and b) screening of women age 30 and older 
in combination with cytology. The APTIMA HPV Assay (Gen-Probe, San Diego, CA, 
USA) is a transcription-mediated amplification-based assay, which allows detection of 
E6/E7 mRNA transcripts of 14 HR HPV types: HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66 and 68. (i.e. IARC 2009 12 HR HPV types plus HPV66 and HPV68). 
The test result is qualitative for the presence or absence of the targeted HPVs and does 
not allow exact determination of the HPV type present in a clinical specimen (114). 
There is also The APTIMA 16 18/45 Genotype Assay which detects E6/E7 viral 
mRNA of HPV16, 18, and 45 from women with APTIMA HPV Assay positive results. 
The test can differentiate HPV16 from HPV18 and/or HPV45, but does not 
differentiate between HPV18 and 45.  
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APTIMA is a single tube test and is based on three main steps: 
1. Target capture of E6/E7 mRNAs using HPV-specific capture oligomers linked 
to magnetic microparticles (Fig1). The procedure works by first lysing the cells 
to release the target mRNA. 
2. Amplification of target E7 mRNA using transcription-mediated amplification 
(TMA) by using two enzymes: RNA polymerase and reverse transcriptase. The 
reaction is performed at the same temperature unlike PCR and results in ten-
billion-fold amplification within 15 to 30 minutes. 
3. Detection of resulting amplicons by hybridization protection assay (HPA) using 
chemiluminescent labelled probes. A selection reagent inactivates the label on 
the unhybridized probes. Emitted light is measured in Relative Light Units 
(RLU) in a luminometer. The assay result is based on the interpretation of the 
analyte signal-to-cutoff (S/CO). 
 
Fig 9 Aptima HPV Assay, Target Capture 
The target sequence is hybridized to an intermediate capture oligomere with 
complementary sequences to specific regions of the HPVmRNA molecules and a string 
of deoxyadenosine residues. The complex is captured by poly-deoxythymidine 
oligomeres bound to the surface of magnetic particles. The particles are drawn to the 
side of the tube by magnets, concentrated and washed 
 
Fig 10. Transcription-Mediated Amplification (TMA) 
TMA uses two primers in the reaction. A primer contains a promoter sequence, which 
is a specific sequence that signals the enzyme to start transcribing at a particular site 
on the DNA/RNA template. RT; Reverse transcriptase creates a DNA copy of the target 
RNA. RNAse H degrades the resulting RNA: DNA duplex. A second primer then binds 
to the DNA copy and a new strand of DNA is synthesized. RNA polymerase recognizes 
the promoter sequence of the double-stranded DNA molecule and initiates 
transcription. 
 
An internal control transcript is added to each reaction (via the Target Capture Reagent) 
to verify performance at each step of the assay: capture, amplification and detection 
(111). The internal control signal in each reaction is differentiated from the HPV signal 
by the magnitude of light emission from probes with different labels by the method, 
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Dual Kinetic Assay (DKA)). Internal Control-specific amplicon (and HPV 16 when use 
of APTIMA HPV16 18/45) are detected using a probe with a rapid emission of light 
(flasher), while amplicon specific to HPV (and 18 and 45 when use of APTIMA 
HPV16 18/45) are detected using probes with relatively slower kinetics of light 
emission (glower)(115). One positive calibrator (in vitro transcript in buffered solution) 
and one negative calibrator (buffered solution) are tested in triplicate at the beginning 
of each run. The purpose is to determine the validity of the run and to establish the 
assay cut-off values for the internal control and analyte signals.  
The signal observed for each reaction is then compared with the cut-off values. Those 
reactions with an analyte signal to cut-off (S/CO) ratio >1.00 is considered positive for 
HPV. Samples with an analyte S/CO ratio <1.00 must have an internal control signal 
greater than or equal to the internal control cut-off value in order to be considered a 
valid negative result. (114). The analyte S/CO of the Aptima was recently changed 
(lowered) and now a S/CO ratio > 0.50 is considered positive. In our studies we 
considered S/CO >1 to be positive according to the manufacturer at the time of the 
studies (114). The assay software determines test results. 
Analytical evaluation estimated the 95% detection limit for Aptima to be 38-488 
mRNA copies/reaction in the DTS system (semi-automated) and 17-275 HPV mRNA 
copies in the TIGRIS DTS system (fully automated). 
Analytical evaluation of APTIMA also showed that it did not cross-react with any low-
risk HPV types, or with normal flora or opportunistic organisms that may be found in 
cervical samples (114). APTIMA was considered to be a robust test with low inter- and 
intra-run variability. Getman et al. demonstrated that Aptima detected not only HPV 
mRNA, but also HPV dsDNA, but the sensitivity for HPV16 mRNA was substantially 
higher than for HPV16 DNA (116). However, recently published manufacturer 
instructions state “False positive results may occur with this test. In vitro transcripts 
from low-risk HPV genotypes 26, 67, 70 and 82 exhibited cross-reactivity with the 
Aptima HPV Assay.” 
 
2.8.5 Accuracy of APTIMA in triage and primary screening 
In a meta-analysis including eight studies, the pooled sensitivity and specificity of 
APTIMA to triage ASC-US was 95.7% and 56.4%, respectively, for CIN2+ and 96.2% 
and 54.9%, respectively, for CIN3+. APTIMA and HC2 showed similar sensitivity for 
CIN2+ and CIN3+ lesions. However the specificity of APTIMA was significantly 
higher (ratio: 1.19 for detection of CIN2+ and ratio: 1.18 detection of CIN3+).  
In LSIL triage, when considering CIN2+ as the outcome, pooled sensitivity and 
specificity were 91.0% and 42.5%, respectively, whereas for CIN3+, the figures were 
96.7% and 38.7%, respectively. Here too the APTIMA was as sensitive as HC2, but 
substantially more specific for both outcomes (ratio: 1.37 and 1.35) (117). A study by 
Castle et al. seemingly corroborates this statement, though it is not included in the 
meta-analysis (118). The meta-analysis by Arbyn et al. concluded that Aptima is as 
sensitive as HC2 for detection of CIN2+ or CIN3+ in women with ASC-US or LSIL. 
The specificity of Aptima is on average 19% (95% CI= 8-29%) better in triage of ASC-
US and 37% (95% CI=22-54%) better in triage of LSIL. They supported the use of 
Aptima in triage of ASC-US and suggested that the test might also be considered for 
triage of women with LSIL.  
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The largest trials supporting the use of ASC-US triage are a Canadian study of 1400 
women (119), the PREDICTORS-1 study involving 950 UK women (112) and a 
French study involving 750 women (120). 
In a primary screening setting, the FASE and CLEAR trials also demonstrate similar 
sensitivity, but higher specificity compared with HC2 (121). These were the studies that 
supported the FDA approval of Aptima for the indication of primary cervical cancer 
screening. The CLEAR study (Clinical Evaluation of Aptima mRNA) involved 11 000 
US women and the FASE study 5000 French women. One part of the CLEAR study 
investigated Aptima HPV Assay as an adjunctive method for the triage of women with 
ASC-US over 21 years (939 women). They showed that Aptima HPV-positive women 
had a risk of CIN2+ 9 times higher than women with negative results and the risk for 
CIN3+ was nearly 13 times higher. Aptima sensitivity and specificity was 87 % and 63 
% for CIN2+ (122). The overall prevalence of high-risk HPV mRNA was 42 % among 
women with ASC-US and 5.0% among women with a normal cytology test result over 
30 years (123). A recent study compared clinical performance of the APTIMA for 
CIN2+ with the HR HPV GP5+/GP6+ PCR in a cross-sectional clinical equivalence 
analysis with > 900, cervical samples from population-based screening. The Aptima 
HPV assay showed a clinical sensitivity for CIN2+ of 94.2% and a clinical specificity 
for CIN2+ of 94.5%. These figures were 97.1% and 93.6%, respectively, for the 
GP5+/GP6+ PCR. The authors comment their findings are in line with those of other 
studies that compared the clinical performance of Aptima for ASC-US/LSIL or primary 
screening. In addition, high reproducibility was found for the Aptima HPV assay, as 
reflected by the intralaboratory reproducibility over time (kappa = 0.89) and 
interlaboratory agreement (kappa = 0.91) (124). They concluded that the Aptima meets 
the criteria of the international guidelines for HPV test requirements for cervical 
screening, but longitudinal data are needed to ensure that the long-term negative 
predictive value is similar to that of validated HPV DNA tests. 
 
2.8.6 Other HPV mRNA tests 
The other two commercially available mRNA tests based on NASBA technology are 
the PreTect HPV Proofer (NorChip, Klokkarstua, Norway) and the NucliSens EasyQ® 
HPV V1 test (Biomerieux, Marcy l’Etoile, France). They detect E6/E7 mRNA 
transcripts of the five most frequently identified HR HPV types in cervical cancer: 
HPV16, HPV18, HPV31, HPV33 and HPV45. Several studies have shown that they 
have lower clinical sensitivity for detection of CIN2+ than DNA-based tests, but 
significantly higher clinical specificity. The lower sensitivity has partly been explained 
by the detection of only five HR HPVs.  
 
2.8.7 HPV test validation 
HPV tests should be clinically validated before use in clinical practice, but only 10-
15% of available tests on the market meet this recommendation. Furthermore, 
manufacturer's instructions for most HPV tests do not specify nucleic acid extraction 
methodology, which is a crucial step in molecular testing. Professional 
recommendations on how to evaluate a novel HPV test for safe use in primary cervical 
cancer screening have been published (125). New HPV assays should have an optimal 
balance between clinical sensitivity and specificity (111, 125). The new test should 
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show non-inferiority when compared with HC2 assay. The guidelines also incorporated 
an assessment of the technical robustness of new assays through the measurement of 
intra- and inter laboratory reproducibility. Stoler et al. proposed a minimum sensitivity 
of 92+3% for the detection of CIN3+, and a specificity of 85% to achieve an adequate 
positive predictive value (PPV) for CIN3+ for any new HPV DNA test (108, 126). 
These criteria aim to achieve a balance between excessive referral and risk of missing 
high-grade disease. When designing an HPV test the inclusion of HPV types that are 
rarely associated with cervical cancer must be carefully weighed against the loss of 
clinical specificity (e.g. HPV53 and HPV66). The World Health Organization has 
developed an international proficiency panel for HPV DNA detection and typing to 
establish international standards for all carcinogenic HPV types, to allow evaluation of 
analytical performance of HPV tests and compare data between different laboratories. 
Their manual also provides instructions on best practice and quality control procedures 
for laboratories performing HPV testing (107, 127).  
 
2.8.8 HPV self-sampling 
One advantage of HPV DNA testing is suitability for self-sampling. Self-sampling is 
likely to improve compliance and is particularly appealing in hard-to-reach populations 
where social or religious practices limit acceptance of vaginal examinations. A 
Canadian review found that women who were under/never screened and were offered 
HPV self-testing were twice as likely to participate in cervical cancer screening, but it 
was still unclear what HPV self-collection device is best for collecting reliable samples 
with minimal discomfort for women (128). 
In addition, a UK study by Szarewski et al. (129) found that sending a self-sampling kit 
to women doubled response rate compared with repeat invitation to attend screening. 
Although the response rate for the self-sampling group was only around 10%, 
Wikström et al. found a response rate of around 40% to test kits sent by mail (130, 
131). A recent meta-analysis of screening data from 36 studies on a total of 155 000 
women (132) found that self-sampling for HPV detected, on average, 76% (95% CI 
69–82) of CIN2+ and 84% (72–92) of CIN3+. The pooled absolute specificity to 
exclude CIN2+ was 86% (83–89) and to exclude CIN3+ 87% (84–90). The pooled 
sensitivity and specificity of HPV testing on self-samples was lower than HPV testing 
on samples taken by a clinician. The conclusion was that sampling by a clinician is 
preferable and should be recommended. Lower sensitivity of self-sampling can be 
explained by lower loads of HPV DNA in the vagina. At present, cytology triage 
cannot be carried out on self-samples and therefore an adequate molecular reflex test 
needs to be developed for triage of HPV-positive women. Hyper-methylation of some 
viral or human genes involved in carcinogenesis has shown promising accuracy profiles 
and may be applicable to self-sampling, but further validation is needed (133). 
 
2.9 HPV TESTING IN SECONDARY PREVENTION  
Detection of high-risk HPV DNA is considered to be useful for three clinical 
applications: (134, 135).  
1. 1 As a triage test to select women with equivocal or mildly abnormal cytology, 
needing referral for further diagnostic evaluation (colposcopy)  
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2. As a follow-up test for women treated for high-grade CIN to predict cure or failure 
of treatment  
3. As a primary screening test, to detect or rule out cervical precancer in the 
population over age 30. 
 
2.9.1 Triage of women with minor cytological abnormalities 
The management of women with minor cytological lesions has been subject to 
discussion (49, 136, 137). Until recently, follow-up recommendations for women with 
ASC-US or LSIL varied from conservative repeat cytology (138) to immediate referral 
for colposcopy and biopsy (139). The natural history of minor cytological lesions is 
difficult to predict on morphological grounds. These lesions often regress 
spontaneously without treatment (43, 140). Therefore, referring all women with minor 
cytological lesions for further gynaecological examination would entail increased risk 
for over-diagnosis and over-treatment, as well as risks for adverse obstetric outcomes 
following excision of CIN lesions (135). Over-referral would also cause unnecessary 
anxiety among women (141), substantially increased costs to the healthcare system and 
a shortage of colposcopic resources. ASC-US and LSIL are the most common 
cytological abnormalities and in ASC-US, one to two thirds of cases is not associated 
with HPV. The majority of women do not have clinically significant disease, but a 
substantial proportion of them do have histopathologically-confirmed high-grade CIN 
(142). From a population of women screened in the US, an estimated one third of CIN 
cases were discovered on follow-up of a previous smear showing ASC-US (143). 
An appropriate triage method should therefore be able to identify women who have or 
will develop cervical cancer precursor lesions while at the same time reducing the risk 
of over-diagnosis (144, 145).Since evidence exists concerning the etiological role of 
high-risk HPV infections for the development of cervical cancer and its precursors 
(146) (147) (148), HPV testing has been proposed as a triage method to distinguish 
between women with minor cytological lesions who need referral for colposcopy, and 
women who can be referred back to the normal screening schedule (149). 
 
2.9.1.1 ASC-US 
A recent Cochrane review of diagnostic test accuracy of HPV testing (HC2) versus 
repeat cytology for triage of minor cytological cervical lesions (135) corroborates 
conclusions from previous meta-analyses, which all indicated that HC2 triage of 
women with ASC-US predicts presence of underlying high-grade CIN with greater 
accuracy than repeat Pap smear, considering ASC-US+ as cut-off (significantly higher 
sensitivity, similar specificity)(150). mRNA testing with the APTIMA (Gen-Probe Inc., 
San Diego, CA, USA) test has similar sensitivity, but higher specificity than HC2, 
which leads to the conclusion that APTIMA is also useful for triage of ASC-US. The 
pooled absolute sensitivity of APTIMA to find underlying CIN2+ was 95.7% and the 
specificity 56.4% in ASC-US triage. 
 
2.9.1.2 LSIL 
A productive HPV infection usually manifests as LSIL with low potential for 
neoplastic transformation (151). Therefore, HPV DNA testing is nearly always 
positive, which limits its capacity to distinguish between cases with or without severe 
underlying lesions. The prevalence of LSIL in women with a positive HC2 test, which 
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was reported in the studies included in the Cochrane review by Arbyn et al., ranged 
from 55% to 89%. Test positivity rates were always higher than in ASC-US. HPV 
positivity is clearly age-dependent with a decline after age 30. A study by Moss showed 
that 89% of women under age 35 with mild dyskaryosis on Pap smears tested positive 
by HC2, as were 69% of women between the ages of 35 and 49 and 51% of women 
aged 50 or over (152). The specificity of HC2 for the outcome CIN2+ in the ALTS 
study was 16% in women under 29 years, and 30% in women 29 years or older (153). 
However, the Cochrane conclusions concerning triage of LSIL differ from previous 
reviews, which stated that HC2 triage was associated with no significant gain in 
sensitivity, but a substantial and statistically significant loss in specificity compared 
with repeat cytology (154) and therefore could not be recommended. The current 
Cochrane review, which included more studies, confirmed the lower specificity of HC2 
triage of LSIL, but demonstrated a significant gain in sensitivity, which could justify 
recommending HR HPV DNA testing for triage of LSIL. However, recommendations 
should be based on local cost-effectiveness analyses, local HPV prevalence, 
performance of the specific HPV test in use and compliance with follow-up. Swedish 
guidelines recommend HPV triage of all women with minor cytological abnormalities 
regardless of ASC-US or LSIL diagnosis. HPV-positive women are referred for 
colposcopy and HPV-negative women are recommended to undergo repeat cytology 
testing one year later, just to be certain (39, 155). 
However, there is a need for more specific triage tests for women with LSIL (135). 
Virological triage could be made more specific by increasing viral load cut-off, adding 
a second triage test, or by excluding young women. A few studies have used a higher 
test threshold (HC2), resulting in gains in specificity, but simultaneous loss of 
sensitivity (156). Triage of ASC-US or LSIL with new molecular markers is the focus 
of ongoing research (E6/E7 transcripts of different HPV types, p16 immunostaining). 
Analyses have also identified a significant increase in specificity by age in triage of 
LSIL when the outcome was CIN3+. The increase in specificity reflects the drop in 
HPV test positivity rate with increasing age. The break-even point for lower costs in 
HPV triaging policy was found to be at an HPV prevalence of about 70%, 
corresponding with an age of >35 years for ASC-US and >40 years for CIN1 according 
to a Swedish randomised health services study by Dillner et al., (155). 
Since the APTIMA test was more specific than HC2 without showing loss in 
sensitivity, the meta-analysis by Arbyn concluded that APTIMA could also be 
recommended for triage of women with LSIL (117). Pooled sensitivity and specificity 
for CIN2+ in triage of LSIL were 91.0% and 42.5%, respectively. 
Table1. Absolute and relative pooled sensitivity and specificity comparing HC2 with 
HPV DNA or RNA testing for triage of women with ASC-US or LSIL to find 
underlying CIN2+, based on a meta-analysis by Arbyn (134). 
 
	   	   Absolute	  
accuracy	  













ASC-­US	   HC2	   90	   58	   	   	  
	   LA	   94	   46	   1.0	   0.9	  
	   PreTect	   81	   79	   0.8	   1.8	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   APTIMA	   96	   56	   1.0	   1.2	  
	   HPV16	   54	   87	   0.6	   1.6	  
	   HPV16/18	   58	   83	   0.6	   1.7	  
LSIL	   HC2	   95	   28	   	   	  
	   LA	   99	   28	   1.0	   1.0	  
	   PreTect	   76	   77	   0.8	   2.8	  
	   APTIMA	   91	   42	   0.96	   1.4	  
	   HPV16	   51	   81	   0.6	   2.5	  
	   HPV16/18	   58	   75	   0.6	   2.3	  
 
Table 4. Absolute and relative pooled sensitivity and specificity comparing HC2 with 
HPV DNA or RNA testing for triage of women with ASC-US or LSIL to find underlying 
CIN2+, based on a meta-analysis by Arbyn (134). 
 
2.9.2 Follow-up after treatment of high-grade CIN 
Neither the section margins nor cytology used for evaluation of treatment efficacy has 
proven sufficiently accurate for detection of residual or recurrent disease. However, 
detection of HR HPV DNA has been recommended as a follow-up test for women 
treated for high-grade CIN in order to predict cure or failure of treatment (154). The 
short-term rate of residual or recurrent high-grade CIN, evaluated over a 2-year period, 
is estimated at an average of 8% (4-18%). The risk of recurrent CIN2+ is higher in 
women older than 50 years, consistent with the observation that viral persistence 
increases with age (157). A study by Castle et al. (158) indicated that women treated 
for CIN are at increased risk for cervical cancer, compared with the general population, 
for at least 10 years and perhaps up to 20 years after treatment. Currently available data 
suggest that HPV testing picks up residual disease quicker and with higher sensitivity 
and similar specificity compared with follow-up cytology or histological assessment of 
section margins (134, 159). Pooled sensitivity was 93% for HPV DNA and 72% for 
cytology. Pooled specificities for HPV DNA and cytology were 81% and 84%, 
respectively. HPV testing was significantly more sensitive (ratio of 1.25), but not less 
specific (ratio of 0.97%). Combined testing with cytology and HPV was not 
significantly more sensitive, but was significantly less specific than HPV DNA testing 
alone.  
Kocken et al. reported on long-term follow-up risk of recurrent high-grade CIN after 
treatment (160). If the woman was HR HPV negative at 6 months after treatment, the 
10-year risk of CIN3+ was 2.1%. If the woman cytology-negative, the risk was 2.8% 
and if both tests were negative, the risk was 1.4%. Three consecutive negative cytology 
results at 6, 12, and 24 months, or negative findings in both HPV DNA and cytology at 
6 and 12 months were associated with low risk of residual CIN3+, 0.7% and 0.0%, 
respectively, which is comparable to the risk within the general population. On the 
other hand, a positive HR HPV test at 6 months increased risk of CIN3+ to 29%, a 
positive cytology test (ASC-US+) to 13%, averaging out to 23% when one of these two 
tests was positive. In a recent Swedish study of recurrence after LEEP conisation, no 
women without type-specific persistence of HPV had recurrent or residual disease. 
HPV genotyping appeared to be useful for improving specificity when HPV testing was 
used for in post-treatment follow-up (161). A population-based cohort study of long-
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term incidence and mortality found that women previously treated for CIN3 are at 
increased risk of developing and dying from cervical or vaginal cancer and that risk 
accelerates above age 60, suggesting a need for lifelong surveillance of these women 
(162). More research is needed to identify biomarkers that accurately predict a 
woman’s long-term risk of future cancer. 
 
2.9.3 Primary screening for cervical cancer 
A meta-analysis by Arbyn et al. (134) confirmed that HR HPV testing is substantially 
more sensitive than cytology for identifying underlying CIN2+ and CIN3+. One 
drawback is the lower specificity, especially among younger women where HPV 
infection is usually transient. In both European and North American cross-sectional 
studies, the pooled sensitivity of HC2 for CIN2+ was 96%, whereas the pooled 
specificity was 91%. HC2 sensitivity was on average 23-43% higher than cytology and 
specificity for excluding CIN2+ was significantly lower, ratio 0.97. Four large 
European randomised controlled trials (RCT) of primary screening consistently 
demonstrated second screening round data that showed a significantly lower 
cumulative incidence of CIN3+ and cervical cancer in women over age 30, who were 
HR HPV-negative versus cytology-negative at enrolment (163-166). Moreover, cohort 
studies presented data showing a low cumulative incidence of CIN3+ associated with a 
negative HR HPV test (134). For HPV-negative women without or with cytological 
abnormalities the risk was 0.2% and 1.2%, respectively. For women who were 
cytology-negative without or with HR HPV test, the risk was 0.2% and 6.1%, 
respectively. The baseline HPV-negative group had essentially the same rates of 
dysplasia as the patients who were both HPV-negative and cytology-negative at 
baseline (0.2% cumulative risk to develop CIN3+ over the next 5 years), suggesting 
that screening with HR HPV testing alone without cytology offers similar protection. 
Screening intervals for HPV-negative women can safely be extended to at least 5 years. 
However, in women who were HR HPV-positive, the risk at the second screening 
round was substantially higher: 6% and 17%, respectively, for women without or with 
ASC-US or higher-grade cytology at baseline. Cytology testing of HPV-positive cases 
clearly stratified the risk for CIN3+, indicating that cytology may be a useful method 
for effective triage in HPV-based screening (167-169).  
Other evaluated triage methods include genotyping for HPV16 and HPV16/18, as well 
as HPV retesting to detect persistent infections. Kahn et al. reported the 10-year 
cumulative risk associated with HPV16, HPV18 or other HR HPV infections to be 
17%, 14% and 3%, respectively (170). The ATHENA trial demonstrated similar 
sensitivity and PPV for detection of CIN3+ among HR HPV-positive women using 
either the Cobas 4800 test (allows detection of HPV16/18 while testing for 12 other 
high-risk HPV types) or cytology (171). Additional markers under consideration for 
triage of HPV-positive cases are testing for HPV mRNA, p16INK4a and 
p16INK4aKi67 double staining. However, HR HPV-positive women who are cytology-
negative or HPV16/18-negative must be kept under surveillance and invited for repeat 
testing (134). The cumulative incidence rate of CIN3+ among women who were 
positive for HR HPV with negative cytology results increased continuously over time, 
reaching 10% at 6 years, whereas the rate among women with positive cytology results 
who were negative for HPV remained below 3%(172). A recent follow-up study of the 
four European randomised controlled trials investigated the efficacy of HPV-based 
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screening and found that HPV-based screening provides 60-70% greater protection 
against ICC than cytology (173). 
One reason that HR HPV-based cervical cancer screening has not been recommended 
earlier is that despite the higher cross-sectional sensitivity of HR HPV testing for 
detecting CIN2+ and CIN3+, it could not be excluded that HPV testing simply picks up 
more regressive disease. However, a 13-year follow-up of the Swedescreen RCT of 
primary screening involving 12 500 women aged 32-38 concluded that the cumulative 
incidence of CIN2+ was the same for HPV screening and for cytology, but that HPV 
screening detects CIN2+ earlier rather than over-diagnosing this condition (174). 
In summary, the evidence base at present indicates that HR HPV DNA testing is more 
effective for primary screening of women aged 30 or older than cytology and that 
screening intervals for HPV-negative women can safely be extended to at least 5 years. 
The possible advantages offered by HPV-based screening also require a well-organised 
programme with good compliance to screening and triage policies. 
Four HR HPV DNA tests are currently considered clinically validated for the purpose 
of primary screening according the equivalence criteria of Meijer CJLM et al. (125). 
These are HC2, GP5+/6+, Cobas 4800 and the Abbott Real Time PCR HR HPV tests. 
The author states that in addition to accuracy, other characteristics must be considered 
such as high-throughput capacity, costs, applicability for self-sampling and the option 
of performing ancillary triage tests. 
 
2.10 TREATMENT OF CERVICAL DISEASE 
Most guidelines recommend treatment when CIN2+ is detected. Women with CIN1 are 
usually followed-up and treated depending on persistence and age. Excisional treatment 
is mandatory for women with inadequate colposcopy, suspicion of invasive disease or 
glandular abnormality. The goal of treatment is to eliminate high-grade cervical lesions 
and the cervical TZ, while minimising harm to the cervix. Low morbidity excisional 
methods are preferred to generate specimens for histopathology. Common procedures 
include loop electrosurgical excision procedure (LEEP), cold knife cone biopsy, 
electrofulgaration, laser conisation, laser ablation and cryotherapy. Large loop excision 
of the transformation zone is often abbreviated to LLETZ in the UK or LEEP (loop 
electrosurgical excisional procedure) in the US. Treatment success is reported to be 91-
98% in non-randomised studies. Cold knife cone biopsy is no longer often used. Loop 
excision is easier and faster to learn than conisation with laser, but one advantage of 
laser therapy is the ability to customise the size of the cone. A Cochrane review from 
2012 found no obvious superior technique for treating CIN in terms of failures or 
operative morbidity. No differences were found between laser conisation and loop 
excision regarding risk of residual disease, preoperative severe pain, significant thermal 
artefact, vaginal discharge or cervical stenosis at follow-up. Laser conisation was 
associated with significantly longer operating time and increased risk of perioperative 
severe bleeding compared with loop excision, but no difference in risk of secondary 
haemorrhage. Excisional treatments are estimated to be 90-95% effective (175). 
 
2.10.1 Adverse pregnancy outcomes 
A meta-analysis from 2008 concluded that all excisional procedures to treat CIN 
seemed to be associated with adverse obstetric morbidity, but only cold knife 
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conisation was associated with a significantly increased rate of severe outcomes 
(perinatal mortality RR 2.9 95% CI 1.4-5.8) (144). Concerning LLETZ, the possibility 
of increased risk could not be excluded. Removal of large amounts of cervical tissue is 
a risk factor for adverse obstetric outcomes, but most loop excisions in young women 
with fully visible TZ only need to be 1 cm deep, which should help protect against 
serious dysfunction. Moreover, women with CIN are known to have demographic, 
behavioural, and sexual characteristics that increase their risk of adverse obstetric 
outcomes, which may blur the results of the studies (144). An observational study from 
Dublin revealed that greater thickness and total volume of the excised transformation 
zone were associated with increased risk of preterm labour (<37 weeks of gestation) 
(176). A recent large meta-analysis from China including 37 000 cases also concluded 
that LEEP is associated with an increased risk of subsequent preterm delivery (<32/34, 
<28 weeks) and other adverse pregnancy outcomes. (177). 
 
2.10.2 Development of novel treatments 
The immune system plays an important role in controlling development of HPV-
associated cancer. Two E6/E7 vaccines have shown some clinical promise in high-
grade VIN patients. Clinical response correlated with development of HPV-specific T-
cell response and local immune factors. Treatments that can shift the balance of 
immune effectors locally may be effective (imiquimod) by themselves or may be 
combined with new drugs targeting molecular pathways mediated by HPV in cancer 
(8). Small molecule inhibitors targeting the DNA-binding activities of HPV E1/E2 or 
the anti-apoptotic consequences of E6/E7 oncogenes are in preclinical development. 
Proteosome and histone deacetylase inhibitors, which can enhance apoptosis in HPV-
positive tumour cells, are also being tested in early clinical trials. Combinations with 
vaccination are also now being tested (8). 
 
2.11 NEW BIOMARKERS FOR CERVICAL CANCER SCREENING 
Because of superior sensitivity and reproducibility, HPV DNA testing for detection of 
high-grade CIN is under consideration for use in primary screening for cervical cancer. 
The main objection has been that HPV DNA testing cannot separate transient from 
persistent infections and therefore it could not be excluded that HPV testing may just 
picks up more regressive disease. New approaches with improved specificity are 
needed to triage HPV-positive cases. New technologies include a) genotyping for 
specific HR HPV types, b) p16INK4a staining to identify proliferating cells and c) 
methylation of host and viral genes. Repeated HPV genotyping may also be an option. 
 
2.11.1 Genotyping for HPV16 or HPV18 
Several studies have confirmed the higher absolute risk of CIN3+ among HPV16- and 
HPV18-positive women and these observations have led to the development of newer 
commercially available diagnostic tests. In the ATHENA trial (Addressing the Need for 
Advanced HPV Diagnostics) over 40 000 HPV positive women with ASC-US or worse 
cytology were evaluated using HPV16/18 genotyping for triage. Strategies that referred 
only HPV16- or HPV18-positive women had a sensitivity for detection of CIN3+ 
similar to other strategies which referred only women with ASC-US or worse cytology 
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(50.4%, 59.5%, and 52.8%, respectively), suggesting that triage of HR HPV-positive 
screening tests is equally feasible by cytology or by HPV16/18 genotyping (171). 
Another population-based screening study in the Netherlands evaluated similar triage 
strategies and concluded that triage of HR HPV-positive women with cytology was 
preferable based on relative balance of benefits (high negative predictive value) and 
harms (modest colposcopy referral rate)(167). Studies in both Denmark (77) and 
Sweden (178) have reported that the absolute risks for progression to high-grade 




Over expression of the cyclin-dependent kinase inhibitor p16INK4a is a surrogate marker 
for transforming activity of the E7 viral protein that is essential for initiation and 
maintenance of the neoplastic process. High-level expression of HPV E7 protein can 
up-regulate p16, and increasing levels of p16 correlate with increasing grades of CIN. 
Several studies have evaluated the clinical utility of p16INK4a immunochemical staining 
as a diagnostic adjunct both in cervical histology and cytology specimens. It has been 
shown that diagnostic accuracy, reliability and quality in histopathology of cervical 
lesions can be improved. Studies evaluating potential use of p16INK4a as a progression 
marker for low-grade CIN have consistently revealed that the majority of p16INK4a-
negative lesions regressed, whereas most p16INK4a-positive CIN1 lesions progressed to 
high-grade CIN (179). A meta-analysis of eight studies in which both p16 and HC2 
were performed for triage of low-grade disease concluded that p16 had a similar 
sensitivity compared with HC2 for detection of CIN2+ in ASC-US, but a lower 
sensitivity and higher specificity in triage of LSIL (180). However, p16INK4a single-
staining immunocytochemistry requires a morphologic interpretation of 
immunoreactive cells and it can be very difficult to distinguish a p16INK4a-positive cell 
showing an intraepithelial lesion from a cervical cell that occasionally over expresses 
p16INK4a to arrest its cell cycle. This is seen in squamous metaplastic cells or rare 
endocervical cells. Therefore a combination of antibodies detecting p16INK4a and Ki67, 
a marker of cell proliferation, has been thought to identify true HPV transformation of 
cervical cells. P16INK4a/Ki-67 in dual staining has been evaluated in triage of ASC-US 
and LSIL and provides high sensitivity for detection of CIN2+ as well as improved 
specificity compared with single morphology interpretations (179). Triage studies of 
HPV-positive cases with p16 or cytology have shown similar results, but dual staining 
increased sensitivity while maintaining high specificity. Promising techniques for the 
future may involve a combination of dual staining and computer-assisted image 
analysis. 
 
2.11.3 Markers for aberrant S-phase induction 
Topoisomerase 2 alpha (TOP2A) and minichromosone maintenance protein 2 (MCM2) 
are targets in an assay provided by Becton Dickinson (ProExCTM), which includes a 
cocktail of antibodies against these proteins. The MCM2 reflects an active cell 
proliferation state, but differentiation between benign or HPV-induced neoplasia is 
hardly possible. Top2A is a nuclear enzyme, which regulates DNA topology during 
chromosome replication. Deregulated production of both proteins has been associated 
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with disease and disease progression, but the major drawback is that normal 
proliferating cells also express MCM2 and Top2A to some extent, which limits its use 
(179). 
 
2.11.4 Biomarkers for productive HPV infections: E4 and L1 
Viral proteins that are expressed during the late phase of the replication cycle, such as 
the L1 capsid protein and the E4 protein, are only expressed in terminally differentiated 
squamous epithelial cells. They are capable of replicating the HPV particles. Therefore 
these late gene products have been suggested as markers for CIN1 in histology or LSIL 
in cytology samples. The inclusion of a viral protein marker can help to discriminate 
between viral and non-viral CIN1 and to subdivide lesions that fall into the ambiguous 
CIN2 category. Further work is required to evaluate the utility of disease staging in 
histology. However, markers that detect productive HPV infection are of limited value 
as screening tools since a positive test result will not exclude the presence of HSIL. 
HPV L1 is a major target of the immune response in HPV-infected squamous 
intraepithelial lesions and is only produced during productive HPV infection at the end 
of the natural viral life cycle (181). Studies have reported that the majority of HR-HPV-
related LSIL expresses HPV L1, whereas HR-HPV-related HSIL fails to synthesise L1 
(182). Therefore, loss of L1 expression could be used as a prognostic marker for 
development of preinvasive lesions. A 2013 study by Norman et al. showed that HPV 
L1 capsid protein detection can predict the clinical outcome of early dysplastic lesions, 
allowing differentiation between transient HPV infections and risk of progression to 
cancer, and can be used as an objective standard to optimise clinical management of 
squamous intraepithelial lesions (183). 
 
2.11.5 Methylation of host cell genes and viral genes 
Epigenetic changes are heritable changes in gene activity that are not caused by 
changes in the DNA sequence. DNA methylation (DNAme) and histone modification 
are two examples that alter how genes are expressed. Methylation is the transfer of 
methyl groups (CH3) to G–C-rich areas of a genome through the action of dimethyl 
transferases. Methylation affects gene regulation either through blocking of 
transcription factor access to promoter and enhancer regions (an enhancer is a short 
region of DNA that can bind proteins which enhance transcription of genes), or by 
altering conformation of nucleosomes (a nucleosome is the basic unit of DNA packing 
and consists of a segment of DNA wound in sequence around a histone protein core) 
favourable or unfavourable to transcription. This could lead to chromosomal instability, 
cell immortality and malignant transformation (108). The methylation status of both 
host and viral targets seems to be a promising biomarker. Mounting evidence suggests 
that methylation of CADM1 (host) and L1 and L2 genes (virus) is associated with a 
worse prognosis, but more studies are needed. Aberrant methylation can be detected in 
cervical smears up to seven years prior to diagnose of ICC and analysis is applicable to 
self-collected lavage samples. 
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2.11.6 E6 and other protein markers 
Detecting overexpression of proteins E6 or E7 in the cervical epithelium allows 
differentiation between transient HPV infections and pre-cancer or cancerous changes. 
Currently two HPV-E6 tests are undergoing validation. Another E6 test has been 
developed by OncoHealth Corporation (San Jose, CA, USA) and is based on the use of 
antibodies against HPV E6-E7 proteins. It can be run using samples collected for 
liquid-based cytology and the preliminary results are promising. 
 
2.12 HPV VACCINES  
Virus-like particles (VLPs) are empty non-infectious viral shells consisting of 
recombinant L1 capsid proteins without containing any viral DNA. Systemic 
immunization with VLPs is able to evoke an immune response and offers protection via 
antibodies to L1, but precisely what epitopes are recognized remains unknown. The 
generated antibody concentration is 50 times higher than following natural infection, 
and then wanes to levels many times lower than peak concentration, where they remain 
stable for several years. The protective effect is likely made possible by high antigen 
concentrations and the delivery routes that grant access to lymph nodes and the spleen. 
IgG1 responses predominate, but high levels of IgA, IgG3 and IgG4 are also detected. 
The two available vaccines have demonstrated seroconversion in virtually 100% of 
vaccinees. No protective level of antibody concentration against infection has yet been 
defined and therefore the minimum protective antibody titre remains unknown. Affinity 
and avidity are likely to be important factors, but very low antibody titres may still be 
protective. L2 protein vaccines are poorly immunogenic compared with the L1 VLPs, 
but concatenated multitype L2 proteins can boost immunogenicity and show cross-
protection against HPV 16, 18, 45 and 58 pseudovirions (8). 
Antibodies against L1 appear 6–8 months following natural infection in about 50–70% 
of infected individuals. Other viral proteins like E1, E2 and E6 do not elicit antibody 
responses. Initially, the IgM response occurs, then decays and is followed by the IgG1 
response, which is more persistent. The protective role of antibodies following a natural 
infection is still unclear (8). 
 
2.12.1 Therapeutic and prophylactic vaccines 
Lesion regression is often associated with cell-mediated immune responses to E2 and 
E6. When CD8+ T cell gain access to dysplastic lesions, they are likely to regress. Two 
clinical trials tested HPV therapeutic vaccines in patients with vulvar epithelial 
hyperplasia who showed complete responses in approximately 50% of cases over a 52-
week follow-up period. The expected rate among unvaccinated women was 5%. 
However, more studies are needed (8). 
After a long period of development, two licensed prophylactic HPV vaccines are now 
available on the market. Gardasil®, (Merck & Co., Whitehouse Station, NJ, USA) 
which is a quadrivalent vaccine containing VLPs of types 6, 11, 16 and 18, and 
Cervarix®  (GlaxoSmithKline Biologicals, Rixensart, Belgium), a bivalent vaccine 
containing VLPs of types 16 and 18. Two phase III studies, FUTURE I and FUTURE 
II, evaluated Gardasil® and two studies, PATRICIA and the Costa Rica HPV Vaccine 
Trial (CVT), evaluated Cervarix®. All four trials studied young women (mean age 20, 
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range 15-26) and were large (5 500-18 500 vaccinees) blinded, randomized controlled 
trials (RCT). Both vaccines demonstrated high and similar efficacy against HPV-
related genital disease in women naïve to the corresponding HPV types. However, the 
vaccines had no therapeutic effect on established infections or on CIN. Both vaccines 
demonstrated cross-protection for infections and lesions related to non-vaccine types: 
HPV 31 for Gardasil (70%) and HPV31, HPV33, HPV 52, HPV45, and HPV51 for 
Cervarix. Gardasil has also been shown to protect mid-adult women (age 24-45) from 
incident infections and CIN caused by the vaccine types and to protect men (age 16-26) 
from incident infection, genital warts and AIN (anal intraepithelial neoplasia). One 
concern – removing HPV16 and HPV18 might leave an empty ecological niche for 
other HPV types to fill in, but so far there have been no such indications. Both vaccines 
demonstrated excellent safety in these clinical trials. Mild to moderate injection-site 
symptoms, headache and fatigue were the most common adverse events. Symptoms 
were transient and did not increase with the number of doses. Safety evaluations after 
vaccine introduction have also shown good results. The vaccines were introduced in 
2006 and in recent years they have become more available due to reduced market 
prices. Australia was one of the first countries to reach high coverage with Gardasil; 
evaluations have shown great impact on genital warts in the vaccinated age groups, as 
well as decreased rates among men, suggesting herd immunity (8). In Sweden, HPV 
vaccination of fifth-grade girls has been included in the national vaccination 
programme since 2010. In Stockholm County, free catch-up vaccination is offered to 
girls up to age 18 and subsidized up to age 26. Vaccinated women are informed of the 
importance of continued participation in the national cervical cancer-screening 
programme since current vaccines do not offer 100% protection against ICC. The 
included HPV types are responsible for only 70% of ICC cases. A new nine-valent 
vaccine targeting additional HPV types (31, 33, 45, 52, and 58) has been developed and 
is expected to prevent almost 90% of ICC (184). Phase III trials are currently 
underway. A recent Swedish study demonstrated a considerable reduction in the risk of 
acquiring condyloma after only 2 doses of vaccine, a finding that requires further 
investigation since this may reduce costs and increase vaccination programme 
feasibility (185). 
 
2.12.2 Cost-effectiveness of including males  
Including males in the vaccination programme would have a direct benefit on 
protection against HPV-related cancer and genital warts in men. Indirect benefits would 
include protection of non-vaccinated females and males through increased herd 
immunity (a form of immunity that occurs when the vaccination of a significant portion 
of a population or herd provides protection for individuals who have not developed 
immunity) and some protection for men who have sex with men. However, any cost-
effectiveness analysis should take into account that the HPV-related burden of disease 
in males is lower than in females and that males benefit from female vaccination via 
herd immunity. If vaccine coverage in females is less than about 50% it can be cost-
effective to include males in the HPV vaccination programme but increase of female 
coverage is probably more effective (8). Intense debate concerning male vaccination is 
currently underway. The Australian government approved male vaccination (Gardasil) 
in 2012 and commenced in 2013. Results from a mathematical model of HPV 
  43 
transmission concluded that this would lead to the near elimination of genital warts in 
both female and male heterosexual populations (186). 
 
2.13 HPV, HIV AND IMMUOSUPPRESSION 
The majority of women infected with HIV will be co-infected with HPV. Studies 
indicate that the rate of cervical cancer among HIV-positive women is 2 to 22 times 
greater than in HIV-negative women. It has also been reported that 
immunocompromised individuals are resistant to treatment of HPV-related diseases and 
prone to accelerated development of HPV-associated cancers. HIV-positive women are 
also more likely to have multiple HPV infections. Possible explanations include 
alteration in cell-mediated immunity, increased susceptibility and possible reactivation 
of latent HPV infections. Prevention of HPV-associated diseases in HIV-positive 
individuals includes HPV vaccination, although the efficacy of HPV vaccination in 
HIV-positive children requires further research (8). 
 
2.14 TRANSLATIONAL RESEARCH AND BIOBANKING 
Successful cancer research depends on the availability of biological specimens derived 
from individuals who have been followed-up for several years and who finally 
developed the outcome of interest. This can be achieved by using biobanks that are 
linked to population-based cancer registries. These registries generate high-quality, 
standardised and complete data, but the main advantage is the opportunity to obtain 
extremely long follow-up data on health outcomes without having to wait. A variety of 
information such as living conditions, lifestyle and risk factors can be accessed, and 
different kinds of bio-specimens from both patients and volunteers can be stored after 
collection. “Translational research” is a crucial part of prevention research and includes 
searching for new biomarkers for early diagnosis or for use in new screening tests. The 
Swedish biobank, including Pap smears from the screening programme, has served as a 
useful resource for research concerning HPV-based cervical screening (187). In the 
past, each research study or laboratory had to develop its own biospecimen storage 
system, which was a major endeavour. In many cases the specimens were of limited 
use due to inappropriate handling or storage. Naturally, such factors could hamper 
comparability between different studies, making them less effective. Given the 
increasing complexity of biobanks, nowadays researchers use specialised services to 
handle acquisition, quality control, storage, processing and distribution of biospecimens 
for laboratories. International biobanking networks have been developed to foster 
common international standards. Examples of such major biobanking networks are the 
Biobanking & Molecular Resource Infrastructure (BBMRI) and the Public Population 
Projects in Genomics (P3G). The SCCB was first established in 2012 as a pilot project 
of the clinical cytology centre at Karolinska Hospital in Stockholm. The Swedish 
BBMRI supported the financing, development and implementation of this first national 
prospective repository for LBC obtained from women participating in organised 
cervical cancer screening. Standardised methods for handling and long-term storage 
were evaluated and developed and to date at least seven other counties across Sweden 
have become involved. Information from the biobank will be linked to the national 
cancer registry and will become an invaluable resource for future research. An 
aspiration volume of 4 ml was chosen to obtain the largest amount of cells from the 
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LBC sample, but the final storage volume is only a 300-ml aliquot of cells. The 
samples will be stored in “96-well format vials” and systematically labelled. Evaluation 
of storage conditions demonstrated that cells remain intact in fluid at temperatures 
ranging from + 4°C to - 35°C, but were frozen at - 80°C. Therefore, - 25°C was found 
to be the optimal temperature for long-term storage, since all cells remained intact in 
the fluid medium. This is an advantage since it allows new slides to be made for 
cytological diagnosis, immunohistochemistry, and in situ-hybridizations. At the same 
time, the low temperature used for storage is advantageous for preserving high-quality 
DNA and RNA for long-term use. Patient information is provided in the screening 
invitation letters. The Open Access principle prevails, which does not discriminate 
against or favour any requesting organisation and which will make samples available 
for health-related research (188).  
A randomised health services study (RHS) entails a randomised design with 
observations in routine health care, regardless of whether randomisation is at the 
individual, population or process level (189). Unlike the randomised controlled trial 
(RCT), which is recognised as the most valid study design, implementations of new 
methods and policies in routine health care have not been defined by formal design, 
which has impaired the ability to evaluate and improve health care. Therefore the RHS 
design should be considered when incorporating new routines into clinical practice in 
order to generate valid, large-scale data on effectiveness and safety of medical practices 
in routine health services (155).  
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3 AIMS 
 
3.1 GENERAL AIM 
The general aim of this thesis is to evaluate new diagnostic methods and to identify 
long-term risk factors for development of cervical cancer among women either with 
minor cytological abnormalities or who have been treated for cervical high-grade 
disease.  
 
3.2 SPECIFIC AIMS 
3.2.1 Paper I 
The aim of this study was to compare the sensitivity of HR HPV DNA testing to detect 
high-grade cervical disease with conventional Pap smear among women with minor 
cytological abnormalities. 
 
3.2.2 Paper II 
To assess the utility of HR HPV mRNA testing after treatment of high-grade cervical 
intraepithelial neoplasia and to compare the prognostic value of HPV mRNA with HR 
HPV DNA and cytology. 
 
3.2.3 Paper III 
To assess the usefulness of HR HPV mRNA to triage HR HPV DNA-positive women 
with minor cytological abnormalities and to compare this method with testing for HPV 
16 DNA, HPV16/18 DNA and repeat cytology. 
 
3.2.4 Paper IV 
To assess long-term risk of high-grade cervical disease among women with minor 
cytological abnormalities as stratified by HPV-status, cytology and age, to serve as a 
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4 MATERIALS AND METHODS 
4.1 STUDY SUBJECTS AND STUDY DESIGN 
4.1.1 Paper I 
Women with minor cytological abnormalities (ASC-US and LSIL) detected through 
population-based screening were referred for colposcopy 4-6 months later to the 
department of gynaecology at three different university hospitals in Stockholm. We 
consecutively enrolled 177 of these women. All women underwent pelvic examination, 
repeat cytology (Pap smear), HPV DNA testing and colposcopy either with directed 
biopsies from acetowhite areas, or with biopsy near the squamocolumnar junction at 12 
o’clock if no lesions were observed. We compared the results from HPV DNA tests 
and Pap smears with the histopathological diagnoses. Diagnosis was based on the most 
severe grade of atypia found in each biopsy. A local pathologist evaluated the samples 
and classified them according to the cervical intraepithelial neoplasia (CIN) 
classification (World Health Organization). 
 
4.1.2 Paper II 
The present study considered women who were treated for CIN by conisation between 
September 1999 and June 2009 and all of the 149 women who returned for at least one 
follow-up visit were invited to participate. In all, 143 women were treated by loop 
electrosurgical procedure (LEEP) using a C-LETZ electrode (Utah Medical Products 
Inc., Midvale, UT, USA) (190). Six of the study women did not undergo LEEP; 
instead, 2 were treated by cryotherapy and 4 by cold knife or laser conisation. Table 1 
presents the histopathological diagnoses and margin status of the cone specimens. 
Since no information on histopathology or margin status was available for the two 
women (1%) treated with cryotherapy, the pre-treatment histopathological diagnoses 
(CIN1 and CIN2) were used. Six (4%) cone specimens contained no CIN and therefore 
they were excluded from further analysis, leaving 143 women (96%) eligible for the 
study.  
 
Table I. Conisation results for 149 invited women and for 143 included women. 
 
Characteristics	   N	  (%)	  
Histology	  results	  in	  
cone	  specimens	  of	  
invited	  	  women	  
(n=149)	  
	  
CIN3+/AIS	   78	  (52.3)	  
CIN2	   32	  (21.5)	  
CIN1	   33	  (22.1)	  
No	  CINb	   6	  (4.0)	  
Margin	  status	  of	  
women	  included	  in	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final	  analyses	  (n=143)	  
Free	  margins	   89	  (62.2)	  
Positive	  margins	   52	  (36.4)	  
No	  information	  about	  
marginsc	  
2	  (1.4)	  
CIN, cervical intraepithelial neoplasia; AIS, adenocarcinoma in situ; b Excluded from 
analyses; c treated by cryotherapy. 
 
Inclusion follow-up and subsequent visits.  
The inclusion visit consisted of a complete work-up, including pelvic exam, cytology 
testing, HPV DNA, and HPV E6/E7 mRNA testing. When indicated, colposcopy-
directed biopsies were also taken. Women were divided into two groups based on when 
post-surgical HPV DNA and mRNA analysis were performed: ‘early’ (<12 months) 
and ‘late’ groups (>12 after conisation). All 143 women came for at least one additional 
follow-up visit after the initial inclusion visit (subsequent/final visit), during which Pap 
smear and, when clinically indicated, colposcopy-directed biopsies were performed. 
Cytological results from these subsequent/final visits were available for 137 (96% of 
143) women and histological results for 30 (21% of 143). Average follow-up time was 
1333 days (3.6 years), median 1182 days (3.2 years), with a range of 71-5622 days (2.4 
months -15.4 years).  
 
4.1.3 Paper III 
This study included LBC samples from 219 high-risk HPV (HR HPV)-positive women 
with minor cytological abnormalities detected within the population-based screening 
programme. Of these, 190 women had low-grade squamous intraepithelial lesions 
(LSIL) (87%) and 29 had atypical squamous cells of undetermined significance (ASC-
US) (13%) (34, 191, 192).  
Briefly, women with ASC-US or LSIL were referred for further investigation, 
including colposcopy, directed biopsies, and/or repeat cytology according to screening 
programme guidelines. Histological samples were evaluated and classified as within 
normal limits, CIN1, CIN2+ or CIN3+ based on the most severe lesion present (47). (In 
the absence of histological results, the most severe cytological result was used.) 
Cytological results were classified according to the CIN classification of the Swedish 
Society for Clinical Cytology (47)[, but were re-classified using the Bethesda system 
for the purposes of this study, although excluding koilocytosis without nuclear atypia 
from the LSIL diagnosis (37). Women were followed for 4 years after the ASC-
US/LSIL index cytology, during which time all histological and cytological results 
were obtained through medical and laboratory records, as well as from the Stockholm 
Oncology Centre in cases where information was insufficient. All women were offered 
annual follow-up and were treated by conisation if high-grade disease was diagnosed or 
if low-grade disease persisted for more than two years. HR HPV mRNA testing was 
performed on residual material from the LBC samples in April 2010. Mean age of 
study participants was 32.0 (range: 23-60 years (standard deviation (SD) 8.5 years). 
Half the women were aged 30 or younger and there was no statistically significant 
difference in age between the ASC-US and LSIL groups (p=0.60). Mean age in the 
ASC-US and LSIL groups was 32.8 years (SD 9.0) and 31.9 years (SD 8.4), 
respectively. The age distribution of study participants was as follows: 25.1% were 23-
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24, 23.7% were 25-29, 15.1% were 30-34, 16.0% were 35-39, 10.5% were 40-44, and 
9.6% were 45-60 years of age.  
 
4.1.4 Paper IV 
A total of 326 women were identified with minor cytological abnormalities detected 
through the population-based cervical screening programme in Stockholm, Sweden, 
between September 2005 and December 2008. To be included in this longitudinal 
analysis and contribute to follow-up time, women had to have at least one follow-up 
test (cytology or histology) taken after study-entry. One woman who only had index 
cytology without follow-up testing was excluded. Furthermore, 11 women who were 
diagnosed with CIN2+ lesions on the same day as the ASC-US/LSIL index cytology 
were also excluded, yielding a final study population of 314 women. Of the remaining 
314 women with minor cytological abnormalities, 76 (24.2%) had a cytological 
diagnosis of ASC-US and 238 (75.8%) had LSIL. Baseline characteristics (age, HPV 
status and cytological diagnosis) were cross-checked against the National Quality 
Register for Cervical Cancer Prevention (NKCx). The women were linked to the 
population-based NKCx using personal identification numbers in order to identify 
individuals who develop histologically confirmed CIN2+ during follow-up through 
December 2012. We estimated the cumulative incidence proportion of CIN2+ by 
baseline characteristics (age, cytological diagnosis and HPV status) using one minus 
the Kaplan-Meier curves. Univariate and multivariate Cox regression models were used 
to show the association between index visit data and outcome (CIN2+ in 
histopathology). We also assessed the association between index data and outcome of 
CIN2+. Women were followed according to accepted clinical practice guidelines, 
which stipulate that women with minor cytological abnormalities be referred for repeat 
cytology (Pap smear) and colposcopy with directed biopsies if indicated. HPV 
detection and genotyping were carried out as reflex testing using the liquid based 
cytology (LBC) samples. Women were treated when investigation revealed cervical 
intraepithelial neoplasia grade 2 or worse (CIN2+) or for persistence of minor lesions.  
 
4.2 CYTOLOGICAL SAMPLES 
Sweden uses the old US cytological nomenclature (193) in which CINI is a cytological 
diagnosis as well as a histopathological diagnosis (155). For the purposes of these 
studies the cytological results were translated into the Bethesda nomenclature system 
(37). The Bethesda classification was modified according to Swedish recommendations 
that define samples with koilocytosis without nuclear atypia as non-pathologic findings. 
However, this is a rare event. Therefore, LSIL only includes cases of mild dysplasia 
(CIN1). Local cytotechnologists and/or pathologists read the samples. 
 
Papers I, II, III and IV considered tests incorporating conventional cytology, where 
cells from the ecto- and endocervix were collected using an Ayres spatula and cervical 
brush, smeared onto a glass slide, immediately fixed in 95% ethanol and air-dried for 
cytological examination (22). The slides were stained according to the Papanicolaou 
method (Papanicolau GN, 1941) and read by local cytotechnologists and/or 
pathologists. In addition, the cervical material on the endocervical brush was used for 
HPV DNA detection and genotyping for the purposes of Papers I and II.  
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Papers III and IV studied LBC samples. Cells were collected from the ecto and 
endocervix just as for conventional smear, but using a plastic spatula. The cells were 
rinsed into a vial containing PreservCyt solution (ThinPrep®, Hologic, Marlborough, 
Ma, USA), which is used to prepare slides for cytological analysis. Local 
cytotechnologists and/or pathologists read the samples. 
 
4.3 HPV TESTING 
Hybrid Capture 2 (HC2, Qiagen, previously DiGene Inc, Gaithersburg, MD) was 
approved by the US Food and Drug administration (FDA) in 2003. It is the most 
commonly used HPV DNA test worldwide and is associated with the largest evidence 
base for HPV DNA applications (108). The Linear Array HPV genotyping Test (LA) is 
one of the most commonly used genotyping assays and has frequently been used for 
discordant analyses in research settings (111). 
The only HPV mRNA assay currently approved by the FDA for clinical use is the 
Aptima HPV Assay (formerly GenProbe Inc., San Diego, CA, USA, which has now 
merged with Hologic), used for detection of E6 and E7 mRNA from 14 high-risk HPV 
types. 
 
Hybrid Capture 2 (Paper I) 
Cell samples were obtained from the ectocervix and endocervix with a cervical brush, 
spread onto a slide for Papanicolaou staining, after which the brush was inserted into a 
transport medium provided by the manufacturer of HC2. The specimens were tested 
according to the manufacturer’s protocol at the Department of Virology, Karolinska 
University Hospital, Stockholm, Sweden. DNA from cervical material was denatured 
and hybridized with a cocktail of 13 RNA probes to oncogenic HPV types 16, 18, 31, 
33, 35, 39, 45, 51, 52, 56, 58, 59, and 68. Hybrids were captured with alkaline 
phosphatase conjugated antibodies specific to HPV DNA-RNA hybrids. A dioxetane-
based chemiluminescent substrate was added, and the resultant relative light units 
(RLUs) were measured in a luminometer. Specimens with RLUs equal to or above the 
mean RLUs of triplicate positive control specimens containing 1 pg of HPV DNA/µl 
(about 5000 copies of the HPV genome) were designated as positive. 
 
Linear Array (Paper II, III, IV) 
In Paper II, cells from the cervix were suspended in PreservCyt fixative. A 1 ml 
suspension was centrifuged and the cell pellet lysed according to instructions supplied 
in the Total Nucleic Acid Isolation kit (Roche, Basel Switzerland). In Papers III and IV, 
2 ml of the cell suspension remaining from the LBC samples were similarly 
centrifuged, lysed and used for HPV DNA detection and genotyping. DNA was 
extracted using the MagNA Pure LC Robot and analysed with the Linear Array HPV 
Detection and Genotyping Test (LA) according to manufacturer’s instructions (Roche, 
Basel, Switzerland). The LA test combines PCR amplification and reverse line-blot 
hybridization for identification of 37 HPV genotypes. It is based on co-amplification of 
a 450 bp region of the HPV L1 gene and a 268 bp region of the human b-globin gene, 
using biotinylated primer sets PGM09/PGMY11.The resulting amplicons hybridize 
with matching type-specific DNA probes coating a nylon strip and are detected by 
colorimetric determination. The result is a pattern of blue lines that is visually read by 
comparing patterns with a reference guide. The HPV types were categorized into 12 
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HR HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59), 6 probable high-risk 
(pHR) HPV types (26, 53, 66, 68, 73, 82) and 19 low risk or undetermined risk (LR) 
HPV types (6, 11, 40, 42, 54, 55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84, IS39, 
CP6108) according to Munoz et al. (194).  
 
HPVmRNA testing by APTIMA HPV Assay (Paper II,III,IV) 
In Papers II and III, LBC samples previously used for HPV DNA analysis were 
retrieved from the archives and used for HPV E6/E7 mRNA analysis using the Aptima 
HPV Assay (formerly GenProbe Inc., San Diego, CA, USA, has now merged with 
Hologic). All analyses were performed in April 2010. One ml of Thin Prep liquid 
specimen was transferred to an Aptima Specimen Transfer tube containing 2.9 ml of 
buffered detergent solution (Specimen Transport Medium) that lyses the cells and 
releases mRNA. Four hundred microlitres of the diluted liquid specimen were tested by 
Aptima HPV Assay according to manufacturer’s instructions. Aptima is a qualitative 
nucleic acid amplification test that detects the HPV E6/E7 mRNA of 14 HR HPV types 
(HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The test involves three 
main steps: capture, amplification and detection of target mRNA. The assay provides 
results that are positive or negative for the presence or absence of these high-risk HPV 
types, but does not determine the specific HPV type in the sample. An internal control 
transcript was added to verify performance at each step of the assay. One positive and 
one negative calibrator were used at the beginning of the run to determine the validity 
of the run and to establish the assay cut-off values for the internal control and analyte 
signal to the cut-off values. The signal observed for each reaction was compared with 
the cut-off values. An analyte signal to cut-off (S/CO) ratio equal to or greater than 1.00 
was considered positive. The analyses were performed at the Department of Virology, 
Karolinska Hospital. 
 
4.4 COLPOSCOPY AND BIOPSIES  
In Paper I, all women were examined with colposcopy, using a Zeiss OMPI colposcope 
for magnification. The ectocervix and distal part of the endocervix were stained with 
5% acetic acid. Punch biopsies were obtained from acetowhite areas. If no acetowhite 
areas were observed, a biopsy was taken close to the squamocolumnar junction, at 12 
o’clock. The biopsies were fixed in buffered 4% formalin, embedded in paraffin and 
then sectioned and stained with haematoxylin/eosin for histological diagnosis. The 
samples were evaluated by a local pathologist and classified according to the cervical 
intraepithelial neoplasia (CIN) classification (WHO) system. Diagnosis was based on 
the most severe grade of atypia found in each biopsy and was compared with results of 
HPV testing and Pap smear. In Paper II, all women were examined with colposcopy at 
the inclusion visit after treatment of CIN. Punch biopsies were obtained if indicated by 
an abnormal colposcopy examination during follow-up. The biopsies were handled and 
assessed in the same manner as described above by a local pathologist. 
In Papers III and IV, all women with minor cytological abnormalities were routinely 
referred for further examination by a gynaecologist including colposcopy and punch 
biopsies if lesions were suspected. Women were followed annually according to 
clinical practice; colposcopy and directed biopsies were performed when indicated. In 
paper III, information about histology and cytology results was obtained from medical 
and laboratory records, and from the Stockholm Oncology Center (OC). In paper IV, 
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information about high-grade disease was obtained from the National Quality Register 
for Cervical Cancer Prevention (NKCx).  
 
4.4.1.1 Cervical conisation (Paper II) 
In paper II, women treated for high-grade CIN underwent loop excision electrosurgical 
procedure (LEEP) using a C-LETZ electrode (Utah Medical Products Inc., Midvale, 
UT, USA) (190). Six women did not undergo LEEP; two of them were treated by 
cryotherapy and four by cold knife or laser conisation. Following excision the cone was 




In Paper IV, all women were linked through their personal identification numbers to the 
population-based National Quality Register for Cervical Cancer Prevention (NKCx) in 
order to identify individuals who developed histologically confirmed, cervical 
intraepithelial neoplasia grade 2 or worse (CIN2+) during follow-up through December 
2012. The NKCx contains a copy of the same file used to report cytological and 
histopathological diagnoses from all cytological and histopathological laboratories in 
Sweden. The completeness of the NKCx is therefore 100%. All smears, 
histopathological results and hospital visits in Sweden are registered using a Personal 
Identification Number (PIN) that is unique for each individual and either assigned at 
birth or at time of immigration to Sweden. Since the PIN is linked to a complete 
registry, the current study has nationwide information on all follow-up smears and 
histopathological results obtained from all women in the studied cohort. The National 
Cervical Screening Register (NCSR) was initially established ten years ago at the 
Department of Medical Epidemiology and Biostatistics (MEB), KI. In 2011 Stockholm 
County Council took over the register and it is now part of the NKCx. It includes 
screening information dating back to the 1960s, millions of records of cervical smears 
and histological sample results from all Swedish women. A national steering group of 
several different experts runs the register. Data delivery, coverage and multiple quality 
indicators are evaluated annually, which enables feedback. 
 
4.6 STATISTICAL ANALYSES 
Paper I 
Chi2 statistics were calculated to test the significance of the data with evident ordering. 
All statistical tests were two-sided and were considered statistically significant at 
p<0.05. Logistic regression was used to assess the significance of differences in paired 




In the absence of histological data, the most severe cytological finding, ASC-H/HSIL+, 
was considered to be equivalent to CIN2, LSIL to be equivalent to CIN1 and ASC-US 
to be normal. Therefore the outcome was a composite of cytological and histological 
data. Two disease thresholds defined treatment failure: low-grade disease (LSIL-CIN1) 
and high-grade disease (HSIL-CIN2+), including CIS and AIS detected during follow-
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up visits. Accuracy parameters for prediction of treatment failure according to these 
two thresholds were calculated, including sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV). Women without CIN in the cone 
specimen were excluded from accuracy calculations. Data were analyzed with the 
software STATISTICA 6.1 (Statsoft Inc., Tulsa, OK, USA). 
 
Paper III 
The most severe histological diagnosis recorded during the 4-year follow-up period was 
considered to be the outcome. Accuracy parameters for prediction of CIN2+ and 
CIN3+ were calculated for APTIMA, HPV16 DNA testing, HPV16/18 DNA testing, 
and repeat cytology at three different cut-off levels. The parameters that were 
calculated included: sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV), diagnostic odds ratio (DOR) and likelihood ratios (LR), as 
stratified by ASC-US and LSIL diagnoses at baseline. Relative sensitivities, 
specificities, PPV and NPV with 95% confidence intervals (CIs) were calculated for 
APTIMA and compared with HPV16 DNA testing, HPV16/18 DNA testing, and repeat 
cytology at three different cut-off levels: ASC-US+, LSIL+ and high-grade squamous 
intraepithelial lesions or worse (HSIL+). Receiver-operating characteristic (ROC) 
curves were plotted in the same figures to compare the different tests. 
Analyses were performed using Stata 13 (Stata, College Station, TX, USA). 
 
Paper IV 
In this prospective cohort study, we included women with minor cytological 
abnormalities who had complete HPV testing at baseline and at least one follow-up 
cytological or histological test. Follow-up time was counted from the date of the index 
ASC-US/LSIL to the date of the first histologically confirmed CIN2+ lesion, or to the 
last registered cytology date if the individual did not develop a CIN2+ lesion.  
First, we estimated the cumulative incidence proportion of CIN2+ by baseline 
characteristics (age, cytological diagnosis and HPV status) using one minus the 
Kaplan-Meier curves. The log rank test was used for comparisons. Second, univariate 
and multivariate Cox regression models were used to show the association between 
index visit data and outcome (CIN2+ in the histopathology). Hazard ratios (HR) and 
their 95% confidence intervals (95% CI) were obtained from the regression models, 
using time since baseline ASC-US/LSIL result as the underlying timescale. The 
proportional hazards assumption was checked and no evidence of non-proportionality 
was found. A p-value of <0.05 was considered statistically significant and all analyses 
were conducted using STATA version 13 (Stata Corp. Stata Statistical Software, USA). 
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5 RESULTS 
 
5.1 PAPER 1 
5.1.1 Index cytology and age distribution 
A total of 177 women with minor cytological abnormalities were enrolled. 52 (29%) 
had atypical squamous cells of undetermined significance (ASC-US) and 125 (71%) 
had low-grade squamous intraepithelial lesions (LSIL). Mean age was 34 years 
(median: 31; range 23-60). 
 
5.1.2 Outcome 
Histopathological analysis of colposcopy-directed biopsies revealed 101 (57%) normal 
samples and 76 (43%) abnormals, including various degrees of cervical intraepithelial 
neoplasia (CIN). 38 (50%) women had high-grade lesions (CIN2 and CIN3) and 38 
(50%) had CIN1. (Table 1) 
 
5.1.3 Repeat Pap testing and HPV testing 
The second Pap smear was normal in 93 (53%) women and abnormal in 84 (47%). 
Among the 93 women with a normal second smear, 15 (16%) had been shown to have 
high-grade dysplasia (CIN2-3) on histopathological analysis of the biopsy, and among 
the women with an abnormal second Pap smear, 23 (28%) showed CIN2-3 on 
histopathology. (Table 2.)  
A total of 116 women (66%) were HR HPV-positive. 31 (27%) had high-grade 
dysplasia (CIN2-3) on histopathology, while among women with a negative HPV test, 
only 7 (11%) were shown to have CIN2-3 on histopathology. 
48 HPV-positive women had a normal second Pap smear, 11 (23%) of whom had 
CIN2-3 on histopathology.68 HPV-positive women had an abnormal second Pap 
smear, 20 (29%) of whom were shown to have CIN2-3. 
 
5.1.4 Pap smear and HPV test accuracy 
 
The sensitivity of the Pap smear for detection of CIN2-3 was: 23/38=61% (95% CI 45-
74). The specificity of the Pap smear for detection of CIN2-3 was: 78/139=56% (95% 
CI 48-64). The positive predictive value (PPV): 23/84=27% (95% CI 19-38) The 
negative predictive value (NPV): 78/93=84% (95%CI 75-90)  
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HR HPV sensitivity: 31/38=82% (95% CI 67-91). HR HPV specificity: 54/139=39% 
(95% CI 31-47). HR HPV PPV: 31/116=27% (95% CI 20-35). HR HPV NPV: 
54/61=89% (95% CI 78-94) 
 
HPV-positive findings without dysplasia. Among women 30 years or younger, 33 
(42%) were HR HPV-positive but had no signs of CIN, compared with women older 
than 30 years, where 23 (23%) were HR HPV-positive without any signs of CIN. 
In conclusion, our study demonstrates that 39% (false negatives 15/38= 39%) of the 
high-grade cervical lesions would not have been detected using a Pap smear as the sole 
second screening test. If an HPV test had been used instead, 18% (false negatives 7/38= 
18%) of these lesions would have been missed. If these two methods were combined, 
only 11% (false negatives 4/38= 11%) of CIN 2+ cases would have been missed.  





Table 1. Results of the histopathological analysis of biopsies and HPV in women with 
cytological atypia interpreted as LSIL and ASC-US. ASC-US, atypical squamous cells 
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Table 2.  Results of the histopathological analysis of biopsies and HPV in Pap smear-
negative and Pap smear-positive women with a primary diagnosis of cytological atypia 
interpreted as LSIL and ASC-US. ASC-US, atypical squamous cells of undetermined 
significance; HPV, human papillomavirus; LSIL, low-grade squamous intraepithelial 
lesions. 
 
5.2 PAPER 2 
5.2.1 Cytological and histological diagnoses during follow-up.  
Cytological results from subsequent follow-up visits were available for 137 (96%) 
women and histological results for 30 (21%). 20 (14%) women had three or more 
follow-up visits after conisation. In the absence of histological data, we created an 
outcome comprising both cytological and histological results. In the absence of biopsy 
data, a cytology finding of ASC-H/HSIL+ was equated with CIN2, LSIL with CIN1 
and ASC-US and WNL (without neoplastic lesions =negative for intraepithelial 
abnormality) was equated with a normal outcome, even when cytology was ASC-US. 
When all follow-up visits were taken into account, a total of 32 (22.4%) treatment 
failures were detected, 25 (17.5%) of which were low-grade disease and 7 (4.9%) high-
grade disease. Regarding high-grade disease outcomes, 5/7 (71%) of the diagnoses 
were based on histology (Table 2). 
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Table II. Combined cytological/histological outcome during follow-up WNL, without 
neoplastic lesions; CIN, cervical intraepithelial neoplasia; LSIL, low-grade squamous 
intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesions.  aCIN1/LSIL; 
bCIN2/HSIL; chistology was unsatisfactory for diagnosis 
 
5.2.2 Age distribution and follow-up time 
Mean age of treated women (n=143) was 31.3 years, median age 30 years and age span 
ranged from 21 to 56 years. Average follow-up time was 1333 days (3.6 years), median 
1182, (3.2 years) and range 71-5622 days (2.4 months -15.4 years).  
 
5.2.3 HR HPV DNA and HR HPV mRNA at inclusion visit 
33 (23%) women were HR HPV-positive at the inclusion visit. The most frequently 
detected HPV types were HPV52 (4.2%), 33 and 56 (3.5% each). HPV16, 18, 51, 58 
and 66 were equally common, 2.8% each. Six women had multiple infections (4 with 
double infection, 1 with triple and 1 with quadruple infection). 
13 (9.0%) women were positive for HR HPV E6/E7 mRNA. Women who were HPV 
DNA-positive for types 33, 52, 56 (three cases each) and 18 (two cases), expressed 
mRNA more frequently than women who were HPV DNA-positive for types 16, 31, 45 
and 59 (one case each). However, 26 discordant samples were found. Three HR HPV 
E6/E7 mRNA-positive women were HR HPV DNA-negative and had a cytological 
result of WNL. Among the 23 HR HPV mRNA-negative women, two were HR HPV 
DNA-positive for types not included in the Aptima HPV Assay (HPV type 82 and 53). 
These women had a low-grade disease outcome. Among the remaining 21 mRNA-
negative, DNA-positive women 3 had high-grade disease and 4 had low-grade disease 
(Table III). Women were divided in two groups based on an early (<12 months after 
conisation) or late (> 12 months after conisation) inclusion visit. Table VI shows the 
distribution of HPV DNA and mRNA positives in the different groups (Table VI). 
 





HPV	  DNA	  pos	   24	  (31)	   9	  (14)	   33	  (23)	  
HPV	  mRNA	   11(14)	   2	  (3)	   13	  (9)	  
Tot	  	   35	   11	   46	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Table III. Discordant results for 26 women. 
 
 
5.2.4 Accuracy parameters in prediction of treatment failure 
5.2.4.1 High-grade disease 
Presence of HR HPV DNA at the inclusion visit predicted 100% (95% CI 64.6-100) of 
residual/recurrent high-grade disease, with a specificity of 80.9% (95% CI 73.5-86.6) 
(Table V A). Cytology at the inclusion visit (ASC-US+) had a sensitivity of 85.7% 
(95% CI 48.7-97.4), and a specificity of 87.5% (95% CI 80.9-92.1) for prediction of 
high-grade outcome. HPV E6/E7 mRNA was a poor predictor of treatment failure in 
the present study. Sensitivity was 57.1% (95% CI 25.0-84.2), but specificity was 93.4% 
(95% CI 87.9-96.5) for prediction of high-grade outcome. The positive predictive value 
(PPV) was 30.8% (95% CI 12.7-57.6) and the negative predictive value (NPV) 97.7% 
(95% CI 93.4-99.2) (Table V B). Biopsy margin status and presence of CIN2+ in the 
cone specimen were also poor predictors of treatment failure with sensitivities of 57.1% 
(95% CI 25.0-84.2) and 71.4% (95% CI 35.9-91.8) and specificities of 64.2% (95% CI 
55.8-71.8) and 22.8% (95% CI 16.5-30.5), respectively. (Table IV A) 
  
5.2.4.2 Low-grade disease 
Considering low-grade disease or worse as the threshold for treatment failure resulted 
in lower sensitivity and higher specificity values. (Table IV B) 
 
Table V.A Accuracy of HR HPV DNA testing 
HPV	  DNA	  test	   Disease	  
(CIN2+/HSIL)	  
Disease	  free	   Total	  
Positive	   7	   26	   33	  
Negative	   0	   110	   110	  
Total	   7	   136	   143	  
 
¥HPV DNA Sensitivity 7/7=1.00 Specificity: 110/136=0.809 
¥PPV 7/33=0.212  NPV 110/110=1.00 
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Table V. B Accuracy of HR HPV mRNA testing 
HPV	  mRNA	  test	   Disease	  
(CIN2/HSIL)	  
Disease	  free	   Total	  
Positive	   4	   9	   13	  
Negative	   3	   127	   130	  
Total	   7	   136	   143	  
 
HPV mRNA Sensitivity 4/7=0,571  Specificity 127/136=0,934 
PPV 4/13=0,308   NPV 127/130=0,977 
Table IV A Accuracy parameters in prediction of treatment failure of high-grade 
disease or worse. 
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5.3 PAPER 3 
5.3.1 HR-HPV DNA and APTIMA results at index cytology 
Mean age of study participants was 32.0 years (range: 23-60 years (standard deviation 
(SD) 8.5 years)); half of the women were <30 years and no statistically significant 
difference in age was found between the ASC-US and LSIL groups (p=0.60). Mean age 
was 32.8 years (SD 9.0) and 31.9 years (SD 8.4) in the ASC-US and LSIL groups, 
respectively. In all, 190 (87.0%) women had index LSIL smears and 29 had ASC-US 
(13%).  
All 219 women were HR-HPV DNA-positive. HPV16 was the most frequently 
detected HPV type in both the ASC-US (20.7%) and LSIL groups (31.1%). The second 
most common HPV type in the ASC-US group was HPV53 (17.2%), while HPV51 and 
HPV52 were most prevalent in the LSIL group (15.3%). HPV18 was found in 13.8% of 
the ASC-US group and 11.6% of the LSIL group. In the ASC-US group, 31.0% were 
HPV16/18-positive, compared with 41.1% in the LSIL group.  
In all, 162 women (74.0%) were mRNA-positive on the APTIMA test, 17 (58.6%) 
from the ASC-US group and 145 (76.3%) from the LSIL group (Table 1). The majority 
of HPV16/18-positive women were APTIMA-positive, regardless of index cytology.  
Fig 2. Study flow-chart 
 
Table 1. Type-specific HPV DNA distribution in the ASC-US and LSIL groups by 
APTIMA status 
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5.3.2 Cytological and histological results during follow-up  
Altogether, 205 women came for follow-up visits within 12 months of index cytology 
and were included in the final analysis. Four women came for follow-up visits more 
than 12 months later and therefore their cytological test results could not be categorized 
as repeat cytology. Ten women were lost to follow-up for unknown reasons. The 
characteristics among those lost to follow-up did not substantially differ from those 
who were followed, although mean age was 30.3 years (slightly younger) (Fig 2). 
Repeat cytology test results were available for 198 women. Seven women had only a 
biopsy test result available. If indicated, biopsies were taken by colposcopy.  
Results for repeat cytology were as follows: normal cytology in 113 (57.0%) women, 
ASC-US in 16 (8.1%), LSIL in 52 (26.3%) and atypical squamous cells-cannot rule out 
high-grade lesions (ASC-H) in 17 (8.6%) women.  
The histopathological results for the 209 women during follow-up were as follows: 
missing for 8 (3.8%) women, non-representative in 3 (1.4%), absence of CIN in 56 
(26.8%), CIN1 in 69 (33.0%), CIN2 in 37 (17.7%) and CIN3+ in 36 (17.2%). Nine of 
25 (36.0%) women in the ASC-US group and 64 of 180 (35.6%) women in the LSIL 
group developed CIN2+ during the 4 years of follow-up. Three of 25 (12%) among 
ASC-US were CIN3+ and 33/180 18%) among LSILs were CIN3+. 
 
5.3.3 Accuracy of different triage options in the ASC-US group 
APTIMA sensitivity to predict CIN2+ and CIN3+ was 77.8% (95% CI 40.0-90.0) and 
100.0% (95% CI 40.0-100), respectively in the ASC-US group. Specificity to predict 
the absence of CIN2+ or CIN3+ was 50.0% (95% CI 30.0-70.0) and 45.5% (95% CI 
30.0-60.0), respectively (Figure 1, Table 2).  
Of the three triage approaches, APTIMA was the most sensitive test in the ASC-US 
group, but only reached statistical significance when using a repeat cytology cut-off of 
HSIL+ to predict CIN2+ (relative sensitivity 7.0, (95% CI 1.1-45.9)). APTIMA was 
significantly less specific than HPV16 DNA testing to predict CIN2+ and CIN3+ 
(relative specificity 0.6 (95% CI 0.3-0.9) and 0.6 (95% CI 0.3-0.9)), respectively, and 
significantly less specific than repeat cytology using a cut-off of LSIL+ and HSIL+ to 
predict CIN3+ (0.6 (95% CI 0.3-0.9) and 0.4 (95% CI 0.3-0.7)) (Table 3). 
The positive predictive value (PPV) for all test options ranged from 29.4%-100.0% for 
CIN2+ and from 12.5%-100.0% for CIN3+. The PPV of APTIMA (46.7% (95% CI 
24.8-69.9) for CIN2+ and 20.0% (95% CI 7.0-45.2) for CIN3+) was lowest among the 
three test methods, with the exception of repeat cytology when using a cut-off of ASC-
US+ to predict CIN2+ (29.4%, 95% CI 13.3-53.1), and HPV 16/18 DNA testing to 
predict CIN3+ (12.5%, 95% CI 2.2-47.1), although the differences were not significant. 
The relative PPV of APTIMA compared with repeat cytology using a cut-off of HSIL+ 
was 0.5 (95% CI 0.3-0.8) to predict CIN2+ and 0.2 (95% CI 0.1-0.6) to predict CIN3+ 
(Table 4), both of which were significant. 
Risk of disease following a negative triage test (calculated as the complement of the 
negative predictive value (NPV): cNPV=1-NPV) ranged from 5.3%-11.8% for the 
outcome CIN3+, except for APTIMA, where no risk was detected. A negative 
APTIMA test resulted in a lower risk of disease compared with the other tests, but the 
difference was only significant when compared with repeat cytology using a cut-off of 
  61 
LSIL+ and HSIL+ to predict CIN2+ (relative cNPV 0.6 (95% CI 0.4-0.9) and 0.6 (95% 
CI 0.4-0.9), for LSIL+ and HSIL+ respectively). (Table 4). 
 
5.3.4 Accuracy of different triage options in the LSIL group 
APTIMA sensitivity for predicting CIN2+ and CIN3+ in the LSIL group was 78.1% 
(95% CI 70.0-90.0) and 75.8% (95% CI 60.0-90.0) respectively. Specificity for 
predicting absence of CIN2+ and CIN3+ was 25.0% (95% CI 20.0-30.0) and 23.8% 
(95% CI 20.0-30.0), respectively (Table 2).  
APTIMA was significantly more sensitive for predicting CIN2+ and CIN3+ compared 
with all other tests, except HPV16/18 DNA testing to predict CIN3+, where the 
difference between APTIMA and HPV16/18 DNA testing was not significant (Table 
3). However, APTIMA was significantly less specific compared with all other tests. 
PPVs ranged from 36.5%-76.9% for CIN2+ and from 18.2%-46.2% for CIN3+. The 
PPV of APTIMA was lowest among the three tests, but this was only significant when 
compared with repeat cytology using a cut-off of HSIL+, for which relative PPV was 
0.5 (95% CI 0.3-0.7) for CIN2+ and 0.4 (95% CI 0.2-0.8) for CIN3+. (Table 4) 
Risk of disease was still high when triage tests were negative (cNPV ranged from 
28.0%-32.7% for CIN2+ and from 14.0%-18.6% for CIN3+). A negative APTIMA test 
did not result in or predict a decrease in risk of disease compared with other tests; risk 
of CIN3+ was significantly higher among women who were APTIMA-negative 
compared with women who were negative for HPV16 DNA, HPV16/18 DNA, or 
repeat cytology result using a cut-off of ASC-US+. (Table 4) 
Most tests showed accuracy estimates that did not deviate strongly from the neutral 
diagonal line (LR+ and LR- near 1), indicating poor triage capacity (Figure 1). 
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Figure 1. Sensitivity & FPR (False positive rate) of the different tests used to triage 
women with ASCUS (upper) or LSIL (lower) to detect CIN2+ (left) or CIN3+ (right). 
Red circle: APTIMA, rhombus without color HPV DNA 16, rhombus blue HPV16/18 
DNA, cross: cytology AS-CUS as cut-off, diagonal cross: cytology with LSIL as cut-off, 
double diagonal cross: cytology with HSIL as cut-off. ASCUS-atypical squamous cells 
of undetermined significance, LSIL-low-grade squamous intraepithelial lesions, HSIL- 
high-grade squamous intraepithelial lesions CIN- cervical intraepithelial neoplasia 
HR-HPV: High-risk human papillomavirus 
 
5.4 PAPER 4  
5.4.1 Characteristics of the women in the study 
39.5% of women with ASC-US were HR HPV-positive, as were 79.4% of women with 
LSIL. Overall, 214 (68.2%) women were positive for at least one of the 13 high-risk 
(HR) HPV types defined by IARC (104), but most infections were due to HPV type 16 
and/or 18 (27.7%). 65 (20.7%) women were HPV16-positive and 26 (8.3%) HPV18-
positive and the next most common HPV type in the group was HPV 51 (10.5%). Mean 
age of the study group was 34 years (median 32 years, range 23-60 years) and 184 
(58.6%) women were older than 30 years. (Table 1) 
Median follow-up time was 3.8 years (range 0.1-7.0 years).  
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5.4.2 Cumulative Incidence Proportion (CIP) of CIN2+  
5.4.2.1 By age at baseline 
A total of 89 (28.3%) women developed histologically confirmed CIN2+ during 
follow-up. The 7-year cumulative risk of developing CIN2+ was greatest among 
women aged 30-39 years at the start of follow-up (CIP 39.8% (95% CI: 30.3-51.0)) and 
among women younger than 29 at study start, the 7-year cumulative risk was 30.8% 
(95% CI: 22.6-21.0) (Figure 1). There were no significant difference between age 
categories (p=0.1499). 
 
5.4.2.2 By index cytology  
In the first two years of follow-up CIP increased quickly among women with a finding 
of ASC-US at baseline, then plateaued after two years. However, in the LSIL group, 
CIP increased steadily over the entire follow-up period. The 7-year CIPs of CIN2+ 
among women with baseline cytology of ASC-US or LSIL were 15.0% (95% CI: 8.6-
25.5) and 37.3% (95% CI: 30.6-44.9), respectively. The difference was statistically 
significant (p=0.0049) (Fig. 2.). 
 
5.4.2.3 By HR HPV status at baseline 
HR HPV-positive women also had a higher cumulative risk of CIN2+ 7 years after the 
index test compared with HR HPV-negative women. CIP was 53.9% (95% CI: 40.6-
68.3) for HPV16/18 and 38.5% (95% CI: 30.2-48.2) for other HR HPV types vs. 6.6% 
(95% CI: 2.3-18.1) for HR HPV negatives. The difference was statistically significant, 
p<0.0001. After 5 years of follow-up, the risk for CIN2+ continued to increase among 
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women who were HPV16/18 positive at baseline, while risk among women positive for 
other HR types did not increase after 5 years (Fig 3). 
 
5.4.2.4 By index cytology and HR HPV status at baseline 
Fig 4 shows CIP of CIN2+ by index cytology result stratified by HR HPV status. 
Overall, HR HPV-positive ASC-US/LSIL had a higher cumulative risk of CIN2+ 
compared with HR HPV-negative ASC-US/LSIL. CIP of CIN2+ for women with HR 
HPV-positive ASC-US was 35.2% (95% CI: 20.7-64.8) after 6.5 years of follow-up 
and the risk for women with HR HPV-positive LSIL was 45.8% (95% CI: 37.7-54.3) 
after 7 years of follow-up. CIP of CIN2+ increased rapidly among women positive for 
HR HPV at baseline and plateaued after 2 years among women with ASC-US, but 
continued to increase among women with LSIL. CIP of CIN2+ for HR HPV-negative 
women with ASC-US/LSIL remained similarly low during the first years, with only a 
few more cases in the LSIL group after 4.5 years of follow-up. The difference between 
ASC-US and LSIL when stratified by HPV status was statistically significant, 
p<0.0001. The 3-year risk of CIN2+ among HR HPV-negative ASC-US and LSIL was 
2.0% (95% CI: 0.5-7.8). The 5-year risk among HR HPV-negative ASC-US remained 
2.0%, but increased to 4.1% (95% CI: 1.2-12.9) for HR HPV-negative LSIL (Fig 4). 
 
5.4.2.5 By index cytology and HR HPV16/18 genotype at baseline 
Fig 5 shows CIP of CIN2+ among ASC-US and LSIL stratified by HPV 16/18, other 
HR HPV types and HPV-negativity. The highest cumulative risk of CIN2+ was 
observed among women positive for HPV16/18 (CIP for HPV16/18 positive ASC-US 
was 48.9% (95% CI: 23.8-51.1) at 5 years of follow-up; for HPV 16/18 LSIL the 
corresponding figure was 54.2% (95% CI: 40.2-45.8)) at 7-years of follow-up. CIP of 
CIN2+ for women with ASC-US who were positive for other HR HPV types was 
27.6% (95% CI: 12.5-54.1) and for women with LSIL who were positive for other HR 
HPV types, 40.4% (95% CI: 31.1-51.1) at 6-years of follow-up. The risk for CIN2+ 
increased rapidly among women with HPV-positive ASC-US/LSIL during the first two 
years, but continued to increase throughout the entire follow-up period. However, risk 
among HPV16/18 positives was always greater than risk among women positive for 
other HR HPV types.  
 
5.4.3 Risk associations with baseline characteristics 
We evaluated age, cytological, and viral risk factors for developing CIN2+ in the study 
group. Unadjusted associations are shown in Table 2. Baseline risk factors significantly 
associated with developing CIN2+ included LSIL cytology (HR 2.4; 95% CI, 1.3-4.5) 
vs. ASC-US and HR HPV-positivity (HR 12.5; 95% CI, 4.6-34.1) vs. HR HPV-
negativity. Testing positive for HPV genotype 16 and/or 18 (HR 2.4; 95% CI, 1.6-3.6), 
HPV16 alone (HR 2.6; 95% CI, 1.7-3.9) or one of the HPV types 31 (HR 3.0; 95% CI, 
1.8-5.0) or 33 (HR 4.1; 95% CI, 2.1-7.9) was also significantly associated with 
developing CIN2+ compared with a negative test for that type. 
In the multivariable model adjusted for age at baseline, index cytology and HPV status, 
the strength of association was greatest for HR HPV-positivity compared with 
negativity (Hazard Ratio HPV16/18 2.3 (95% CI; 1.5-3.5) p<0.001 (Table 3.) 
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6 DISCUSSION 
 
6.1 PAPER 1 
 
6.1.1 Main findings and interpretations 
The aim of this study was to compare the sensitivity of high-risk human papillomavirus 
(HR HPV) DNA testing for detection of high-grade cervical intraepithelial neoplasia 
(CIN) 2-3 with that of a second (repeat) Pap smear in women diagnosed with minor 
cytological abnormalities in their index Pap smear. The HPV DNA test was positive in 
66% of the studied women and 43%(76) of these women had various degrees of CIN. 
The sensitivity to detect CIN2-3 was 82% (95% CI=67-91) for the HPV DNA test and 
61% (95% CI=45-74) for the second Pap smear. The positive and negative predictive 
values of HPV DNA testing to detect CIN2-3 were 27% (95% CI=18-35) and 89% 
(95% CI=80-97), respectively. Our study demonstrates that HPV DNA testing with 
HC2 is a more sensitive method for detecting high-grade CIN lesions than Pap smear. 
Pap smear as the sole second screening test would have missed 39% (15/38) of the 
high-grade cervical lesions, providing false negative results. If an HPV test had been 
used instead, 18% (7/38) of these lesions would have been missed. If these two 
methods were combined, only 11% (4/38) of CIN2-3 cases would have been missed. 
The data also show that women < 30 years were more frequently HPV-positive (42%) 
without signs of CIN compared with older women (23%). 
A follow-up repeat Pap smear was often obtained 4-6 months after the first smear that 
showed minor cytological abnormalities. However, management varies throughout 
Sweden and in Stockholm County all these women were referred for colposcopy and 
biopsy. Our results indicate that HR HPV DNA-testing with HC2 is a more sensitive 
method to select women who need referral for colposcopy and biopsy. For negative 
HPV DNA tests we proposed repeating the test in 1 year and if still negative, these 
women may return to population-based screening at 3-year intervals, thereby reducing 
psychological stress and healthcare costs. 
 
6.1.2 Methodological considerations and validity 
The study women were consecutively enrolled when diagnosed with minor cytological 
abnormalities (ASC-US or LSIL) detected through population-based screening. 
Swedish cytological diagnoses were converted into the Bethesda system. Sweden uses 
the old US cytological nomenclature by Koss, in which CIN1 is both a cytological as 
well as a histopathological diagnosis. The cytological term LSIL is a combination of 
LSIL and koilocytotic atypia. In the Koss system, a diagnosis of koilocytosis can be 
made in addition to any other diagnosis. Since only a small minority (0.85%) (18) of 
smears are reported as normal with koilocytosis as an ancillary diagnosis, the 
cytological diagnosis of CIN1 used in Sweden is essentially equivalent to the term 
LSIL (155).  
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There is a strong association between the LSIL diagnosis and HPV infection. In LSIL, 
75-80% of lesions harbour oncogenic HPV types and another 10-15% are associated 
with nononcogenic HPV types. Only 5-10% are negative for HPV (151). In our study 
HC2 testing found that 93/125 (74%) cases were HPV-positive and 32/125 (26%) were 
HPV-negative LSIL. Zuna et al. question the existence of HPV-negative LSIL as a 
distinct biological entity and found no evidence to support its existence. Possible 
explanations for HPV-negative LSIL include a) infection with nononcogenic HPV 
types that are not targeted by HC2, b) cytological misinterpretation (false positive), c) 
false negative HPV tests and d) viral clearance between original finding and repeat 
cytology with enrolment for HPV testing. All women underwent colposcopy, which 
relies on subjective interpretation. Limiting factors in colposcopy include failure to 
identify an abnormality and failure to properly sample an identified abnormal area. 
Experienced gynaecologists performed all examinations, but studies have shown that 
even under enhanced imaging, an apparently normal cervix has been shown to harbour 
CIN2+ disease in 25% of women referred for colposcopy. This implies that colposcopy 
itself, rather than punch biopsy, is the limiting factor for detecting CIN2+ (195). 
Punched biopsies were carried out on all women regardless of presence of a visualised 
lesion and therefore verification bias could be limited/avoided. Studies have shown that 
increasing the number of biopsies and taking random biopsies from apparently normal 
cervical tissue increase detection rate of CIN3 (55, 57). A meta-analysis by Underwood 
et al. demonstrated that pooled sensitivity for a single punch biopsy is 90%; when one 
or more punch biopsies were performed sensitivity increased to 93%, and with multiple 
biopsies, sensitivity approaches 100%. The TOMBOLA trial identified a false-negative 
rate associated with punch biopsies, but concluded that it did not have an impact on 
clinical outcome because “missed cases would be picked up at the next round of 
screening” (196). Confirming the rate of true false negatives on colposcopy would 
require all women with negative punch biopsies to undergo loop electrosurgical 
excision procedures (LEEP), which is not feasible. 
Other factors that influence the accuracy of colposcopy-directed biopsies are 
cytological findings before biopsy and screening history. All women in our study had a 
diagnosis of minor cytological abnormalities detected through the population-based 
screening programme, which essentially means there were no prior cytological 
abnormalities. Another confounding factor affecting accuracy is possible lesion 
regression during the waiting period for colposcopy. 
Staff cytologists and pathologists, reflecting a real life setting, interpreted cytological 
samples and punch biopsies. No samples were reviewed, which is a practice that could 
alter the diagnosis, since histological interpretation of biopsy material is prone to error 
(49). On the other hand, reflecting routine clinical practice in the healthcare system 
could be a strength of the study since it does more closely duplicate the real life setting. 
We used histological findings from colposcopy as our reference standard, but did not 
accept “negative satisfactory colposcopy” as evidence for absence of high-grade CIN, 
as many studies do. When colposcopy was negative, a biopsy was taken at the 12 
o’clock position. In many situations, however, an ethical and practical dilemma arises 
when performing a gold standard test that is invasive. 
Presence of histologically confirmed high grade CIN was the disease endpoint. CIN3 is 
the most relevant clinical outcome since it is considered to be an obvious precursor to 
cervical cancer and is a more reproducible histological diagnosis than CIN2. CIN2+ is 
an intermediate condition containing over-called CIN1 and under-called CIN3.  
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We chose CIN2-3, which is the clinical cut-off for treatment of precancerous lesions 
and also generates a greater outcome in a small study population. 
HC2 is an FDA-approved test and the system is calibrated using positive and negative 
control samples provided by the manufacturer. The test is known to cross-react with 
nononcogenic HPV types, which lowers specificity and results in higher rates of false 
positives. False-negative HPV test results may be due to errors during sample 
collection, technical problems with the assay process, or the presence of rare, low-risk 
HPV types that are not detected by the current test. Even highly sensitive tests like the 
HPV DNA test will not achieve perfect sensitivity. Another drawback of HC2 is that it 
has no internal cellular control to help adjudicate false negatives. 
The external validity of our study, generalisability to other real-life settings, is good, 
since it utilises the real-life setting. 
Disease prevalence is high and therefore the negative predictive value of the tests will 
not be affected.  
 
6.1.3 Comparison with other studies 
Our study preceded a randomised health services study of human papillomavirus-based 
management contra colposcopy of all low-grade cytological abnormalities in the 
Stockholm area in which they assessed safety and healthcare resource utilisation under 
a real-life healthcare policy using HPV DNA triage. This trial enrolled 3319 women 
who were diagnosed with ASC-US or CIN1 from 2003 to 2006. Clinics were 
randomised to either continue with prior policy (colposcopy of all women with 
ASCUS/CIN1) or to implement a policy using HPV triage and only perform 
colposcopy on HPV-positive women. The primary outcome measure of safety in a 
comparison between the two policies was detection rate of CIN2+. The secondary 
outcome measure was cost-effective use of healthcare resources. The proportion of 
histopathologically verified CIN2+ was similar for both approaches (22.5% for HPV 
triage and 20.3% for CIN2+ with colposcopy). In all, 64% of women with ASCUS and 
77% of women with CIN1 were HPV-positive. HPV positivity was age-dependent: 
81% of women below age 35 and 44% of women above age 45 tested HPV-positive. 
HPV triage was cost-effective only among women above age 35 (155); 32% fewer 
women were referred using the HPV triage policy (155). 
The randomised triage trial ALTS (ASC-US LSIL Triage Trial) found that HPV triage 
of LSIL smears was not cost-effective since a majority of LSIL smears were HPV-
positive. Several studies eventually formed the basis of new management guidelines 
recommending HPV testing to triage minor cytological abnormalities. In 2010, the 
Society of Obstetrics and Gynaecology Working Group for Cervical Cancer Prevention 
revised the Swedish guidelines and no longer recommend repeat cytology (39). The 
main reasons for the new recommendations were the high prevalence of CIN2+ in 
women with ASC-US and LSIL according to reports from both Sweden and abroad, 
along with the risk of decreased compliance with cytological surveillance over time 
(155, 197-199). 
Our study is included in a recent Cochrane review of diagnostic test accuracy 
comparing HPV testing with repeat cytology for triage of minor cytological cervical 
lesions (135). This review corroborates conclusions from previous meta-analyses, 
which all indicated that HC2 triage of women with ASC-US predicts presence of 
underlying high-grade CIN with greater accuracy than repeat Pap smear (150, 154). In 
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triage of LSIL, however, the lower specificity of HC2 was confirmed, although a 
significant gain in sensitivity was demonstrated.  
Recent European and American guidelines now recommend HPV triage of women with 
ASC-US, but not for management of women with LSIL. The recent Cochrane review 
demonstrated significantly higher sensitivity for HC2 to detect CIN2+ and CIN3+, 
which may justify recommending the use of HC2 when deciding whether to refer 
women for colposcopy. However, such recommendations should be based on local 
cost-effectiveness analyses, local prevalence of HPV in LSIL, performance of the HPV 
test used and patient compliance with follow-up recommendations. In addition, HC2 
use should be restricted in situations where access to colposcopy referral is limited 
and/or expensive. 
 
6.1.4 Implications for continued research and practice 
We conclude that virological testing using HC2 is a more accurate method than repeat 
cytology to triage women with minor cytological abnormalities in our study population. 
We used conventional Pap smear, but if the collected cervical specimen is liquid-based 
(LBC), residual material from the same sample can be used for HPV testing, thereby 
avoiding additional medical visits. In the future newer assays developed for HPV self-
sampling could be an option. Several studies have demonstrated a decline in HPV 
prevalence by age. In the health service study by Dillner et al. triage based on HPV 
testing was only cost-effective in women over age 35. Younger women with a high 
prevalence of HPV and profuse mild cellular abnormalities need a more specific 
marker that permits identification of those women at risk for high-grade CIN. 
Optimally, such a test would be as sensitive, but more specific, than HC2 and also more 
sensitive than repeat cytology. HPV testing may also be able to more effectively detect 
rare cytological abnormalities, such as atypical glandular cells or adenocarcinoma. 
 
6.2 DISCUSSION PAPER 2 
6.2.1 Main findings and interpretations 
To our knowledge, the present study is the first to compare the HPV E6/E7 mRNA of 
14 HR HPV types with HPV DNA testing for follow-up of women treated for CIN. 
This study identified high-grade residual/recurrent disease (CIN2+/HSIL+) in 7 (4.9%) 
women and low-grade disease (CIN1/LSIL) in 25 (17.5%) women during follow-up 
after treatment for CIN. These findings are consistent with residual/recurrent disease 
rates in other studies. A meta-analysis of 28 studies estimated treatment failure to range 
from 7.1% to 11.3% (134). Presence of HR HPV DNA predicted all (100%) cases of 
residual/recurrent high-grade disease with a specificity of 80.9%. These findings 
support previously known data and conclude that a positive HR HPV DNA test is a 
better predictor of treatment failure than cytology or positive resection margins (134, 
154). Meanwhile, using the APTIMA HPV Assay to test for HR HPV E6/E7 mRNA 
showed low sensitivity for high-grade outcome, 57.1%, but high specificity, 93.4%. 
However, the Aptima missed three cases of high-grade disease and we concluded that 
this test was a poor predictor of treatment failure and was not useful for follow-up of 
women treated for CIN. Since women treated for CIN are at greater risk of developing 
SCC than the general population, careful surveillance is required. An ideal test in this 
  74 
setting should have high sensitivity and high negative predictive value (NPV)(200, 
201). 
 
6.2.2 Methodological considerations and validity 
Since the post-treatment population is at greater risk of disease, follow-up testing 
should have high sensitivity and high negative predictive value (NPV). Testing for 
HPV DNA fulfils these criteria, while significantly reducing follow-up visits and 
anxiety. However, the performance of most tests, such as the Aptima, has previously 
been evaluated in a different type of patient management setting, including colposcopy 
referral/triage populations in which HPV and disease prevalence are higher than in the 
post-treatment group. These factors could all have affected our results. 
Our study confirms that high NPV (Aptima 97.7%) can be misleading since the HPV 
mRNA test missed 3 of 7 residual CIN2+ cases. The PPV and NPV of a diagnostic test 
depend on disease prevalence. In fact, regardless of diagnostic test, PPV falls with 
disease prevalence, while NPV rises. Simply put, low prevalence means that the person 
we are testing is unlikely to have the disease and therefore, based on this fact alone, a 
negative test is likely to be correct. In our study the prevalence of recurrent disease was 
only 7/143 (4.9%). The HPV mRNA test showed a high specificity and NPV, which 
could partly be explained by the fact that most of the study population had no residual 
CIN2+ according to our criteria. The sensitivity of cytology to detect residual disease 
post-treatment was 85.7%, but the mRNA test did not contribute significantly to 
improving detection of residual CIN2+. A larger study population with a higher rate of 
recurrence would lead to greater test accuracy. 
The sensitivity of HPV mRNA (Aptima) for detection of high-grade disease was only 
57.1%. This may be due to low viral load or low levels of E6/E7 mRNA transcripts in 
the sampled cells, even if the HPV type causing the residual lesion was included in the 
HR HPV mRNA test. Only two cases were positive for HPV types not included in the 
Aptima, HPV53 and HPV82, but the associated lesions were both low grade. HPV82 
and HPV53 are categorised as group 2B, which despite limited epidemiological data 
has been proposed to designate types that are probably carcinogenic because of their 
close phylogenetic relationship with established carcinogenic types. The Aptima test 
was negative in three high-grade lesions (3/7, 43%). One of these lesions had a multiple 
infection with HPV16, 51 and 59, and the other two had single infections with HPV33 
and HPV66, respectively. Lack of detection of mRNA may also be due to sampling 
technique, unevenly distributed oncogene expression in the lesions, or the fact that not 
all HPV-infected cases have transcriptionally active E6/E7 expression. Absent mRNA 
may also represent regressing dysplasia resulting from switched off E6/E7 (202), but 
since guidelines recommend treatment of all women over age 25 with a diagnosis of 
CIN2+, this potential regression cannot be investigated.  
This study reflects a real-life setting, with clinical follow-up after surgical treatment for 
CIN. Pap smears were carried out during follow-up, colposcopy was performed and 
biopsies taken if an abnormality was diagnosed or suspected. If colposcopy or cytology 
were normal the women were considered disease-free. An optimal scenario would have 
been to biopsy (gold standard) every woman, but this is not ethically defensible and 
therefore verification bias may have affected our results. 
Our outcome is based on a composite of both cytological and converted histological 
data for cases where only cytology was performed and where direct histological data 
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were absent. Therefore this study limits evaluation of the accuracy of cytological 
follow-up, because cytology was included in the definition of treatment outcome.  
Strength is that follow-up data was available from all women and that average follow-
up time was 3.6 years. 
The composition of our study population was heterogeneous since some women had 
been treated for more than 12 months before inclusion and others less than 12 months. 
Surgical treatment of CIN affects the clearance rate of HPV infection and is therefore a 
time-consuming process, which means our results may have been affected. How HPV 
mRNA is affected by conisation is unknown since to our knowledge this is the first 
study to investigate HPV mRNA after treatment. Aerssens (203) observed a 
pronounced decrease in presence of HPV immediately after women were treated with 
LEEP conisation or with cryotherapy. Six months, one year and two years after 
treatment the detection rates of HPV in the LEEP group were 20.3%, 15.3% and 8.4%, 
respectively. Kim et al. also concluded that HR HPV infection cleared gradually in 
most patients within 6 months of treatment and that a persistent HPV infection was a 
significant positive predictor of recurrence (204). A study protocol that determined 
exact intervals for clinical follow-up and testing would also have been useful when 
comparing results. Clinical performance on long-term follow-up may advantageously 
be judged by the cumulative incidence of CIN2+, since women may also undergo 
additional treatment such as repeat conisation during the follow-up period. 
Specimen storage 
False negative mRNA test results on the Aptima may possibly result from factors such 
as inappropriate storage conditions and excessive time since collection, which could 
lead to mRNA degradation and help explain the low sensitivity. mRNA is less stable 
than DNA. The liquid-based samples collected at the inclusion visit were stored in 
PreservCyt solution (ThinPrep) vials at room temperature and tested according to 
manufacturer’s instructions. The Aptima HPV Assay is validated for specimens 
collected in ThinPrep Pap test vials containing PreserveCyt solution. Storage time 
ranged from a couple of months up to several years. Further, in our study, a positive 
test result was defined by an analyte signal-to-cut-off ratio (S/CO) of 1.00. According 
to current test interpretations an analyte S/CO>0.50 is considered positive. This 
difference may have resulted in lower sensitivity for high-grade disease in our study. 
However, two other studies, one from Clad et al. (205), the other from Waldstrom et al. 
(206), reported that the APTIMA is able to detect HPV high-risk mRNA with strong 
correlation to disease in retrospective LBC specimens stored at room temperature for 
up to three years. 
  
6.2.3 Comparison with other studies 
To our knowledge this study was the first to compare testing for HPV E6/E7 mRNA 
from 14 high-risk HPV types (APTIMA) with testing of high-risk HPV DNA for 
prediction of residual/recurrent disease in follow-up of women treated for CIN.  
HPV DNA testing to predict cure or failure of treatment has been recommended in the 
Swedish national guidelines since 2010, but there is little data on the comparative 
performance of different HPV tests in a post-treatment setting. A Scottish study 
presented at the 2013 Eurogin meeting (European research organisation on genital 
infection and neoplasia) compared the performance of 5 HPV tests, including the 
Aptima HPV Assay, in a post-treatment setting. The mean follow-up period was 13.2 
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months. All tests were 100%-sensitive for detection of CIN3+ and specificity ranged 
from 75% to 84% according to assay. Detailed information about Aptima test 
performance is not available since this information came from a conference publication 
of abstracts. A Norwegian study by Tropé A et al. evaluated postconisation mRNA 
testing to predict residual high-grade disease. They demonstrated a sensitivity of 45.5% 
for the Pre-Tect HPV Proofer, which detects mRNA from 5 HR HPV types. They 
concluded that the Pre-Tect HPV Proofer did not appear to be suitable for short-term 
follow-up (207). In a recent summary of 15 studies, Arbyn et al. demonstrated the 
pooled sensitivity for HR HPV DNA testing (HC2 and PCR) to predict residual or 
recurrent CIN2+ after treatment to be 93% (95% CI: 85-97%), while sensitivity was 
72% (95% CI: 66-78%) for cytology. The pooled specificities were 81% (95% CI: 74-
86%) and 84% (95% CI: 74-86%) for HPV and cytology, respectively. HPV testing 
was significantly more sensitive (ratio 1.25) but not significantly less specific (ratio of 
0.97) than cytology. These findings are consistent with our results (134). The Aptima 
test has not been evaluated in the post-treatment setting, but has demonstrated equal 
sensitivity but higher specificity compared with HPV DNA testing in other settings 
(triage and primary screening). In a study by Brismar et al. HPV testing predicted all 
recurrent disease while HPV genotyping increased the PPV with a lost in sensitivity 
(208). Söderlund-Strand, however demonstrated that only type-specific HPV 
persistence predicted recurrent or residual disease and that HPV genotyping was useful 
to improve that specificity post-treatment (161). 
 
6.2.4 Implications for continued research and practice 
In the future, one might envisage a follow-up strategy that includes both HPV DNA 
and cytology. Women who are HPV DNA-negative at 6 and 24 months after treatment 
could be safely referred back to the usual screening programme, while HPV DNA-
positive women should be followed annually until negative.  
Meta-analyses, or ideally large RCTs, are needed to compare HPV DNA testing with 
newer biomarkers such as HPV type-specific mRNA over an extended period of time 
to help establish an optimal follow-up strategy for women treated for CIN. Finding an 
indicator that predicts successful outcome and shortens the follow-up period would be 
especially helpful. One area of interest would be to determine the relevance of HPV 
positivity in the absence of cytological abnormality and how to manage these women 
who are referred back for colposcopy due to positive HPV status, but without signs of 
disease. It would also be of interest to evaluate a possible role for HPV self-testing after 
treatment and the efficacy of HPV vaccination to prevent recurrent disease. 
 
6.3 DISCUSSION PAPER 3 
 
6.3.1 Main findings and interpretations 
Aptima was the most sensitive test to predict high-grade CIN among HPV-positive 
women with minor cytological abnormalities diagnosed with ASC-US on index 
cytology and among women with LSIL on index cytology, compared with the other 
tests. Aptima detected 100% of CIN3+ and 77.8% of CIN2+ in the ASC-US group and 
detected 76% of CIN3+ and 78% of CIN2+ in the LSIL group. Specificity to predict 
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absence of CIN2+ or CIN3+ was 50.0% and 45.5% respectively, in the ASC-US group 
and 25.0% and 23.8% respectively in the LSIL group. Specificity for CIN3+ is not 
clinically useful. CIN2 results would be considered to be false-positives, which is 
inappropriate since most clinical guidelines use CIN2 as the cut-off for treatment.  
Aptima was the least specific test in both groups with the one exception of repeat 
cytology, which achieved 25.0% specificity in the ASC-US group when ASC-US+ was 
used as a cut-off. Aptima specificity in the LSIL group is considered too low to be 
useful for triage since too many false positives would be generated. 
The test accuracy of Aptima in the ASC-US group is consistent with findings from a 
meta-analysis of diagnostic accuracy for triage of women with ASC-US or LSIL, 
involving 8 studies where the pooled sensitivity and specificity of Aptima to detect 
CIN2+ was 95.7%  (95% CI 91.5-97.2) and 56.4% (95% CI 44.7-67.5), respectively, 
and 96.2% and 54.9%, respectively, to detect CIN3+ (117). This meta-analysis showed 
greater specificity without loss in sensitivity for Aptima in triage of ASC-US and LSIL 
for detection of high-grade CIN compared with HC2, the most common HPV DNA 
test. Considering the widely accepted evidence for use of HC2 in triage of ASC-US and 
the similar sensitivity of Aptima, the higher specificity of Aptima would support the 
use of Aptima in triage of ASC-US cytology (without knowledge of HPV status). In 
our study, all women were HR HPV-positive and Aptima showed similar accuracy in 
the ASC-US group as in the meta-analysis; we therefore concluded that Aptima is 
suitable for triage in this group too. However, our ASC-US study group was small 
(n=25) and larger studies are needed to confirm these findings. 
However, in triage of HPV-positive LSIL, our results show lower sensitivity (91.0% 
and 96.7%) and specificity (42.5% and 38.7%) for Aptima to detect CIN2+ and CIN3+ 
than the pooled results as reported in the aforementioned meta-analysis and therefore 
they cannot be used to efficiently triage women with HPV-positive LSIL.  
The HPV16 DNA results from our study showed significantly higher specificity than 
Aptima to predict the absence of CIN2+, 87.5%, and CIN3+, 81.8%, in the ASC-US 
group, and 72.4% and 72.1%, respectively, in the LSIL group. No gain in specificity 
was observed with the addition of HPV18 DNA testing; on the contrary, specificity was 
less. HPV16 DNA testing identified women at substantial risk for cervical disease 
(PPV for CIN2+ 60.0% in the ASC-US group and 42.9% in the LSIL group), but 
sensitivity was low (33.3% and 37.5% for CIN2+ in ASC-US and LSIL, respectively), 
indicating a need for more aggressive follow-up of HPV16-positive women. Risk of 
disease among women positive for HPV16/18 was also substantial, albeit slightly lower 
(PPV for CIN2+ was 50% in ASC-US and 39.7% in LSILs). The >30% risk of disease 
(CIN2+) despite a negative HPV16 DNA or HPV16/18 DNA test indicates that these 
women should not return to the normal screening schedule. 
Risk of significant disease among ASC-US cases despite a negative test (the 
complement of the negative predictive value, cNPV=1-NPV) was never low for any of 
the evaluated triage tests, with the one exception of Aptima in the triage of ASC-US for 
the outcome CIN3+ (zero risk). In LSIL triage, risk of disease remained high even 
when triage tests were negative (cNPV ranged from 28.0-32.7% for CIN2+ and from 
14.0-18.6% for CIN3+), indicating that a negative triage test should not allow women 
to return to the normal screening schedule. In ASC-US triage, a negative Aptima test 
resulted in lower risk of disease compared with other tests (cNPV 20.0% for CIN2+); 
the difference was significant when compared with repeat cytology using LSIL+ or 
HSIL+ as a cut-off. In LSIL triage, a negative Aptima test did not decrease the risk of 
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disease. In fact, risk of CIN3+ was even significantly higher compared with a negative 
HPV16DNA, HPV16/18DNA or repeat cytology finding of ASC-US+. 
Overall, in LSIL triage most tests showed accuracy estimates that did not deviate 
strongly from the neutral diagonal line (LR+ and LR- near 1), indicating poor triage for 
the LSIL group (Figure 1).  
Repeat cytology 
Considering ASC-US+ as the threshold for repeat cytology, sensitivity for CIN2+ was 
55.6% and CIN3+ 66.7% among women with ASC-US on index cytology. The 
corresponding specificities were 25.0% and 68.2%. In the LSIL group the sensitivities 
for CIN2+ and CIN3+were 53.1% and 54.5%, and specificity for CIN2+ was 66.4%. 
Risk of CIN2+ was 28.0% even with negative repeat cytology. This study indicates that 
repeat cytology is inadequate for use in triage. 
Our study population comprised HR-HPV-positive women, the majority of whom had 
a cytological diagnosis of LSIL (87.0%). 50% of the women were under the age of 30, 
which might have contributed to the observed low specificity since lesions in young 
women may be more prone to regression. A re-assessment of the data indicates that 
HPV66 is relatively common, though it is rarely found in cancers, which may decrease 
the specificity and PPV of assays in which this type is included (104). HPV66 is 
covered in the Aptima, which may also have contributed to low specificity. We found 5 
cases of a single infection with HPV DNA type 66. The use of CIN2+ as an outcome 
has also come under discussion, since reproducibility of this diagnosis is considered to 
be poor (94). 
The most prevalent HPV type in our study was HPV16, 20.7% in ASC-US and 31.1% 
in LSIL. The second most common type in the ASC-US group was HPV53 and in the 
LSIL group, HPV51 and HPV 52. Our finding that HPV16 was the most common type 
and HPV51 the second most common type in the LSIL group is consistent with HPV 
prevalence in another Swedish study by Söderlund-Strand (3).  
 
6.3.2 Methodological considerations and validity 
The HPV DNA test and the Aptima test were performed on cellular material stored in 
PreservCyt medium, validated for the aforementioned tests. Midwives collected the 
samples as part of the cervical cancer-screening programme (2005-2008). Regardless of 
HPV status, women with ASC-US/LSIL were referred for further work-up and 
colposcopy according to clinical guidelines and thus the clinicians who examined the 
women were blinded to the HPV and mRNA test results. Aptima testing was carried 
out in 2010 on residual material from LBC samples. Aptima detects mRNA, which is 
more fragile than DNA. Therefore test accuracy could be compromised by factors such 
as transport and storage of samples. Our specimens were stored for up to 5 years at 
room temperature in PreserveCyt medium before testing with the Aptima HPV Assay. 
According to instructions from the manufacturer, the Aptima test is validated for 
samples collected in PreservCyt medium, but recommended “storage at 2°C to 8°C, 
with no more than 30 days at temperatures up to 30°C. If longer storage is needed, the 
PreservCyt liquid Pap specimen or the PreservCyt liquid Pap specimen diluted into the 
Specimen Transfer Tube may be stored at -20°C or colder for up to 24 months.” We 
have previously reported on two other studies that demonstrated that the Aptima is 
retrospectively able to detect HPV high-risk mRNA in LBC specimens stored at room 
temperature for up to three years and retain strong correlation to disease (205, 206). 
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Our group has discussed the issue of RNA strand fragmentation; according to our 
laboratory expert, “if the mRNA strand is around 100 bp long, it is unrealistic to 
conclude that degradation might have caused false negative results.” Aptima was FDA-
approved in 2011, and has proven to be highly robust (114). 
Ideally, to verify or rule out disease we would have obtained biopsies from all women 
regardless of colposcopy test results, but this was not feasible. Therefore a negative 
colposcopy was taken as absence of disease and when lesions were observed by 
colposcopy they were biopsied. This management introduces a type of verification bias 
known as the double gold standard bias, in which different gold standards are used for 
those with positive and negative test results, which increases both sensitivity and 
specificity. The best way to avoid such bias is to design a prospective study in which all 
patients receive definitive verification of disease status. The delay between sample 
collection (triage testing) and disease verification (clinical policy is 3 months) may also 
have influenced test accuracy since some lesions may have undergone interim 
regression. It would have been interesting to follow mRNA positive and negative 
lesions over time to see if negatives were more prone to regression, but this is not 
feasible due to current screening guidelines that use CIN2+ as a cut-off for treatment. 
The ASC-US study population was small for drawing robust conclusions. 
The strength of the present study lies in case verification and in the quality of follow-up 
data via medical records; in cases with insufficient information, data were 
supplemented with information from the Stockholm Oncology Centre. The long 
observation time (4 years) covers a full 3-year screening interval, allowing us to 
comment on the performance of the triage tests within the context of a 
programmatically relevant follow-up period. 
 
6.3.3 Comparison with other studies 
A triage test should be able to decide whether women need referral for colposcopy; in 
other words, able to differentiate a high-risk group for disease from a low-risk group. A 
test that maximizes sensitivity and specificity would allow effective triage. 
One useful strategy may be to use the most sensitive test first (i.e. HPV DNA testing), 
followed by a more specific test (cytology or a new biomarker) afterwards to rule out 
false positives. In triage of LSIL cytology, more specific tests would be preferable, 
given the high prevalence of HPV. That might allow identification of the women at 
lowest risk and justify returning them to the regular screening program, but the problem 
so far has been low sensitivity and the risk of not detecting disease. 
We studied a select group of women who were already at higher than average risk for 
precancer; the aim of a triage test in such a setting would be to identify the women at 
highest risk for immediate follow-up, since a negative test does not justify allowing 
these women to return to the regular screening programme.  
Until now, most studies have focused on triage of ASC-US/LSIL cytology or HPV 
positivity. The Aptima HPV Assay is an attractive option due to its theoretical ability to 
detect oncogenic transforming infections of 14 HR HPV types, in contrast to the 
PreTect HPV-Proofer, which only detects HPV mRNA of 5 HR types (HPV16, 18, 31, 
33 and 45). Aptima has been shown to be substantially more sensitive (ratio 1.91 (95% 
CI: 1.43-2.56)), but less specific (ratio 0.47 (95%CI: 0.34-0.63)) for predicting CIN2+, 
compared with the PreTect HPV-Proofer. Arbyn et al. proposed rules of thumb for test 
accuracy regarding the use of equivocal cytology for triage: a) Clinical sensitivity of at 
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least 90% for detection of CIN2+ with a relative sensitivity compared with HC2 not 
significantly lower than unity and a lower confidence interval (CI), but no lower than 
0.90. b) Relative specificity not significantly below unity with a lower CI not below 
0.95. Aptima has been shown to fulfil these criteria, but Arbyn writes “it should be 
recognised that the specificity for excluding high grade CIN2 (in the range 40-60% and 
consequently also the PPV (range 20-30% for CIN2+, range 10-15% for CIN3+)) is not 
optimal, allowing for the use of more specific markers, such as genotyping for HPV16 
and 18 or RNA testing for 5 types. These markers allow identification of women at 
highest risk (PPV for CIN2+ >30%), warranting more intensive follow-up but women 
who test negative must not be referred back to routine screening, but require follow-up 
(117).” Arbyn et al. conducted the aforementioned meta-analysis of the diagnostic 
accuracy of Aptima vs. HC2 in women with either ASC-US or LSIL (HPV status was 
not known). Castel et al. also presented a risk management model for cervical cancer 
prevention according to which a triage test is considered feasible when the NPV is 
equal to or exceeds a predefined threshold of 98% (209). 
Not many studies, to our knowledge, have evaluated triage of HPV-positive women 
with minor cytological abnormalities. Mesher et al. compared several HPV- (HC2, 
Abbot Real-time PCR, BD HPV test, Cobas 4800, PreTect HPV Proofer and Aptima) 
and p16INK4a-test strategies to triage women referred for low-grade cytological 
abnormalities in a fusion of the two Predictor studies. Five HPV tests were found to be 
highly sensitive and were able to reduce the number of referrals for colposcopy by 
20%-30%. Aptima had sensitivity of 99% for detection of CIN3+, and a specificity of 
34.7% for CIN2+. The sensitivities for detecting HPV16 ranged from only 66.0%-
75.5% and the specificities from 81.3%-87.6%. Specificity could be improved by an 
additional 20%-30% if referrals were limited to women testing positive for HPV16 or 
p16INK4a. That strategy had little impact on sensitivity for CIN3+ but sensitivity for 
CIN2+ was slightly reduced. The authors concluded that short-term surveillance would 
be needed (210). A study by Rijkaart et al. compared 14 different triage strategies of 
HPV DNA-positive women for colposcopy referral rate, for detection of CIN3+. Triage 
with cytology, followed by repeat cytology at 12 months yielded a high negative 
predictive value (99.3% CI 98.1-99.8) and a markedly lower colposcopy referral rate of 
33.4% (95%CI 30.2-36.7)(166). By comparison, triage with HPV DNA16/18 at 
baseline for detection of CIN3+ had a sensitivity of 65.4% and a specificity of 72.5%. 
Another study by the same author investigated whether HR HPV mRNA detection by 
Pretect HPV Proofer can be used as a reflex test to stratify HR HPV DNA-positive 
women with different cytological diagnoses for risk of CIN2+. The results showed that 
a positive mRNA test conferred an increased risk of CIN2+ in HR HPV DNA-positive 
women, especially among women with normal cytology (211). The mRNA test result 
did not influence risk of CIN2+ in cases of borderline or worse cytology.  Rossi 
evaluated mRNA (Pretect HPV Proofer) as a prognostic biomarker for progression to 
CIN2+ following negative colposcopy or CIN1 histology among women referred for 
colposcopy because of minor cytological abnormalities, where the majority of women 
were HR HPV-positive. He found the absolute CIN2+ risk to be 18.4/1000 
person/years in the mRNA-positive group and 3.6/1000 person/years in the mRNA-
negative group. He concluded that mRNA is a good candidate for management of HR 
HPV DNA-positive women, especially to help reduce intensity of follow-up among 
women who test negative. However, only a small number of patients had the outcome 
CIN2+. A study by Benevolo et al. evaluated the diagnostic and prognostic 
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performance of the PreTect HPV Proofer among HR HPV-positive women with minor 
cytological abnormalities and found that mRNA positivity was significantly more 
associated with CIN2+ lesions than CIN2- lesions. Longitudinal specificity after 2 
years of follow-up was high, 89%, but sensitivity low, 50%. 
Methods with higher specificity and lower sensitivity, such as the PreTect HPV Proofer 
or genotyping for HPV16DNA or for HPV16/18DNA should perhaps be considered as 
a two-step management strategy, with referral for triage-positive women and repeat 
testing for triage-negative women. To date, the best evaluated triage strategy among 
HPV positives is repeat cytology. However, loss to follow-up may be a problem when 
implementing a screening strategy that involves a repeat test when reflex testing is not 
feasible. Rijkaart reported about a 40% loss to follow-up among HR HPV-positive 
women with normal cytology at baseline and other studies have reached similar 
conclusions. Therefore, adequate communication is important. In the POBASCAM trial 
(primary screening study for HPV) in the Netherlands, 77% of women followed up 
with repeat testing (167). 
 
6.3.4 Implications for continued research and practice 
At present we are experiencing an increasing trend of minor cytological abnormalities 
among younger women (135) who also have a high prevalence of HPV. In a Stockholm 
study, 64% of women with ASC-US and 77% of women with CIN1 were HPV-
positive. HPV-positivity is age-dependent, with 81% prevalence among women below 
age 35 and 44% prevalence among women above age 45 (155). All young women (<30 
years) referred for colposcopy because of minor cytological findings are HPV-positive. 
Colposcopy may lead to increased detection of lesions that normally would have 
regressed spontaneously. In addition, it leads to increased workload for gynaecological 
clinics, increased risk for overtreatment, perhaps with adverse obstetric outcomes, and 
increased anxiety among women.  
We need to learn more so we can provide optimal clinical management of young 
women since their risk for cancer in general is extremely low. Studies of new 
biomarkers such as HPV16/18DNA, E6/E7mRNA, p16INK4a/Ki 67 or DNA 
methylation may contribute additional knowledge, but it is important to conduct more 
age-stratified analyses in the future. So far we lack data from long-term follow-up 
studies of HPV in primary screening for women under 30. Studies of women over age 
30 have shown that HPV testing contributes to early detection of high-grade CIN 
without resulting in over-diagnosis. 
 
6.4 DISCUSSION PAPER 4 
6.4.1 Main findings and interpretations 
HR HPV status had the significantly greatest impact on risk of developing high-grade 
cervical disease among women with minor cytological abnormalities. 
We found that the long-term risk of developing CIN2+ following a negative HR-HPV 
DNA test was low during follow-up, regardless of ASC-US or LSIL diagnosis. For HR 
HPV-negative women with LSIL on index cytology, risk increased after 4.5 years of 
follow-up, suggesting that these women should be followed at intervals shorter than 4.5 
years. The 3-year interval of the organised screening programme would seem 
  82 
appropriate. The additional few cases identified among women with HPV-negative 
LSIL may reflect false negative cytology or newly acquired HPV infections during 
follow-up, but are less likely to be due to false negative HPV DNA tests. 
Many studies have shown that the risk of developing pre-cancerous lesions and ICC is 
very low among women who are negative on both cytology and HR-HPV DNA testing 
(78, 174, 212). Therefore triage using HPV DNA testing for ASC-US cytology has 
been extensively evaluated and is now recommended to identify women at the highest 
risk of cervical disease who need referral for colposcopy and biopsy. A negative HPV 
DNA test is also reassuring and these women can wait at least one year for retesting. 
Triage of LSIL was not previously recommended, since the most commonly used HPV 
DNA test for evaluation, Hybrid Capture 2 (HC2), was no more sensitive and 
substantially less specific than repeat cytology (154). However, a recent Cochrane 
review demonstrated that HC2 had significantly higher sensitivity, which could justify 
recommending HR-HPV DNA testing for triage of LSIL. Recommendations should be 
based on local cost-effectiveness analyses, local HPV prevalence and compliance with 
follow-up (134, 135). Swedish guidelines recommend HPV triage of all women with 
minor cytological abnormalities regardless of whether the diagnosis is ASC-US or 
LSIL, but recommend repeat cytology at one year among women who were HPV 
DNA-negative, just to be on the safe side (39, 155). Recent years have seen an increase 
in the diagnosis of minor cytological abnormalities, resulting in increased colposcopy 
referrals. Since referrals require significant time and resources from the healthcare 
system and can be stressful for women, this begs the question of whether HPV-negative 
women could return to the three-year screening interval. Our results demonstrate a 
consistently low risk for CIN2+ among HPV-negative women with minor cytological 
abnormalities during the first four years of follow-up and therefore (at least with the 
performance of the HPV test used in the present study) retesting after 1 year is not 
required.  
We found that women diagnosed with HPV16/18 at baseline were at significantly 
higher risk of developing CIN2+ than HPV-negative women. Furthermore, our data 
imply that a positive HPV16/18 test at baseline is a better predictor than other HR-HPV 
types of who is at increased risk of developing high-grade lesions, even after 5 years. 
However, the risk of developing CIN2+ was substantial, even among women who were 
positive for HR-HPV types other than HPV16/18. 
Risk stratification by genotyping in this group probably will not alter clinical 
management in any way because the risk of pre-cancer is so high that immediate 
colposcopy will be required. However, in populations with limited access to follow-up 
immediate treatment may be motivated. Identifying the presence of HPV16/18 may 
focus attention on this high-risk group, but may also cause considerable anxiety among 
these women. Commercially available FDA-approved HPV DNA tests such as the 
Cobas 4800 (Roche Molecular Systems, Pleasanton, CA, USA) can simultaneously 
detect HPV16 and HPV18 individually, as well as 12-pooled HR-HPV types (213). The 
rather high risk of developing CIN2+ among women with LSIL reflects the high 
prevalence of HR-HPV (79.4%) in this diagnostic category. 
 
6.4.2 Methodological considerations and validity 
A major strength of our study is the link to the National Quality Register for Cervical 
Cancer prevention (NKCx) from which we retrieved all follow-up data and to which all 
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cytological and histological results are reported. Correct links are ensured by using 
personal identification numbers for all women, which reduces loss to follow-up.  
Furthermore, our study reflects a real-life clinical setting in Sweden, as well as long-
term follow-up in clinical practice. One study reported that most slides diagnosed as 
ASC-US in the US and UK is reported as normal in Sweden, which could affect 
comparisons of results between countries (26). Furthermore, we have a high prevalence 
of HPV among our ASC-US and LSIL cases, which could also affect comparability of 
cumulative risk estimates between countries. We have not adjusted for verification bias. 
Colposcopy biopsies were taken from visual lesions and women were considered 
disease-free if no lesions were seen. This could have affected our calculations, but it 
also allows our results to apply to other real-life settings. Some women might have 
been treated because of persistent low-grade disease, which may have censored 
outcome development. Because low and moderate CIN lesions often regress and the 
diagnosis is often poorly reproducible, ideally the outcome would have been CIN3+ or 
cancer (94), but that would have required a larger study population. However, in a 
clinical setting CIN2+ is of great interest since it represents the threshold for patient 
treatment (214). 
 
6.4.3 Comparison to other studies 
Several large randomised controlled studies (RCT) and longitudinal cohort studies have 
demonstrated that HPV negativity is protective against development of pre-cancer (78) 
(212, 215), though 100% assurance can never be guaranteed. Castle et al. reviewed case 
histories of 33 baseline HR-HPV negative CIN3 cases and found evidence that these 
cases were due to incident (new) cases (n=12), non HR-HPV (n=5), misclassified 
histology (n=8) and false negative HR-HPV (n=8) tests. They concluded that among 
women with cytological abnormalities, a few cases of cervical pre-cancer would be 
found that would test HR-HPV negative for one or more reasons (216). The low risk of 
HPV-negative ASC-US was confirmed in a large cohort study by Katki et al. that 
followed over one million women (217). They concluded that women with HPV-
negative ASC-US were at similar 5-year risk for CIN2+/CIN3+ as women with a 
normal Pap smear and therefore could be managed similarly, namely with a 3-year 
retesting interval. In the same cohort, Katki et al. (218) also studied the risks of LSIL 
and found that HPV test results do modify risk, but only enough to consider repeat 
testing of HPV-negative LSIL at one year, rather than to refer for immediate 
colposcopy (219). Conclusions were based on a risk stratification concept introduced 
by Castle et al. that involves “equal management of equal risks” (209, 220), which 
states it is safe to return the patient to the regular screening programme if the 5-year 
risk of CIN3+ is <2%. If risk is 2%-10%, follow-up at one year is recommended, and if 
>10% referral for colposcopy is required. A study from Norway investigated a 
composite group of ASC-US and LSIL in delayed testing (6-12 months after screening 
detected ASC-US/LSIL cytology) in order to allow for viral clearance. They concluded 
that it is safe to return women with a negative HPV DNA test (Amplicore) to the 
regular 3-year screening schedule (221). The risk of CIN2+ was only 1.8% 3 years after 
a negative Amplicor HPV test. A recent study from the Norwegian Cervical Cancer 
Screening Programme (NCCSP) compared the short-time (6 months) and long-term (3 
years) effectiveness of different HPV tests (Amplicore, HC2 and Pretect HPV Proofer) 
in the) and reported that the risk for CIN2+ among HPV-negative women with 
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persistent ASC-US/LSIL was over 2% and that returning these women to the normal 
screening programme was potentially unsafe. However, a normal repeat cytology (after 
6 months) following an ASC-US/LSIL resulted in a low risk of severe abnormalities 
during the next screening round, justifying a return to the regular screening programme 
(222). Long-term follow-up of test accuracy after implementation of a new test in a 
prevention programme is of great importance. The Norwegian study illustrates the 
differences in the protective effect of different HPV tests, which underlines the 
importance balancing clinical sensitivity and specificity (clinical performance) to 
ensure safety for women participating in screening. It also highlights the importance of 
ongoing program evaluation when new screening routines are implemented. In a long-
term follow-up of women with borderline and mild dyskaryosis (BMD), Kocken et al. 
reported that a negative HR-HPV test at baseline corresponded to a 5-year risk of 
CIN2+ of 9.9%, whereas a positive test increased the risk to 44.9%. They concluded 
that HR HPV-negative women may be referred for routine screening since their 5-year 
CIN3+ risk is negligible, which is also consistent with our results (223). 
As in our study, several others have previously demonstrated high risks for pre-cancer 
among HPV-positive women and especially among those positive for HPV16 and/or 18 
(77, 224). Kocken reported that women with borderline and mild dyskaryosis (BMD) 
who were positive for HPV16 were at higher risk for CIN3+ than women infected with 
other HR-HPV types. Their 5-year risk was 49.8%, vs. 29.8% among women infected 
with other HR-HPV types (223). 
 
6.4.4 Implications for continued research and practice 
In this fourth study we have taken advantage of the excellent Swedish register, NKCx 
and linked data from our own “biobank” to get 100% follow-up results. LBC is an 
excellent method, which allows sample material that is left over after cervical cytology 
slides preparation (with large amounts of cells with well-preserved DNA, RNA, 
proteins and cellular morphology) to be used for additional analyses. Systematised 
collection and storage of biological samples in biobanks, as well as linkage to 
nationwide registers such as the cancer registers or histopathology registers, provide 
invaluable resources for research in the future. Great effort should be dedicated to such 
initiatives. The Swedish Cervical Cytology Biobank (SCCB) is one such project that 
began a couple of years ago and will help ensure these endeavours for the future. 
As discussed in other sections of this thesis, more knowledge of biological markers will 
hopefully help us to stratify risk in clinically challenging groups such as HPV-positive 
young women with minor cytological abnormalities, with CIN2+ lesions, or in 
discordant cases of high-grade dysplasia with normal or minor colposcopic findings.  
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7 CONCLUSIONS 
7.1.1 Study I: 
We found that testing for HR-HPV DNA with HC2 is a more sensitive method than 
repeat cytology with Pap smear to detect high-grade CIN. HR-HPV DNA testing for 
triage of women with minor cytological abnormalities has now become an established 
method. However, test specificity needs to be improved and will be a task for future 
research. 
 
7.1.2 Study 2: 
Our second study confirms the finding of previous studies that detection of HR-HPV 
DNA after treatment by conisation identified 100% of women with residual/recurrent 
high-grade disease. However, detection of HPV E6/E7 mRNA was a poor predictor of 
treatment failure.  In this study we suggest that a negative HPV mRNA result cannot 
exclude the risk of malignant progression, and that HPV E6/E7 mRNA testing by 
APTIMA HPV assay is not useful to follow up women treated for CIN. More specific 
markers are needed to predict long-term results on follow-up after treatment. 
 
7.1.3 Study 3 
Our study was the first (to our knowledge) to investigate detection of HR-HPV E6/E7 
mRNA by Aptima HPV Assay for triage of HR-HPV DNA-positive women with minor 
cytological abnormalities. Our results support Aptima triage of women with ASC-US 
cytology, but not with LSIL cytology. HR-HPV genotyping for HPV16 and HPV16/18, 
as well as repeat cytology were all more specific markers, but had low sensitivity and 
were associated with a higher than negligible risk for cervical disease, despite negative 
test results. Therefore these women could not return to the standard screening 
programme. Finding biological markers with the ability to distinguish between transient 
and persistent infection remains a challenge for future research. 
 
7.1.4 Study 4 
We found that HR-HPV DNA status had the greatest impact on development of high-
grade cervical lesions among women with minor cytological abnormalities. The risk for 
cervical pre-cancer was low during the first 4.5 years of follow-up among HPV DNA-
negative women, suggesting that these women could safely be returned to the standard 
screening programme instead of undergoing repeat testing after one year, as currently 
recommended. The highest risk of developing high-grade lesions was observed among 
HPV16/18-positive women, suggesting a need for a more aggressive follow-up. 
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8 FUTURE RESEARCH 
Research on prevention of cervical cancer has progressed rapidly and extensively over 
the past 25 years. The understanding that HPV infection is the central and necessary 
cause of cervical cancer has inspired new approaches to disease prevention through 
improved screening methods and HPV vaccination. The first HPV vaccine was 
approved in 2006, and in 2008 Dr Harald zur Hausen received the Nobel Prize in 
Physiology or Medicine for his pioneering work concerning the role of HPV in the 
development of cervical cancer (225). Many areas in this field remain to be elucidated 
by future research, but I will concentrate here on a discussion of questions related to 
our studies. In current population-based cervical cancer screening programmes, the vast 
majority of abnormal findings are of minor grade. The risk of underlying high-grade 
cervical disease cannot be ignored, but the overwhelming majority have transient HPV 
infection. Clinical management of minor cytological abnormalities has recently 
changed course (HR-HPV DNA triage) in an effort to reduce the number of women 
requiring further examinations. However, our diagnostic tools are still too blunt at the 
price of heightened anxiety among affected women and a heavy burden on the 
healthcare system. Basic research on the natural history of HPV infection is important 
to elucidate the mechanisms involved in clearance or persistence of infection and how 
HPV evades the immune system. Specific biological markers are needed. One 
unanswered question is whether infections clear completely, or become latent, only to 
reappear later in life. Studies indicate that “clearance” simply reflects a dip in viral load 
below the threshold of detectability. HPV DNA testing is carried out on exfoliated cell 
smears, which sample the upper cellular layers of the ectocervix, and may therefore 
miss low viral load infections confined to the basal layers, making it difficult to verify 
whether infections have fully cleared or remained latent. Could reactivation occur later 
in life? If so, what are the triggers? Could this explain the second peak of HPV 
prevalence in the perimenopausal age? Or the higher risk of recurrence among women 
treated for CIN, which is higher still among women treated later in life, as a recent 
study has suggested? Perhaps we could also find an answer to the question about 
whether there might be an indication for vaccination to prevent recurrent 
disease/reinfection following conisation. 
How do we improve the specificity of HPV DNA testing? Should thresholds for viral 
load in the tests be increased, or can new biomarkers help us? Again, the elucidation of 
these questions requires more knowledge of the biology and life cycle of HPV.  
HPV typing is the most important predictor of the likelihood of lesion progression, 
especially in regard to HPV16, but even HPV18 makes a substantial contribution. 
Genotyping for HPV16/18 and perhaps for additional high-risk types improves the 
PPVs, but will it be safe and effective enough for screening or in triage, since risks 
associated with other HR-HPV types still remain? 
Measurement of mRNA from the HPV E6 and E7 oncogenes provides high specificity 
for differentiating benign productive infections from those that have initiated neoplastic 
progression and those that are already cancerous. However, our studies, which reflect 
the real-life setting, were unable to confirm the usefulness of this approach. Although 
few studies have addressed the predictive value of mRNA testing following treatment 
for CIN, or among HR-HPV positive women with minor cytological abnormalities, the 
role of such mRNA testing is still worth elucidating through additional and larger 
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studies. However, it raises the question of whether measurement of HPV E6/E7 mRNA 
in clinical practice is sufficiently adequate to assess a transforming infection, or are 
other molecular events of greater importance? What triggers the irreversible step of 
HPV DNA integration? Is there an early indicator of this step? Are there other 
biomarkers that are more useful? Another interesting area of research that has received 
great attention in recent years involves epigenetic changes in HPV viral and host genes. 
The hypothesis is that methylation of genes affects expression through silencing and 
thereby the natural history of cervical neoplasia. This process may result from a host 
response to a foreign intracellular agent, or from a signal that indicates viral integration 
into the host genome. Our studies have confirmed the acceptance of histopathology as 
the gold standard, though even this method is prone to subjective interpretation. This 
field would also benefit from identifying more objective biological markers.  
Last but not least, HPV positivity leads to patient anxiety and confusion related to 
guidelines, as does the shift from an oncologic to a sexually transmitted infection (STI)-
directed approach. This shift will require educational programs for both healthcare 
providers and patients concerning HPV testing in the future (8, 226). 
HPV transmission is increasingly common among young women worldwide and 
several markers such as TERC, specific proteins, and immunological markers may help 
us to develop more effective strategies for early detection and treatment of women with 
ICC. If we could identify women at risk of developing this cancer on the basis of a 
single marker, or a combination of different markers, such analyses would likely 
become a substitute for, or a complement to, cytological screening. Studies indicate that 
the first generation of HPV vaccines may prevent at least two-thirds of ICC. A 
combination of improved detection of precursor lesions by molecular markers in 
screening programs, and vaccination against HPV could make this the most preventable 
cancer on earth. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Incidensen av livmoderhalscancer har minskat med 60 % i Sverige sedan 
populationsbaserad vaginalcytologisk screening infördes men fortfarande drabbas ca 
450, till övervägande del unga kvinnor, av denna cancertyp årligen. 
Livmoderhalscancer orsakas av infektion med särskilda högrisk-typer av humant 
papillomvirus (HR HPV). Sådana infektioner är vanliga, särskilt bland unga kvinnor, 
men läker oftast ut spontant. Om infektionen blir kronisk kan den dock leda till 
cancerutveckling. De flesta cellförändringar övergår inte heller i cancer utan förblir 
stationära eller läker ut spontant. Målet med denna avhandling var att identifiera 
riskfaktorer för att kunna prognostisera en senare cancerutveckling hos kvinnor med 
lätta cellförändringar och hos kvinnor som genomgått behandling för cellförändringar. 
Genom utvärdering av nya känsliga diagnostiska metoder, ökad kunskap och ett 
förbättrat omhändertagandet av kvinnor med lätta cellförändringar skulle den 
gynekologiska hälsokontrollen kunna förbättras.  
Den första studien publicerades redan 2005. Ett problem inom cellprovsbaserad 
screening är att merparten av alla avvikande prov består av lindriga cellförändringar 
(ASC-US -svårvärderad skivepitelatypi och LSIL -lätt dysplasi). Dessa förändringar är 
ospecifika. Det behövs bättre metoder för att identifiera riskpatienter, så att risken för 
överdiagnostik, överbehandling och onödigt psykiskt lidande kan minimeras. En 
möjlighet är att komplettera cellprovet med HPV-test, så kallat HPV-triage, för att 
kvinnor med ökad risk för framtida livmoderhalscancer skall kunna särskiljas från dem 
med reaktiva förändringar. HPV-test har en betydligt högre känslighet än cellprov att 
upptäcka behandlingskrävande cellförändringar (cervikal intraepitelial neoplasi grad 2 
eller värre, CIN2+) och därmed även en god förmåga att förutse frånvaro av CIN2+. En 
nackdel är dess låga träffsäkerhet (specificitet), dvs. stor andel falskt positiva prover 
med avseende på CIN2+, som är mest uttalad bland unga kvinnor. 
I den första studien vi har sammanställt resultat från 177 kvinnor med lindriga 
cellförändringar på livmodertappen. LSIL och ASC-US upptäcks hos mer än 5 % av 
kvinnor som kommer till gynekologisk cellprovtagning. Endast en liten del av dessa 
utvecklas till precancerösa och invasiva förändringar. Det har varit svårt att avgöra 
vilka lindriga cellatypier som behöver avlägsnas i profylaktiskt syfte. På de flesta håll i 
Sverige tog man enligt de rutiner som fanns ett nytt cellprov efter 3-4 månader om det 
första provet visat lindrig atypi. Logiskt sett borde kvinnor som är negativa för HPV 
inte behöva genomgå utredning och behandling. Med det arbetet jämförde vi HPV-
testets och cellprovets känslighet (sensitivitet) vid uppföljningen av kvinnor med 
lindriga cellförändringar. Vi fann att HPV förekom i 66 % av dessa förändringar. 
Känsligheten för en upprepat cytologi prov var 61 % och för HPV-test -82 %.  
Resultatet av den studien och andra har visat att HPV testet är mycket bra på att sortera 
ut kvinnor med ökad risk för allvarliga cellförändringar bland kvinnor med lindriga 
cellförändringar och därför har riktlinjerna i Sverige sedan ett par år tillbaka ändrats. 
Numera kallas endast HPV positiva med lätta cellförändringar till utredning hos 
gynekolog medan HPV negativa inte utreds vidare. HPV negativa kvinnor kallas dock 
för säkerhets skull till ny cellprovs kontroll efter ett år. Detta har resulterat i vissa 
besparingar, både beträffande ekonomiska resurser och beträffande kvinnors psykiska 
hälsa. 
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Det är känt sedan länge att närvaro av HPV är en nödvändig, men inte tillräcklig faktor 
för utveckling av livmodershalscancer. Nu är det bevisat att en kronisk infektion med 
en HR-HPV typ är en betydande riskfaktor. De virala onkoproteinerna 
(cancerframkallande proteiner) E6 och E7 har störst betydelsen för omvandlingen av en 
normal cell till en cancercell och för upprätthållandet av cancerutvecklingen då de stör 
funktionen av cellens tumörsupressor proteiner (proteiner som normalt förhindrar att en 
cell omvandlas till en cancercell); pRb (retinoblastomprotein) och p53. Detta leder till 
en störd reglering av celldelningen och en minskad förmåga hos cellen att ”ta död på 
sig själv” vid allvarlig genetisk skada, vilket sammantaget kan leda till utvecklingen av 
cancer. Uttryck av de virala generna E6 och E7 har man kunnat mäta genom analys av 
så kallat E6/E7 mRNA (messenger ribonucleic acid) och det har visat sig användbart 
som markör för transformerande, cancerframkallande HPV infektioner. En ny metod 
för mätning av onkogen expression av E6/E7 mRNA från 14 HR-HPV typer (Aptima 
HPV Assay) har utvärderats i den andra studien. Förhoppningen var att testet med 
bibehållen känslighet och förbättrad träffsäkerhet (specificitet) skulle kunna identifiera 
tranformerande HPV infektioner för att bättre kunna hitta kvinnor med risk för 
utveckling av livmodershalscancer.  
HPV E6/E7 mRNA (Aptima) testet utvärderades vid uppföljning av kvinnor efter 
behandling för att om möjligt bättre kunna förutsäga återfall i sjukdom. Alla kvinnor 
hade genomgått en så kallad koniseringsoperation, vilket innebär att en centimeter av 
livmodertappen tagits bort som behandling för allvarliga cellförändringar. När 
kvinnorna kom på sin första kontroll (143 st.) togs ett ”vanligt HPV test” (som mäter 
HPV DNA), ett HPV mRNA test (Aptima HPV Assay) och ett vanligt cellprov. Endast 
sju av 143 (5 %) kvinnor hade återfall sjukdom (CIN2+) under uppföljningstiden som i 
medeltal var 3,6 år. Det visade sig att HPV DNA testet var känsligast och upptäckte 
alla kvinnor med återfall i sjukdom, följt av cellprovet som upptäckte 86 %. Det minst 
känsliga testet var Aptima som missade tre kvinnor med behandlingskrävande 
cellförändringar (CIN2+). Vi konkluderade att Aptima inte lämpade sig som test för att 
förutsäga återfall efter behandling. 
I det tredje arbetet utvärderades detektion av E6/E7 mRNA expression med Aptima 
HPV Assay hos kvinnor med lindriga cellförändringar. Eftersom metoden kan skilja 
mellan ofarliga HPV infektioner och farliga transformerande infektioner, skulle den 
kunna användas hos kvinnor under 30 år för att om möjligt reducera antalet 
gynekologiska besök med ca 70-80%. Särskilda HR HPV typer, som HPV16 och 18 
har också visat sig speciellt betydelsefulla för utvecklingen av livmoderhalscancer och 
är därför intressanta. I studien testades 219 kvinnor med Aptima HPV Assay, HPV16, 
HPV16/18 och upprepat cellprov. Kvinnorna var alla HPV positiva och uppdelades i en 
ASC-US respektive LSIL grupp. 36 % av kvinnorna i varje grupp utvecklade 
behandlingskrävande cellförändringar under uppföljningstiden som var 4 år. Resultaten 
visade att Aptima var det känsligaste testet och upptäckte 78-100% av alla allvarliga 
cellförändringar (CIN2+) hos kvinnor med ASC-US men Aptima var inte lika känsligt 
hos kvinnor med LSIL (76-78%). Specificiteten var dock lägst och ett negativt Aptima 
test kunde heller inte i tillräcklig utsträckning utesluta frånvaron av CIN2+. Att testa för 
HPV16 och/eller HPV16/18 hade generellt låg känslighet men ett positivt test resultat 
innebar samtidigt en stor risk för CIN2+. Sammanfattningsvis visade studien att 
Aptima var tillräckligt bra för att rekommendera som triage-test av kvinnor i ASC-US 
gruppen, vilket också överensstämmer med resultat från en stor metaanalys från 
2012(117). Inget av testerna var dock tillräckligt bra att rekommendera som triage-test 
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av LSIL då negativa test resultat inte kunde garantera att kvinnorna riskfritt kunde 
återgå till den normala screeningen. 
I det fjärde arbetet studerade vi faktorer som har betydelse för utvecklingen av lätta 
cellförändringar till allvarliga (CIN2+) över tid. Vi följde 314 kvinnor i sju år med 
avseende på ålder, typ av lätt cellförändring (ASC-US/ LSIL), HR HPV status 
(positiv/negativ) och HPV typ (HPV16/18) vid studiens början. Information om 
kvinnorna utvecklade cellförändringar eller inte erhölls via det Nationella 
Kvalitetsregistret för Cervix Cancer Prevention (NKCx) vilket har 100 % täckning. 
Totalt utvecklade 28 % av kvinnorna CIN2+ under uppföljningstiden. Den största 
risken hade kvinnor som var HR HPV positiva vid studiens början och då särskilt om 
de var positiva för HPV16 och/eller HPV18. 54 % av HPV16/18 positiva utvecklade 
CIN2+ men hela 38 % av kvinnorna positiva för andra HR HPV typer utvecklade också 
CIN2+. HPV negativa hade den lägsta risken att utveckla allvarliga cellförändringar, 
särskilt under de första 4,5 åren. Endast ca 2 % av kvinnorna utvecklade CIN2+. Med 
detta som bakgrund föreslås att man överväger att avskaffa det ”kontroll test” som idag 
utförs efter ett år av HPV negativa och istället återför kvinnorna till det ordinarie 
screening programmet. Åldern hade ingen avgörande betydelse för utvecklingen till 
allvarlig cellförändring. Vårt övergripande syfte har varit att etablera klinisk 
användbara tidiga molekylära markörer för att förutsäga cancer progression hos 
kvinnor med lindriga cellförändringar vilket skulle kunna leda till en förbättring av den 
gynekologiska hälsokontrollen.  
Sammanfattningsvis visar avhandlingen att HPV test kan användas för att identifiera 
kvinnor med störst risk för allvarliga cellförändringar och som därför bör utredas vidare 
av gynekolog. HPV mRNA test (Aptima HPV Assay) var i vår studie för okänsligt för 
att användas vid uppföljning efter behandling men fler och större studier bör utföras. 
Aptima visade sig däremot kunna användas för att sortera ut en högrisk grupp bland en 
subgrupp HR-HPV positiva kvinnor med lätta cellförändringar (ASC-US) men ett 
negativt testresultat kunde inte utesluta risken för sjukdom i framtiden. Infektion med 
högrisk HPV och då i synnerhet med HPV16/18 har störst betydelse för risken av 
utveckling från lätta cellförändringar till mer allvarliga. HPV negativa kvinnor har 
däremot så låg risk för CIN2+ att man kan överväga att avskaffa det nuvarande 
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